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Development of an Inhalational Formulation of Coenzyme Q10 to Treat 
Lung Malignancies 
 
Thiago Cardoso Carvalho, Ph.D. 
The University of Texas at Austin, 2011 
 
Supervisor: Jason T. McConville 
 
Cancer is the second leading cause of death in the United States and its onset is 
highly incident in the lungs, with very low long-term survival rates. Chemotherapy plays 
a significant role for lung cancer treatment, and pulmonary delivery may be a potential 
route for anticancer drug delivery to treat lung tumors. Coenzyme Q10 (CoQ10) is a 
poorly-water soluble compound that is being investigated for the treatment of 
carcinomas. In this work, we hypothesize that formulations of CoQ10 may be developed 
for pulmonary delivery with a satisfactory pharmacokinetic profile that will have the 
potential to improve a pharmacodynamic response when treating lung malignancies. The 
formulation design was to use a vibrating-mesh nebulizer to aerosolize aqueous 
dispersions of CoQ10 stabilized by phospholipids physiologically found in the lungs.  
In the first study, a method was developed to measure the surface tension of 
liquids, a physicochemical property that has been shown to influence the aerosol output 
characteristics from vibrating-mesh nebulizers. Subsequently, this method was used, 
together with analysis of particle size distribution, zeta potential, and rheology, to further 
evaluate the factors influencing the capability of this nebulizer system to continuously 
and steadily aerosolize formulations of CoQ10 prepared with high pressure 
homogenization. The aerosolization profile (nebulization performance and in vitro drug 
 x
deposition of nebulized droplets) of formulations prepared with soybean lecithin, 
dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC) and 
distearoylphosphatidylcholine (DSPC) were evaluated. The rheological behavior of these 
dispersions was found to be the factor that may be indicative of the aerosolization output 
profile. Finally, the pulmonary deposition and systemic distribution of CoQ10 prepared as 
DMPC, DPPC, and DSPC dispersions were investigated in vivo in mice. It was found that 
high drug amounts were deposited and retained in the mouse lungs for at least 48 hours 
post nebulization. Systemic distribution was not observed and deposition in the nasal 
cavity occurred at a lower scale than in the lungs. This body of work provides evidence 
that CoQ10 may be successfully formulated as dispersions to be aerosolized using 
vibrating-mesh nebulizers and achieve high drug deposition in the lungs during 
inhalation. 
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Chapter 1: Introduction 
 
1.1. FORMULATIONS FOR PULMONARY ADMINISTRATION OF ANTICANCER AGENTS TO 
TREAT LUNG MALIGNANCIES 
 
Abstract 
Chemotherapy plays a significant role both as primary and as supportive care for 
lung cancer treatment. The majority of currently available anticancer agents are 
administrated intravenously, causing side effects due to the systemic drug distribution. 
Alternatively, the bioavailability of orally administrated anticancer agents is usually 
compromised by the first-pass metabolism. Pulmonary administration may be a potential 
route for anticancer drug delivery to treat lung tumors, due to its site specific delivery, 
avoidance of first-pass metabolism, possibility of fewer side effects, and improved 
comfort for cancer patients using a needle-free delivery device. However, to attain an 
effective inhalational delivery, there is a requirement to design a formulation with 
appropriate aerodynamic properties with well-suited excipients. This review explores 
work to date related to the formulations developed for pulmonary delivery of small 
molecule antineoplastic agents to treat primary and metastatic lung carcinomas. 
Ultimately, it highlights the importance of formulation design to define the role of 
inhalational chemotherapy. 
 
1.1.1. Introduction 
Parts of this chapter were taken from Carvalho TC, Carvalho SR, McConville JT. 
Formulations for Pulmonary Administration of Anticancer Agents to Treat Lung 
Malignancies. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 
2 
 
2011;24(2):1-20 and from Carvalho TC, Peters JI, Williams III RO. Influence of particle 
size on regional lung deposition - What evidence is there? Int J Pharm. 2011;406(1-2):1-
10. The co-authors in these publications have contributed by providing comments to 
improve the quality of these review papers. 
Second only to heart disease, cancer is the leading cause of death in the United 
States. Although a total of $228.1 billion USD was spent on cancer treatments in 2008[1] 
there was still an estimated 565,650 deaths in that year.[2] These cancer related deaths 
represented 25% of total mortality when compared to other diseases.[3] Among the many 
different possible sites for the onset of cancer, this disease has a high incidence in the 
lungs. It has been estimated that 219,440 new cases of lung cancer were diagnosed in 
2009, which represents 15% of the total incidence of cancer. Moreover, lung tumors are 
the most lethal amongst all types of cancer. Alone, it accounts for 28% of all the cancer 
deaths estimated for 2009. This means it is expected to kill more than the next three most 
deadly cancers in men put together (i.e. prostate, colon, and pancreatic cancer). Tobacco 
is the most expressive risk factor for lung cancer development in both males and 
females[4] and is related to quantity and duration of exposure to tobacco smoke.[1] 
Lung cancer is classified as two subtypes, according to the histological 
characteristics of the tumor: small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC). Their distinct biological profiles lead to different prognosis and, 
consequently, different clinical treatments. Without treatment, the median survival of a 
diagnosed SCLC patient is less than 4 months, due to its rapid growth and high 
propensity for dissemination throughout the body. Although this malignancy presents an 
aggressive nature, its response to chemotherapy and radiotherapy is greater than 
NSCLC.[5] The incidence of SCLC in the United States in 2002 was approximately 13% 
of all new cases, with a decreasing annual rate of 2.4% since 1973.[6] Inversely, at the 
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time of diagnosis, NSCLC represents the greatest majority among all new cases of lung 
cancer. Usually, several different types of cancer cells are presented at the NSCLC tumor 
aggregate, including squamous cell carcinoma, large cell carcinoma, and adenocarcinoma 
which is currently the most expressive type.[4, 7] Malignancy to the lungs may also be a 
result of metastases from tumors originated in other organism sites, such as melanoma, 
and breast cancer.[8, 9] 
The Tumor-Node-Metastasis (TNM) staging system is the most commonly used 
classification in the clinical practice.[10] Given the nature of SCLC, to easily 
metastasize; a simpler concept of the staging system is also used: Limited Disease (LD) 
and Extensive Disease (ED).[11-13] 
Surgery, radiotherapy, and chemotherapy are the treatment options for lung 
cancer patients. Due to the high mortality outcomes from this cancer subset, different 
treatment modalities are frequently combined in several ways, attempting to increase the 
life expectancy of the patients. 
Surgery is considered effective when the early stage tumor is localized in a 
defined area. NSCLC patients normally benefit more with this modality, given the 
intrinsic characteristic of the tumor cells to spread less than SCLC.[14] Although surgery 
alone is not recommended, this medical procedure should always be considered as part of 
a multi-modality treatment, including neoadjuvant (or induction) and adjuvant therapy. 
For instance, both neoadjuvant chemoradiation after tumor resection and postoperative 
chemotherapy have provided favorable survival outcomes in NSCLC patients.[15, 16] 
Supposedly, these treatment modalities shrink the tumor prior to surgery and/or attempt 
to avoid disease relapses in the long-term. 
Radiotherapy is recommended for patients with localized tumors, usually in the 
early stages of lung cancer. However, individuals that are medically inoperable or refuse 
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surgery may also benefit with radiation treatment. Radiotherapy can be used for both 
types of lung cancer.[17] For instance, given the radiosensitivity of SCLC cells, 
radiotherapy is a good treatment option for LD patients, requiring a lower radiation dose. 
Studies have shown a significant decrease in the recurrence of local failure and increase 
in the survival rate of LD-SCLC patients when chemotherapy is combined to 
radiotherapy.[18-22] Interestingly, LD-SCLC has different types of cells and, 
consequently, different morphological and biologic characteristics. Although, these kinds 
of LD-SCLC react with different intensity to small radiation, they are still more reactive 
than normal tissue. However, the incidence of metastases and local recurrence is still very 
common in those patients.[18] 
Either alone or in combination with other modalities, chemotherapy plays a 
significant role in the treatment of cancer. In general, numerous drug delivery strategies 
for different routes of administration have been applied in the formulation development 
of anticancer drugs, regardless of tumor site. For instance, liposomes, solid lipid 
nanoparticles (SLNs) and polymeric micro/nanospheres, have been investigated as 
possible colloidal delivery systems.[23] 
When it comes to lung cancer, in most cases, the currently available drugs are to 
be administered by the intravenous route (bolus or infusion). For instance, the paclitaxel 
formulation designed for intravenous (IV) infusion administration contains the water-
insoluble Active Pharmaceutical Ingredient (API) solubilized in a mixture of Cremophor 
EL (polyoxyethylated castor oil) and dehydrated alcohol. However, as thoroughly 
reviewed by Marupudi et al.., hypersensitivity reactions, myalgias and hematologic, 
neuro and cardiac toxicities have been reported due to infusion administration of 
paclitaxel, which lead to a certain limitation in treating cancer patients.[24] While 
myelosuppression (mainly neutropenia) and peripheral neuropathy appear as fairly 
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common adverse effects, others are not only related to paclitaxel itself, but also to the 
presence of cremophor in the formulation (certain neurotoxic events and hypersensitivity 
reactions). Nevertheless, the review also highlights that paclitaxel having characteristics 
of lipophilicity, high protein affinity, and a volume of distribution much higher than total 
water volume in the body; make the current infusion treatment with paclitaxel 
demonstrate a low therapeutic index. This small concentration of anticancer agent 
administered that reaches the site of interest is also caused by the presence of cremophor 
in the formulation, altering the drug pharmacokinetic profile.[24] 
To a lesser extent, some anticancer agents have also been administered orally.[25] 
For instance, etoposide treats lung malignancies and is commercially available as soft 
gelatin capsules containing 50 mg of API in a solution of purified water, citric acid, 
glycerin and polyethylene glycol 400. Although the need of hospitalization has been 
surpassed with the advent of this dosage form, etoposide bioavailability is still a concern, 
ranging from 40 to 75% and varying inter and intra-patient doses.[26] In addition, 
ethanol, bile salts, cimetidine, metaclopromide and propantheline administered along 
with etoposide have not shown to be successful in improving bioavailability and avoiding 
patient variability.[26, 27] 
Generally speaking, either IV or oral administration routes are able to provide 
relatively high systemic drug concentrations. However, a rather low drug amount 
effectively reaches the desired site of the lungs.[28] As a result, this small lung-to-plasma 
ratio of drug concentration could lead to a low therapeutic efficacy and increased 
systemic side effects. Thus it has been the goal of several research groups to develop a 
locally acting anticancer delivery system for the lung using aerosol delivery. 
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1.1.1.1. Pulmonary Delivery  
The lungs can potentially be a route of administration for both local action and 
systemic absorption. In either case, pulmonary delivery exposes the lung tissue to drug 
concentration levels significantly higher as compared to other routes of administration, 
such as intravenous or oral. For instance, pulmonary administration of itraconazole in 
mice has achieved lung tissue concentrations greater than 10-fold as compared to oral 
administration.[28] As for other respiratory diseases, such as asthma and Chronic 
Obstructive Pulmonary Disease (COPD), inhalation therapy for treatment of lung cancer 
might be considered reasonable for the same pharmacokinetic and pharmacodynamic 
reasons. With the lungs as the target organ, a focused drug exposure may avoid potential 
systemic side effects due to high plasma levels. Any reduction in systemic side effects 
could be highly beneficial to lung cancer patients given the current available 
chemotherapy options. From this standpoint, by local delivery of anticancer agents, lower 
doses compared to intravenous or oral routes would be expected to achieve higher drug 
levels at the site of lung malignancy. Consequently, more effective treatments may 
potentially be achieved, while systemic toxicity could possibly be reduced by decreasing 
plasma levels. The rationale and potential limitations for inhaled chemotherapy are 
discussed in detail in the literature.[29, 30] 
To generate the aerosol particles, there are currently three major categories of 
devices for clinical use: nebulizers, pressurized-metered dose inhalers (pMDI), and dry 
powder inhalers (DPI). More detailed information on these delivery technologies are 
explained elsewhere in the literature.[31, 32] Nebulizer formulations can be administered 
by passive breathing; therefore lung cancer patients should not experience any difficulty 
in using this type of device whatsoever. On the other hand, pMDIs require patient 
synchronization to actuate the device and inhale the drug in an active maneuver. This can 
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be overcome when pMDIs are coupled with spacers that may act to assist the necessary 
effective inhalation maneuver. DPIs and pMDIs have been extensively investigated for 
the therapies to treat asthma and COPD. The fact that severe COPD patients are able to 
use these devices may allow us to assume that lung cancer patients could also potentially 
operate them in an effective manner. However, a consideration has to be made for the use 
of pMDIs to deliver the currently available anticancer drugs. Considering their relative 
low potencies, the dose necessary to treat a lung cancer patient via inhalation may well be 
in the order of milligrams. To deliver this level of dose, the number of actuations in a 
pMDI device may easily approach the order of the hundreds. Therefore this requisite 
would turn it into a low patient adherence therapy, nullifying one of the advantages of 
inhalation therapy. Therefore, despite the potential to deliver anticancer drugs using 
pMDI, the limitation of this device should be carefully evaluated. 
Despite the potential of regional chemotherapy for primary and metastatic lung 
carcinomas, the development of inhalational formulations is in general very technically 
challenging. Aerosol particle size is of extreme importance for inhalational formulations, 
and is a determinant factor in the drug deposition region in the respiratory airways and, 
consequently the lung clearance mechanism. Given their different delivery methods, 
aerosol formulations are very device-specific. Hence, aerodynamic characterization of 
formulations for pulmonary delivery is essential to determine the likelihood of the drug to 
reach a specific lung region. Cascade impactors can be used for this purpose.[33] In 
general, particles with a mass median aerodynamic diameter (MMAD) of 1-5 µm are 
considered to deposit in the deep lung and settle by inertial impaction. In the alveolar 
region, they may be cleared mainly by dissolution followed by diffusion through the lung 
tissue, macrophage uptake and subsequent phagocytosis (unless they are smaller than 
about 260 nm), or metabolism.[34-36] On the other hand, aerosol particles smaller than 
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approximately 1 μm are predominantly exhaled at normal breathing patterns whereas 
those with an MMAD of about 5-10 μm are considered to deposit predominantly in the 
upper airways (oropharynx), being subsequently swallowed due to mucociliary 
clearance.[34, 36, 37] Along with MMAD, the geometric standard deviation (GSD) 
should be reported as it indicates the magnitude of dispersity from the MMAD value.[33] 
These particle aerodynamic profiles are influenced by particle size, shape and density. 
Recently, an in vitro/in vivo comparison has shown that particles of 1-3 μm are the ones 
that more effectively deposit in the lower airways.[38] Therefore, formulation 
aerodynamic properties may be a determining factor defining the fate of the drug in the 
pulmonary tissue. Alternatively, laser diffractometry equipments allow comparative 
evaluation for in vitro characterization during formulation development.[39] 
 
1.1.1.2. Dose and Drug Deposition in the Lungs 
Lung carcinomas can both be presented with diffuse nature (e.g. SCLC and 
bronchoalveolar carcinomas) or as solid tumors; and yet localized anywhere from the 
bronchi (central portion) to the alveoli (lung periphery). Thus, in many cases the 
pulmonary administration of anticancer agents should be expected to target very specific 
areas of the lungs. However, aerosol particles are more likely to deposit in well ventilated 
areas of the lungs, such as the central airways (trachea and bronchi). With that, solid 
tumors positioned in peripheral regions of the lungs may be limitedly exposed to inhaled 
drugs, thereby restricting treatment efficacy. Recently, an investigation has shown that 
co-administration of phospholipids induces particle migration towards lung 
periphery.[40] Although this finding brings some expectation for improvement of poorly-
water soluble drug distribution throughout the lungs, it is still a major challenge to 
develop formulations that can effectively be deposited in the vicinity of the lung 
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carcinoma in order to potentially provide the desired pharmacodynamic response. Yet, 
even if the drug is available for absorption at the carcinoma site, the asymmetric diffusion 
throughout the solid tumor may cause a heterogeneous delivery.[41] Ruenraroengsak et 
al..[42] discusses that not even the advances in nanotechnology for drug delivery systems 
may be able to enhance drug uptake into the tumor. This may be due to the low 
probability of the nanoparticles to find, bind and consequently been up taken by the 
tumor cells in a complex in vivo structure. From this standpoint, formulation scientists 
face a huge obstacle to turn antineoplastic agents into an effective chemotherapy 
inhalation option. For this reason, recently some believe that the role of antineoplastic 
inhalation may be restricted to adjuvant therapy.[41] With tumor removal by surgery, 
tumor penetration is no longer needed. Alternatively, aerosolized chemotherapy may also 
potentially be applied to treat more diffuse forms of lung cancer, such as bronchoalveolar 
carcinoma. In this case, the chemotherapy treatment via inhalation would possibly reduce 
the side effects to patients that could eligibly benefit from it. Nonetheless, the studies 
presented later in this review mainly focus on pulmonary delivery as primary treatment to 
eliminate the tumors. 
No matter which treatment modality the anticancer inhalation therapy may fall 
within, determining the dose exposed to the lungs is also a challenging task for in vivo 
studies. Aerosol formulation performance is highly dependent on aerodynamics of 
formulation provided by a specific aerosol device.[43] The many different aerosol 
systems and animal dosing methods that can be used are able to produce different 
droplet/particle sizes. Consequently, different profiles of drug deposition can be 
achieved.[44] Therefore, dose determination of inhalation formulations is challenging, as 
opposed to other dosage forms, such as tablets, in which the API dose is very well 
defined. Planar gamma scintigraphy is the most widely used direct method to determine 
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the drug deposition in the lungs.[45, 46] By mixing the drug with radiolabeled substances 
(e.g. Technetium-99m, 99mTc), the deposited drug may be estimated using scintigraphic 
images. One major drawback of this method is that it requires the formulation itself to be 
altered in order to contain the radionuclide. This formulation modification may 
misrepresent the actual drug deposition. Nonetheless, the two-dimensional image results 
are not sensitive to drug deposition differences in distinct planes throughout the 
pulmonary tridimensional structure. Being able to identify the drug deposition three 
dimensions is an important feature when the aim is to target solid tumors in specific lung 
regions. This could be accomplished, with certain limitations, by single photon emission 
computed tomography (SPECT) or positron emission tomography (PET). Alternatively, 
calculation of estimated deposited drug has been used to determine inhaled dose from 
nebulizers.[47] This method is based on the minute-volume of respiration,[48] the 
estimated deposited index (both species-specific), the duration of treatment and the drug 
concentration in aerosol volume. Analysis of the later is more suitable for homogeneous 
systems (e.g. solutions) than for disperse dosage forms (e.g. emulsions and liposomes) 
due to their content uniformity during nebulization. By changing the respiratory patterns, 
the inhalation of 5% CO2-enriched air increases drug deposition by approximately 3-
fold.[49] Whenever this technique is applied, the CO2 factor is also added to the 
calculation of the estimated dose. It is also worth mentioning that, although better dose 
control may be achieved by endotracheal instillation, since it bypasses nasal deposition, 
this technique does not allow assessment of the aerodynamic characteristics of the 
formulation. Therefore, conclusions from studies using this technique should be done 
using caution. Despite the estimation that the aforementioned methods provide, the 
accurate determination of drug deposition in the lungs remains yet a major issue to be 
considered in preclinical studies. 
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For clinical studies, concerns should be addressed in order to protect health care 
providers from fugitive aerosol. As we will see later in this review, this can appear as 
device adaptations, scavenging tents equipped with HEPA filters covering the patient, or 
special gowning. 
 
1.1.1.3. Formulation Aspects 
The physicochemical properties of a drug play a significant role in formulation 
design. For instance, the poor water solubility of taxanes (e.g. paclitaxel and docetaxel) 
and some recently discovered camptothecin derivatives, such as 9-Nitrocamptothecin 
(9NC), are a challenge for the development of aqueous formulations for nebulization 
delivery.[50] The partition coefficient (log P) and acid dissociation constant (pKa) also 
provide important information about drug clearance from the lungs. Schanker and 
coworkers have previously demonstrated that, in general, hydrophilic drugs (log P < 0) 
present lung residence times in the magnitude of hours. Conversely, lipophilic drugs (log 
P > 0) are absorbed from the lungs in matter of minutes.[51, 52] Additionally, they have 
demonstrated that nonionized drugs are more rapidly absorbed as compared to the ionized 
form.[53] In order to achieve the desirable pharmacodynamic response, it is obvious that 
antineoplastic agents need to be available to tumor cells for a minimum period of time. 
Drugs readily absorbed by the lungs may then not effectively treat the disease. Table 1 
shows the water solubility and log P values of selected drugs, including the use and 
dosage regimen to combat lung cancer.[54] 
By suitably designing a formulation for lipophilic drugs, the delivery system can 
maintain sustained release of the anticancer agent to potentially prolong the drug 
exposure time to carcinomas. There are a number of excipients that can provide the 
sustained release feature for oral administration. However, for certain formulation 
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components, the relatively low clearance rate in the alveolar bronchial region may render 
an exceedingly long residence time. Consequently, the accumulation of poorly or non-
biodegradable materials in the lungs may compromise pulmonary function.[34] When 
considering lung cancer patients in a later stage disease state, this accumulation may be 
of significant negative health impact. This fact restricts the use of a large number of 
excipients well tolerated by administration through other routes in the drug development 
of pulmonary delivery systems.  
Still, a major issue for choosing appropriate excipients for aerosol medications 
has been the scarce information about their pulmonary delivery safety. In a recent study, 
Montharu and coworkers have investigated the safety of delivering water (control), 
ethanol (10%), propylene glycol (30%), and polysorbate 80 (10%) to the lungs.[55] Rats 
receiving 150 µL of solutions for four consecutive days via intratracheal instillation 
presented signs of local reaction only with polysorbate 80 (foamy macrophage and 
inflammation). In contrast, lower levels of polysorbate 80 can apparently be aerosolized 
to mice with no signs of inflammation or changes in pulmonary histology.[56] Excipients 
in previously approved products by the United States Food and Drug Administration (US 
FDA) can be found elsewhere.[57] Also, scale-up capabilities of the process used to 
prepare the formulation must highly be considered to turn preclinical results into clinical 
trials and successively into a market product. 
Finally, it cannot be excluded the possibility that pulmonary delivery may impact 
lung function according to the formulation design. Possible pulmonary toxicity caused by 
excipients may then compromise the lung tolerance to the neoplastic agent. This in turn 
may lead to a reduction in the maximum tolerated dose (MTD) and consequently affect 
the chemotherapy efficacy. 
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1.1.2. Anticancer Agents 
The next part of this review invites the reader to a commentary of the formulation 
aspects of delivery systems, which have been investigated specifically for the inhalation 
of anticancer small molecule drugs for the treatment of lung malignancies. This section of 
the review is subdivided into the different antineoplastic agents. The formulation of 
biopharmaceutical (macromolecules) and chemopreventive agents are not discussed as 
they are beyond the scope of this review. Summary tables from preclinical and clinical 
studies discussed in this review are presented in Tables 2, 3 and 4. 
 
1.1.2.1. Methotrexate 
Although not used alone for the primary treatment of lung cancer, methotrexate 
has been used as proof of concept for the inhalation delivery of chemotherapeutic agents 
using a pMDI delivery system.[58] Chlorofluorcarbon (CFC)-free formulations were 
prepared by cryomilling methotrexate, with or without Poloxamer 217 as a physical 
mixture. The low solubility of this drug in 10% ethanol/hydrofluoroalkane (HFA) 134a 
gave rise to a suspension dosage form. As investigated by X-ray diffraction, the grinding 
process did not alter the crystalline drug morphology. The first evident result from this 
study is that cryomilling only was not an effective method to reduce particle size for 
pulmonary delivery of methotrexate. The highest Respirable Fraction (RF) was achieved 
by taking the cryomilled particles and further processing by sieving (5 µm sieve). The 
values were as high as 35% RF for this formulation, while non-sieved preparations did 
not greatly vary from about 15% RF, regardless of grinding media and duration of 
process. Respirable fractions were defined as the percentage of particles deposited in 
stages of an Andersen cascade impactor with diameter less than 4.7 μm, to the total 
amount of drug emitted from the device (including all impactor stages, throat and 
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actuator). These results show that characterization of particle size distribution prior to 
formulation is highly beneficial to assess the potential to deliver the drug to the lungs. In 
general, the formulations presented MMADs of 2.2 to 3.2 μm and GSDs greater than 2. 
Undoubtedly, a greater reduction in particle size would be necessary to decrease GSD 
and consequently improve the respirable fraction results. Nevertheless, with this model 
anticancer drug, the investigators found in vitro cytotoxicity results of greater than 50% 
cell kill and comparable results between aerosolized and non-aerosolized doses were 
obtained. This outcome was sufficient to encourage further investigation of the 
pulmonary route for the delivery of other chemotherapeutic agents.  
 
1.1.2.2. COX-2 inhibitors 
The aerosol characteristics of different combinations of anticancer agents and 
selective COX-2 inhibitors against NSCLC cell lines have been examined for the in vitro 
cytotoxicity. For these studies, aerosolized nimesulide and aerosolized celecoxib have 
been formulated to evaluate cytotoxicity potentiation in conjunction with, respectively, 
doxorubicin and docetaxel.[59, 60] The COX-2 inhibitors nimesulide and celecoxib are 
practically insoluble in water and slightly soluble in ethanol.[61] After a solubility study 
in both HFAs 134a and 227 of the drug to be aerosolized, solution formulations for pMDI 
delivery were prepared. Water soluble drugs can be simply dissolved in an aqueous 
mixture prior to nebulization. Alternatively, solutions may be prepared for pMDI devices, 
by dissolving the drug in the propellant. In these cases, given the relatively recent change 
of propellant type from CFC to HFA,[62] it may be necessary to have a co-solvent (to 
dissolve the drug) that is miscible with HFA. Ethanol can often fulfill these two 
requirements. Stages 3 to 6 of the cascade impactor (particles with cutoff diameters of 
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less than 4.7 µm) were used to assess respirable fraction. The formulations, the devices 
and the particle size characterization are shown in Table 2.  
The formulations of COX-2 inhibitors presented in Table 2 demonstrated feasible 
MMADs for drug delivery to the lungs, although with a relatively broad GSD for 
nimesulide formulation. From the studies with celecoxib, the formulations with higher 
drug loading have presented higher medication delivery. Also, it has been previously 
shown that as ethanol concentration decreases, either in HFA 134a or 227, the fine 
particle fraction increases.[63] This event has also been observed for aerosolized 
celecoxib formulations. Importantly, the aerosolization process has been reported not to 
alter the activity of the aerosolized drug. In addition, these two formulations presented 
satisfactory physical and chemical stability for 1 month at room temperature, and 
elevated temperature (40 ºC). The celecoxib formulation also presented a similar stability 
at room temperature only. The aerosolized selective COX-2 inhibitors have shown to 
satisfactorily decrease IC50 values of the aforementioned anticancer agents in lung cancer 
cell lines. But, are COX-2 inhibitors potent enough to be delivered via pMDI? In the case 
of COX-2 inhibitors, each actuation was able to deliver about 50 to 100 µg of drug. From 
this, only about 40 to 50% was potentially able to reach the deep lungs. That means that 
at least 20 actuations may be needed to achieve about 1 mg of COX-2 inhibitors to the 
lungs. Once more, we emphasize the dose restriction of pMDI delivery of anticancer 
drugs. Therefore, the capability of pMDI formulations of COX-2 inhibitors to effectively 
treat lung cancer in conjunction with other chemotherapeutic agents is yet to be 
answered. 
Celecoxib has also been prepared as an emulsion for inhalation delivery via 
nebulizer.[64] Based on a previous study,[65] the antitumor activity was tested in a 
human orthotopic NSCLC xenograft model. Aerosolized celecoxib was compared with 
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oral delivery, both concurrently with an intravenous administration of docetaxel. 
Celecoxib (5 mg/mL) was dissolved in ethanol and polyethylene glycol (PEG) 400 before 
emulsification with molten D-α-tocopheryl polyethylene glycol 1000 succinate (vitamin 
E TPGS). Vitamin E TPGS has previously demonstrated to increase drug bioavailability 
via oral administration by inhibition of the multidrug resistant transporter P-
glycoprotein.[66] The expression of P-glycoprotein in NSCLC patients is activated 
during chemotherapy.[67] Therefore, the use of vitamin E TPGS could potentially be 
more important than simply acting as an emulsifier agent. On the other hand, to our 
knowledge, there has been no report so far on the safety of pulmonary administration of 
this excipient. A Pari LC Star® jet nebulizer was used to generate particles with MMAD 
of 1.68 μm and GSD of 1.36 as measured by a Mercer Cascade Impactor (airflow rate not 
reported). Female Nu/Nu mice were exposed to aerosolized drug using a nose-only 
inhalation chamber for 30 minutes per day during 28 days. According to the authors, the 
estimated total deposited dose was 4.56 mg/kg/day, this calculation was based on 
concentration of drug in aerosol volume, volume of air inspired by the animal during 1 
min, estimated deposition index for mice and duration of treatment. Compared to a 
control group, reduction in the tumor volume was 61 and 54%, following aerosolized and 
oral treatments in combination with IV docetaxel, respectively. The accuracy of the 
estimated deposited dose is questionable. To explain, this dispersion system may be 
considered to present similar thermodynamic characteristics to that of liposomes. Due to 
the stress applied, liposome structure is significantly disrupted by jet nebulizers.[68] In 
the study of aerosolized celecoxib emulsion, the system behavior under aerosolization via 
jet nebulizers was not evaluated. This could raise questions as whether the drug was 
homogeneously released from the device throughout the duration of exposure. 
Nevertheless, other factors are very relevant from the formulation aspect and therefore 
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should also have been evaluated, such as the particle size distribution of the emulsion and 
its stability over time. 
 
1.1.2.3. Gemcitabine 
In combination with other antineoplastic agents, gemcitabine has shown 
effectiveness against a number of types of cancer, including advanced stages of 
NSCLC.[69] A salt form is currently commercialized under the trade name Gemzar® 
(Gemcitabine HCl) by Eli Lilly. Gemzar® is supplied as a freeze-dried powder with 
mannitol and sodium acetate, hydrochloric acid, and sodium hydroxide as excipients. 
Reconstitution with saline gives the final solution of this marketed injection formulation, 
with pH ranging from 2.7 to 3.3. Clinical and toxicological studies have been performed 
by drug aerosolization using this solution for injection in mice, rats, dogs and 
baboons.[70-74] The most important features of these studies can be seen in Table 3. 
The accuracy in the characterization of aerodynamic profile and drug deposition 
in some of these studies are questionable, particularly as one of the studies fails to 
mention the specified type of nebulizer used. Nonetheless, these gemcitabine preclinical 
studies give very significant therapeutical and toxicological data about inhaled solution 
for both primary and metastatic lung cancer. For instance, five weekly treatments of 8 
mg/kg to mice bearing human orthotopic NSCLC tumors were able to significantly 
inhibit the primary cancer growth. Meanwhile, increasing the dose to 12 mg/kg caused 
acute and fatal pulmonary edema events.[71] Similarly, lung metastases incidence was 
significantly reduced by doses of 1.0 mg/kg biweekly for 6.5 weeks.[70] Also, 
gemcitabine has been shown to be safe in rats and dogs at a MTD of 9 weekly treatments 
of 4 mg/kg and 20 biweekly treatments of 2.38 mg/kg, respectively.[72, 74] 
Pharmacokinetic studies in baboons have shown that tmax is achieved at approximately 10 
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minutes after starting nebulization (in this case, still during inhalation process).[73] After 
60 minutes, the drug was undetectable in the plasma; not a surprising result, given the 
low partition coefficient of gemcitabine (log P = -1.24).[75] 
Despite the number of studies in different species, so far, only the commercialized 
injection formulation of this anticancer agent has been investigated for the possibility of 
aerosolization to the lungs. With an acidic pH, the desired water dissolution of 
gemcitabine for injection (pKa = 3.58) is assured.[76] When inhaled, the prompt drug 
availability for lung absorption will highly contribute to a rapid pulmonary clearance by 
diffusion mechanism. On one hand, the hydrophilic characteristic of gemcitabine 
provides an advantageous lung residence time as compared to its lipophilic 
chemotherapeutic counterpart. On the other hand, more investigation exploring its water 
solubility properties are yet to be performed so as to ascertain the full potential of 
gemcitabine to treat lung malignancies. 
 
1.1.2.4. Doxorubicin 
Doxorubicin is a relatively lipophilic and water soluble drug that has long been 
used for the treatment of pulmonary malignancies. Based on its physicochemical 
characteristics, namely water solubility and partition coefficient (see Table 1), one would 
expect a prompt absorption of doxorubicin by the lungs. 
A DPI formulation was studied to evaluate the in vitro cytotoxicity of doxorubicin 
nanoparticles.[77] The drug was incorporated into poly(butylcyanoacrylate) nanoparticles 
by emulsion polymerization and coated with polysorbate 80 (0.5 % v/v). 
Poly(butylcyanoacrylate) had previously been used for the intravenous administration of 
anticancer drugs for the treatment of brain tumors.[78] Inclusion of a surfactant coating 
has been shown to facilitate particles translocation across the capillary barrier.[79] The 
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doxorubicin-loaded nanoparticles were then mixed with lactose (carrier) in a spray 
freeze-drying procedure. This manufacturing process, which may be scaled up, was able 
to yield a loading capacity of 1.39 μg of doxorubicin per mg of powder. The results from 
this study showed that doxorubicin-loaded nanoparticles of 173 ± 43 nm mean particle 
sizes were effectively incorporated into a 10 ± 4 μm overall lactose geometric particle 
size. Using a passive DPI, the MMAD obtained was 3.41 ± 0.22 µm, as measured at 60 
L/min by Mark II Anderson Cascade Impactor. This powder formulation has 
demonstrated an increased cytotoxicity against A549 and, more significantly, against 
H460 lung cancer cell lines as compared to free drug. However, the presence of 
polysorbate 80 in the formulation does not provide confirmation that endocytosis of 
doxorubicin-loaded nanoparticles has occurred more readily due to drug particle size 
alone or by some improvement in the translocation of these particles across the cancer 
cell barrier. Interestingly, the blank formulation (drug-free nanoparticles) showed certain 
levels of cytotoxicity as well. While similar low levels of polysorbate 80 has been safely 
aerosolized to mice,[56] to our knowledge, there has been no report to date verifying the 
safety of delivering poly(butylcyanoacrylate) to the lungs. Therefore, despite the 
encouraging cytotoxicity and aerodynamic results as well as the possibility of process 
scale up, this formulation may find restrictions for pulmonary delivery. Nevertheless, 
more studies are yet to be performed in order to define the feasibility of nanoparticle 
uptake by cancer cell lines.[42]  
Dogs with naturally occurring primary or metastatic lung tumors were also treated 
with doxorubicin.[80] A solution was prepared by dissolving the drug in 20% ethanol at a 
concentration of 16 mg/mL. Under anesthesia, the dogs were exposed to the drug during 
a certain period of time by means of a Pari LC® jet nebulizer coupled to an endotracheal 
tube; this special assembly was designed to prevent fugitive aerosolization. The animals 
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received 6 treatments of 3 mg of doxorubicin once every 2 weeks. The dose calculation 
was based, not only on stabilized minute-volume of respiration under light anesthesia, but 
also assuming a body surface area of 1 m2 (as a result small dogs were naturally exposed 
to a higher drug concentration in this study). Although 22% of the treated dogs (n = 18) 
achieved partial responses (a tumor volume reduction greater than 50%), no formulation 
characterization was reported. This lack of information does not allow us to evaluate 
whether the outcomes were maximized due to formulation and device performances. For 
instance, airflow rates, viscosity and surface tension may all influence the aerosol output 
from jet nebulizers.[81] Nevertheless, no systemic toxicity was evident, while pulmonary 
toxicity was observed (mainly as a cough).  
The encouraging outcomes from the previous study have set the stage for a 
clinical trial. Doxorubicin was selected to be nebulized in patients with primary or 
metastatic tumors to the lungs for a phase I study.[82] The inhalation solution was 
provided at 16 and 24 mg/mL in ethanol:water 1:4 (pH 3). The aerosolization system 
consisted of a Pari LC Plus® jet nebulizer in a sealed, mouth-only inhalation apparatus 
(OncoMyst® model CDD-2a). As a precaution in this study, a demistifier tent with a 
HEPA filter was setup to protect the health care provider from potential fugitive aerosol. 
The dose was calculated on the bases of inhaled technetium-99m deposition and 
scintigraphy, and a limited pharmacokinetic evaluation was performed in this study. Due 
to the required number of breaths in the aerosolization system, administration of higher 
drug concentrations resulted in dosing times as long as 45-60 minutes. During this period, 
no drug plasma levels were analyzed. Maximal plasma concentration was observed at the 
first sampling point, 5 minutes after finishing treatment. Similarly to the study in dogs, no 
systemic toxicity was observed while cough was the most frequent adverse event 
observed in the patient population. Dose limiting pulmonary toxicity was observed at 7.5 
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mg/m2 every 3 weeks. Therefore, dose escalation of this formulation by pulmonary 
administration has been suggested not to be adequate. Despite the nominal nebulizer 
capability to generate aerosol particles of 2-3 μm mentioned by the authors, again, the 
aerodynamic characteristics of the formulation were not confirmed by in vitro analytical 
tests. On one hand, the acidic solution (pH 3) present ionizes the doxorubicin (pKa = 
8.34) increasing the drug solubility.[83] On the other hand, the drug lipophilicity favors 
diffusion across membranes, considering the partition coefficient of doxorubicin (log P = 
0.65). As a result, the fraction of unionized drug would be quickly absorbed and a 
relatively low lung residence time would be expected. Therefore, the long dosing time 
required to administer high drug concentrations may have biased these pharmacokinetic 
data. Another important aspect from this formulation is its pH. Previous studies have 
demonstrated that acidic aerosols stimulate coughing and increase lung resistance, with 
consequent bronchoconstriction.[84-86] In this study, pulmonary toxicity has been 
observed at high delivered doses, in so far as higher volume of liquid formulation was 
deposited. As the formulation pH increases the drug solubility, the acidic solution evokes 
airway irritation that may potentially be aggravated by increase in volume of liquid 
formulation deposited from the aerosol. Therefore, this formulation parameter appears as 
a confounding factor that may compromise the determination of the MTD of doxorubicin. 
Doxorubicin is one of the few drugs to advance from preclinical studies to clinical 
trials for the pulmonary delivery to treat lung malignancies. Whether its intrinsic dose 
limiting toxicity may impose restrictions to its use as a single chemotherapy treatment 
modality is yet to be determined. In our opinion, formulations containing doxorubicin 
should be more appropriately designed and characterized prior to defining their intrinsic 
dose limiting toxicity, before an adequate assessment of the associated benefits of 
inhalational therapy. This will ultimately determine the role of this chemotherapeutic 
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option as single modality treatment. Furthermore, a neoadjuvant strategy is yet another 
option that still needs to be investigated prior to defining the role for pulmonary delivery 
of doxorubicin in lung cancer treatment. 
 
1.1.2.5. Farnesol 
Farnesol is a lipophilic (log P = 5.31) and very slightly water soluble drug that 
induces apoptosis in lung carcinoma cells.[87-89] An emulsion of this anticancer agent 
was prepared for nebulization by mixing farnesol (10.5 mg/mL) with polysorbate 80 (0.5 
mg/mL) in a 20% v/v ethanol/normal saline mixture.[90] Emulsion stability was verified 
by storing a mixture of farnesol, ethanol and polysorbate 80 at 4 ºC for up to 14 days, 
with saline added just before use. The aerodynamic profile of this formulation was 
measured by a Phase Doppler Anemometer coupled to a breath simulator (average 
airflow rate of 18 L/min and tidal volume of 0.75 L).[91] According to this method, Pari 
LC Star® and LC Plus® nebulizers were able to generate aerosol particles with MMADs 
of 4.96 μm and 6.87 μm and GSDs of 1.48 and 1.67, for each nebulizer respectively. 
Also, the nebulization efficiency of this emulsion was estimated to be approximately 30% 
deposited drug out of the total volume submitted to aerosolization for either device. 
Finally, in vitro cytotoxic effects of nebulized farnesol were observed against A549 and 
H460 lung cancer cells. In our opinion, these data suggest that a low drug deposition in 
vivo as well as fast lung clearance may be expected. Firstly, only one-third of drug 
amount from the emulsion volume was effectively aerosolized by these jet nebulizers 
Considering solution dosage forms, both jet and ultrasonic nebulizers have similar 
performances to deliver the drug to the lungs. When it comes to suspensions though, drug 
aerosolization is more effective using jet nebulizers since the ultrasonic effect may 
aerosolize empty droplets (no drug present).[92] Now, fragile disperse systems like 
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emulsions may be vastly disrupted by the high energy imparted by jet nebulizers. 
Therefore, the amount of drug that ends up reaching the deep lungs may be compromised. 
Secondly, the aerodynamic results of this system are not very favorable for deposition in 
the lower airways. With MMAD values varying from 5 to 7 μm, most of the aerosol 
droplets would be deposited in the throat and upper airways, subsequently being 
swallowed. Finally, farnesol is a very lipophilic drug, with a log P value considerably 
higher than zero; an almost instantaneous absorption is more likely to occur.  
In case of poorly-water soluble drugs, emulsification may be a preferred strategy 
for delivering the agent to the lungs. However, some important formulation 
characteristics should always be evaluated. The particle size distribution of the emulsion 
internal phase may be determined by the energy input during nebulization process. The 
emulsion particle size may greatly influence the final droplet size aerosolized. Also, it is 
important to determine whether the type of device chosen for aerosolization will be able 
to gently deliver the drug, without disrupting the emulsion formulation. In addition, the 
excipients and production method applied may influence the short and long-term 
emulsion formulation stability. In selecting the excipients, the scientist should strive to 
extend the drug release from the delivery system while being aware of possible toxic 
effects due to low clearance rates. Considering its physicochemical properties, the 
potential of farnesol as an anticancer agent to treat lung malignancies via inhalation may 
be improved with different formulation designs.  
 
1.1.2.6. Paclitaxel 
In the study of primary or metastatic lung tumors naturally occurring in dogs 
being treated with doxorubicin, a paclitaxel solution was also investigated.[80] The taxol 
(75 mg/mL) was dissolved in a mixture of polyethylene glycol 200 and ethyl alcohol. 
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Using the same drug deposition system and regimen, the doses ranging from 10 to 90 
mg/m2 were administered with no signs of systemic toxicity. As opposed to doxorubicin, 
local toxicity was not evidenced either. Out of 15 treated dogs, only one partial and one 
complete response were observed. The drug plasma levels after aerosolization for both 
doxorubicin and paclitaxel were less than one-tenth of plasma levels observed in normal 
dogs after intravenous injection of therapeutic range doses. However, the lack of 
information about the formulation characteristics makes it difficult task to speculate on 
the performance of this solution. 
Drugs formulated within biodegradable polymers can present pharmacokinetic 
profiles with a delayed and/or extended release compared to the free drug. This sustained-
release system can be controlled based on size and porosity of prepared spheres.[93] The 
feasibility of delivering anticancer agents within this type of dosage form has been 
investigated using paclitaxel.[94] Microspheres of the polymer poly-(L-glutamic acid) 
(PGA) were loaded with 20% (w/w) paclitaxel (PGA-PTX). For comparison purposes, 
0.6% w/w paclitaxel was dissolved in cremophor, making a similar taxol solution to the 
commercially available product (Taxol®, Bristol-Myers Squibb). Aerosol output ratio 
tests demonstrated that PGA-PTX formulation was able to deliver 80-400 times faster 
than taxol solution. Although the drug was only deposited in mice lungs via intratracheal 
injection, the aerosol characteristics was evaluated when generated by a Salter Labs® 
8900 jet nebulizer at 5 or 9 L/min. Using a 7-stage cascade impactor, the authors reported 
that approximately 50% (wt) of the aerosolized polymer formulation presented droplets 
with less than 5 μm. However, the amount of drug in each stage was measured by 
weighting the filters pre- and post-aerosolization instead of using an analytical method 
such as an UV spectrophotometer. Notably, this can render significant measurement 
errors. Firstly, the authors did not consider the differences in concentration from the taxol 
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solution (6 mg/mL) to the PGA-PTX formulation (not specifically mentioned, but 
ranging from 3 to 25 mg/mL). Secondly, the instrumental errors generated by the balance 
to measure formulation amounts in the milligrams were neglected. Therefore, the aerosol 
characteristics of this formulation are highly questionable. Nevertheless, the authors 
reported a concentration- and time-dependent in vitro cytotoxicity against H358 and 
H460 NSCLC cell lines. In addition, after single intratracheal administration, a MTD of 
30 mg/kg (paclitaxel equivalents) was observed. Three weekly doses of taxol solution 
(2.5 mg/kg) or PGA-PTX (20 mg/kg paclitaxel equivalents) were both sufficient to 
significantly improve survival at about 135 days. Although the results may seem 
encouraging for further preclinical studies with pulmonary delivery of this formulation, 
the authors did not consider a potential accumulation of the polymers in the lungs. Due to 
a 10-fold greater dose of PGA-PTX needed to provide a similar survival as with the taxol 
solution, the dosage regimen outlines multiple administrations needed. Therefore, the 
PGA lung accumulation may be significantly high and could consequently compromise 
even more the pulmonary function of the lung cancer patients. 
The pharmacokinetics and the therapeutic efficacy of a liposomal paclitaxel 
aerosol have also been investigated against pulmonary metastases in a murine renal 
carcinoma model. Since the excipients used are mainly surfactants naturally occurring in 
the lung fluid (e.g. phosphatidylcholine), liposomes present a relatively low local 
toxicity. Also, given their lipophilic nature, formulations of this type are able to 
encapsulate poorly-water soluble drugs.[95] Liposomes of paclitaxel (10 mg/mL) were 
composed of dilauroylphosphatidylcholine (DLPC) at drug-to-lipid ratio of 1:10 (w/w). 
Both components were prepared in t-butanol and subsequently lyophilized.[96] Prior to 
use, the formulation was reconstituted with sterile water and vortexed until 
homogeneously dispersed. With this method to produce liposomes, scaling up is feasible. 
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However, as there was no energy input to form the liposomes (e.g. high pressure 
homogenization), it is not surprising that particle size analysis revealed a wide size 
distribution (2.0 to 25.3 μm). An Aeromist® jet nebulizer generated aerosols with an 
MMAD and a GSD of 2.2 μm and 1.9, respectively, as measured using an Andersen 
Cascade Impactor at 10 L/min. Interestingly, the shear force applied by the jet nebulizer 
was able to disrupt the liposomes during the nebulization process. The particle size was 
reduced drastically to less than 0.4 μm. Despite that, the authors estimated the dose to be 
of 5 mg/kg by chamber aerosol exposure for pharmacokinetic studies. Compared to 
intravenous injection, the AUC in the aerosol treated group was 26-fold higher, with 
distribution half life of only 0.71 hours. Nevertheless, treatment 3 times a week over 2 
weeks with paclitaxel-DLPC aerosolized liposomes, resulted in significant reduction in 
tumor number and an increased survival time compared to untreated and DLPC-only 
treated mice. These results were encouraging for further studies. 
Paclitaxel-induced resistance is related to over expression of plasma membrane 
glycoprotein (P-gp), which acts as an efflux pump decreasing the intracellular drug 
concentration. Cyclosporin A (CsA) has the capacity of reversing this resistance, and, 
when co-administrated with paclitaxel, CsA also acts as an inhibitor of cytochrome P450-
mediated metabolism (enzymes that are involved in the metabolism of this anticancer 
agent).[97] These findings and a dose-limiting toxicity not mentioned in the previous 
study prompted evaluation of the antitumor effect of co-administration of CsA and 
paclitaxel in the same animal model. Paclitaxel liposomes were prepared as mentioned 
above while CsA liposomes differed only by the drug to lipid ratio (1:7.5 w/w) and 
concentration (5 mg/mL). Similarly to the aerosol characteristics measurement in the 
study above, CsA-DLPC liposomes presented an MMAD of 1.6 μm and a GSD of 2.2. 
Chamber aerosol exposure provided an estimated dosage deposition of paclitaxel and 
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CsA liposomes to the lungs of 7.8 and 6.1 mg/kg, respectively. CsA/paclitaxel treated 
animals showed lung weights and tumor surface areas significantly lower than paclitaxel-
only and untreated groups. Dose escalation of CsA has shown to be more effective to 
decrease area and number of tumors. However, the treatment (3 times per week for 2 
weeks) had to be discontinued during toxicity studies due to expressive systemic toxicity 
(body weight loss).[98] 
In terms of safety, the use of phospholipids as excipients to aid the drug delivery 
to the lungs is a viable option. In addition, they have shown to improve particle migration 
to the lung periphery owing to the reduction in surface tension provided by these 
surfactants.[40] In theory, this applies especially to poorly-water soluble drugs, such as 
the taxols. However, the encapsulation efficiency of any method to produce liposomes is 
an issue that should always be addressed. Previous studies have shown that, using the 
same process with similar phospholipids, somewhat low encapsulation efficiencies were 
achieved at a constant drug concentration (<45%).[99] When seeking for a controlled 
release, not only the encapsulation efficiency becomes important, but the selection of 
phospholipids may be crucial. Transition temperatures of phospholipids are highly 
dependent on the saturation and extension of the carbon chain.[100] For instance, DLPC 
(12 saturated carbons) presents a transition temperature of about -1 ºC. At the 
temperature of the human body, the fluid nature of this surfactant will promptly release 
the drug. On the other hand, dipalmitoylphosphatidylcholine (DPPC – 16 saturated 
carbons), with a transition temperature of approximately 41 ºC, may control the drug 
release for the encapsulated drug. In the study above, the lipophilic nature of paclitaxel 
together with the fluid-like characteristics of DLPC at body temperature justifies the low 
lung residence time.  
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After it has been shown in vitro that paclitaxel efficacy is more related to 
exposure time than to increased dose, a conjugation of paclitaxel with fullerene (C60) was 
developed to sustain the release of the anticancer drug at the site of administration. 
Liposomes of paclitaxel-C60 conjugates have been formulated with DLPC similarly to the 
previous method. A mean diameter of 2.77 μm as measured by light scattering was 
determined for the fullerene-DLPC-paclitaxel liposomes. Cytotoxicity tests against A549 
lung cancer cell lines have demonstrated IC50 values similar to those of DLPC-paclitaxel 
liposomes.[101] Impressively, aerosolization of this excipient to the lungs 3 hours per 
day for 10 consecutive days has presented minimal toxicity. Even so, lung half-lives for 
nano- and microparticles of C60 were 26 and 29 days, respectively.[102] These results 
hold promise of increasing exposure time of the anticancer agent at a tumor site, although 
safety studies are warranted. Pharmacokinetic and antitumor activity studies of C60-
paclitaxel are still being performed in vivo by the same group. 
Conversely to previous studies of COX-2 inhibitors where docetaxel was studied 
along with aerosolized celecoxib, aerosolized docetaxel in conjunction with celecoxib has 
also been evaluated.[103] Considering the similarities in their physicochemical properties 
and formulation design, aerosolized docetaxel study will not be further discussed. The 
formulation and its characteristics are summarized in Table 2. 
 
1.1.2.7. Camptothecins 
Camptothecins are topoisomerase I inhibitor drugs that demonstrate significant 
toxicity, especially myelosuppression.[104] Camptothecin (CPT) and its likewise poorly-
water soluble derivative, 9-nitrocamptothecin (9NC), also known as rubitecan, were some 
of the first anticancer drugs to be aerosolized to animal lungs. Similarly to liposomal 
paclitaxel, CPT (10 mg/mL) and 9NC (100 mg/mL) were prepared with DLPC and their 
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anticancer effect tested against human lung cancer xenografts in mice. Following 
lyophilization and reconstitution, an Aerotech II® nebulizer operating at 10 L/min 
aerosolized the formulation into a whole body exposure chamber. In this study, the 
formulations were characterized for liposome encapsulation efficiency by Percoll® 
gradient analysis. In summary, the studies demonstrated that an increase in drug 
concentration required a higher proportion of lipids for efficient drug incorporation. 
Rubitecan concentrations varying from 0.1 to 1.0 mg/mL, in the nebulizer reservoir, 
resulted in MMADs ranging from 0.8 to 1.6 μm. The encapsulation efficiency of 9NC 
and CPT liposomes at a drug to lipid ratio of 1:50 (w/w) and 0.5 mg/mL were 
approximately 80%. To achieve high encapsulation efficiency, the drug concentration 
was compromised and these formulations were chosen to evaluate their anticancer effect. 
The MMAD of the 9NC formulation was 1.2 μm. Significantly reduced tumor growth 
was shown in animals receiving an estimated 9NC dosage of 76.7 μg/kg/day, 5 days per 
week for 35 days. CPT treated animals also presented decrease in tumor volume, 
although 9NC was more effective. Similarly to the liposomal paclitaxel formulation, a 
shear effect promoted a higher than 6-fold decrease in mean size of liposome after 
nebulization process. Nevertheless, this study also demonstrated that aerosol exposure of 
9NC liposomes were more effective to reduce tumor growth than by oral administration. 
This is a significant indication that the drug absorbed following oral administration, due 
to mice grooming has very little antitumor effect on lung carcinomas.[105] Finally, 
evaluation of the effect of delivery route using nose-only aerosol exposure or 
intramuscular administration indicated that the latter showed a significant decrease in 
tumor volume compared to untreated animals, however this was not as nearly effective as 
with nose-only aerosol exposure. Delivering the drug directly to the lungs has been 
shown therefore to be essential for the effective reduction in the tumor growth. No 
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myelosuppression signs were observed in this study, and 9NC liposomes have also been 
shown to be effective against murine melanoma and human osteosarcoma pulmonary 
metastases in mice.[106] 
Following this study, the authors reported the pharmacokinetics of CPT in mice 
after liposomal aerosol inhalation. The formulation containing CPT (0.5 mg/mL) to 
DLPC ratio of 1:50 (w/w) presented an MMAD of 1.6 μm and a GSD of 2.1, as measured 
using an Andersen Cascade Impactor. The same device model used previously 
aerosolized an estimated dose of 80.9 μg/kg after 30 minutes of nebulization. CPT 
concentrations in the lungs after aerosolization using either nose-only or whole body 
exposure chambers were up to 16-fold greater than that found in the blood. Intramuscular 
solution injection (233 μg/kg) provided only trace amounts of CPT that could be detected 
in the lungs, even 2 hours after administration when 80% of the drug had been released 
from the site of injection. The authors compared this aerosolization study with previous 
reports of camptothecin concentration in the lungs after oral, intravenous and 
intramuscular administration. Aerosol treated mice in 50-fold lower concentrations 
presented 7 to 10-fold higher concentrations in the lungs after 30 minutes of exposure, 
compared to the other routes of administration.[47] As discussed earlier, the doses 
reported may be the best estimation possible rather than an accurate measurement. 
Despite this, subacute toxicity of the 9NC liposome aerosol in beagle dogs was not 
observed after an estimated aerosol dose of 24.7 μg/kg/day, 5 days per week, for 8 
weeks.[107] DLPC-only liposomes were determined to be non-toxic as well. Following 
these results, a phase I study has shown that advanced pulmonary malignancy patients 
tolerated this treatment well in doses of 13.3 μg/kg/day, 5 days per week for an 8 week 
period.[108] However, the aerodynamic characteristics of the formulation were not 
reported in this case. Nevertheless, the doses were administered by a mouth breathing-
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only face mask with a HEPA-filtered airborne scavenging tent covering the patient and 
nebulization system, to protect the health care professional. Finally, the authors 
recommended the aforementioned dosage regimen for phase II studies, which have not 
yet been reported. 
Rubitecan liposomes of soybean lecithin and cholesterol were also formulated for 
different studies: in vitro release, biodistribution in mice and local toxicity in rats.[109] 
The thin-film hydration method was used, followed by filtration (0.45 µm) prior to 
lyophilization. The liposomes presented Z-averages of less than 200 nm as measured by 
dynamic light scattering. For the in vivo studies, a 9NC solution (0.25 mg/mL) was 
prepared in dimethyl sulfoxide (DMSO)/PEG400 mixture for comparison purposes. 
Although the authors failed to report the drug concentration and drug-to-lipid ratio of the 
liposomes, which limits the discussion herein, entrapment efficiencies greater than 90% 
were obtained before and after freeze-drying, as measured by centrifugation method. The 
sustained release properties of the formulation were also verified. Using the dialysis 
method, the drug release from the liposomes was 32.5% in 1 hour and approximately 
90% after 24 hours. Following intratracheal administration of 0.8 mg/kg, the 
biodistribution study in mice showed that the mean lung residence time of 9NC 
liposomes and solution was 1.24 and 0.37 hours, respectively. In addition, the sustained 
release formulation presented an AUC in the lungs 3.4-fold higher than 9NC solution, 
and 4.73 times when compared to that of an intravenous administration. Finally, 
intratracheal instillation of rubitecan liposomes demonstrated lower toxicity than the 
solution dosage form, as investigated by histological studies in rats. These results 
illustrate that the use of soybean lecithin and cholesterol may be a feasible option to 
improve lung residence time of anticancer drugs. Yet, aerodynamic characterization of 
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the nebulizer-formulation system followed by further preclinical studies is still needed to 
evaluate the potential of delivering this formulation to human lungs.[109] 
 
1.1.2.8. Cisplatin 
Platinum derivatives, such as cisplatin and carboplatin, are the most traditional 
drugs used for the treatment of lung malignancies. Sustained Release Lipid Inhalation 
Targeting (SLIT) Cisplatin has been investigated in a phase I study of aerosol dosage 
form for the treatment of primary and metastatic lung cancers. Liposomes of cisplatin (1 
mg/mL) were composed of DPPC and cholesterol at drug to lipid ratios of 1:16 and 1:7.5 
(w/w), respectively. Sodium chloride was present as iso-osmotic agent and to enhance the 
stability of cisplatin. The PARI LC Star® nebulizer generated aerosols at 15 L/min with 
an MMAD of 3.7 μm and a GSD of 1.9, as measured using a Next Generation Impactor 
(NGI) at 5 ºC and 15 L/min. The impactor refrigeration increases the relative humidity in 
the inner environment of the NGI to close to 100%, diminishing droplet evaporation prior 
to impaction.[110] In this study, the dose limiting toxicity (DLT) could not be reached 
after dose escalation using different strategies: increasing dose level, reducing interval 
between cycles, increasing number of nebulization sessions per day, and increasing 
amount of drug inhaled (by flow rate increment of the compressor). Although the 
liposome size distribution was not reported, the authors evaluated the dispersion stability 
under nebulization. Approximately 40-50% of total cisplatin is released from the 
liposomes during the aerosolization process. In this case, the cisplatin liposome structure 
is being partially disrupted due to the shear force generated by the jet nebulizer, as 
discussed earlier. Considering the physicochemical properties of cisplatin (water soluble 
and negative log P), one would expect a relatively slow systemic absorption of the free 
drug over time. With that, the supposed liposome capacity of slowly releasing the drug 
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may be confounded with the intrinsic characteristics of the antineoplastic agent. In 
addition, considering that the liposomes are not cleared by macrophages, it is uncertain 
whether any therapeutic effect may be elicited by the drug that remains encapsulated after 
deposited in the lungs. On the other hand, the liposomes may possibly be engulfed by the 
pulmonary macrophages, resulting in no systemic exposure of the anticancer agent, but 
no therapeutic efficacy either. Nonetheless, stabilization of the disease in 12 out of 17 
patients was the best overall response with this treatment.[111] As with doxorubicin 
treatment, long administration times were required for inhalational cisplatin therapy, 
which could reduce patient compliance. This may then impose an alternative criterion, as 
opposed to local and/or systemic toxicity endpoints. On the other hand, defining a 
tolerable administration time will certainly restrict high dose requirements for some 
antineoplastic drugs. Finally, the authors reported their intention to pursue further studies 
to define DLT with a higher cisplatin concentration in the liposomes (3 mg/mL) as an 
alternative strategy. Lately, a phase Ib/IIa study was published with relapsed/progressive 
osteosarcoma metastatic patients. No systemic, but only minor local toxicity was 
observed. The drug was well tolerated by heavily pre-treated patients with one year 
cumulative doses of up to 1020 mg. After the same time period, 2 out of 14 patients 
remained pulmonary disease free.[112] The DLT of this formulation is yet to be 
accurately determined. Furthermore and despite these encouraging results, the 
effectiveness of this formulation is still to be proven throughout the upcoming phases of 
the pharmaceutical product development process. 
 
1.1.2.9. 5-Fluoruracil 
The neoplastic agent 5-Fluorouracil (5-FU) has long been used for cancer 
treatment, although not the first line drug to treat lung malignancies. Liposomes, 
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microspheres and Lipid Coated Nanoparticles (LNP) of 5-FU have been prepared to 
investigate their sustained-release properties, as measured by microdialysis.[113] Lipid 
coated nanoparticles consist of a drug-loaded core coated by a lipid shell; the dosage 
form is dispersed in water in the presence of a surfactant. The submicronized hydrophilic 
core can contain either the drug alone or in combination with other excipients.  
Firstly, DPPC and hydrogenated soy phosphatidylcholine (HSPC) liposomes were 
prepared by the thin film hydration method, and cholesterol was included to further 
sustain the drug release. Also evaluated was whether the presence of negatively charged 
lipids in some formulations, such as dipalmitoyl phosphatidic acid (DPPA) and 
dipalmitoyl phosphatidylglycerol (DPPG), would promote physical stability by inhibiting 
liposome aggregation and fusion. Extruded liposomes with vesicle diameter of 
approximately 0.5 μm presented a higher release constant from a first-order release model 
than nonextruded liposomes. The presence of DPPA was effective in decreasing the 
release rate of extruded liposomes, whilst it was not able to provide the same effect in 
nonextruded preparations. Among the various liposome formulations studied, drug 
loading was not higher than 7% w/w (measured by centrifugation method) and the drug 
release was extended to about 8 hours. Based on these results and considering the drug 
lipophilicity, the authors estimate drug administration three or four times daily by 
inhalation, deeming this formulation ineligible for sustained-release purposes. 
In this same study, polymeric microspheres were formulated by spray drying 
different proportions of the following copolymers: poly-(lactide-co-glycolide) (PLGA), 
poly-(lactide-co-caprolactone) (PLCL) and poly-(lactide) (PLA). In this study the drug 
loading was approximately 8% w/w and the particle size, characterized by light scattering 
of the drug in suspension, was 1.2 to 1.5 μm. Based on microdialysis measurements of 5-
FU, a release constant was calculated from a first order release model. The drug released 
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in 24 hours was about 70 to 90% of the loaded dose. The results also demonstrated that 
an increase in the lactide moiety of the polymer progressively decreased the 5-FU release 
from the microspheres. Microspheres of 5-FU within PLA presented the longest duration 
of release (>32 hours). Importantly, the low 5-FU loading capacity (8% w/w) of this 
dosage form would require a high amount of polymer to be deposited into the lungs of 
cancer patients, especially following repeated administrations. The complete degradation 
time of PLA and PLGA polymers have been reported to be relatively high for this 
application.[114] Therefore, unknown toxicity and respiratory function-related 
consequences, due to cumulative deposition of these polymers in the lungs, has thus far 
prevented further development for the delivery of 5-FU microspheres to the lung. 
Finally, LNPs of 5-FU were prepared by spray drying the drug with poly-
(glutamic acid), poly-lysine, or lactose to form the dosage form core. These cores were 
further spray dried with various combinations of lipids (tripalmitin, tristearin, cetyl 
alcohol, and stearyl alcohol) to form an outer shell. The drug, released over 24 hours, was 
about 70 to 90% of the loaded dose for the different formulations studied, with core and 
total LNP diameters of 500 and 1000 nm, respectively. Based on the release constants, 
the most appropriate combination of core and shell materials for sustained-release 
aerosolization formulation was poly-(glutamic acid):5-FU (4:1), and tripalmitin:cetyl 
alcohol (2:1). The predominance of naturally occurring surfactants (e.g. triglycerides) in 
this dosage form alleviates the concern about low lung clearance rates of polymers. Thus, 
although it presented as low drug loading as microspheres (5% w/w), the LNPs of 5-FU 
were chosen to be further studied by the authors. The myelosuppression and bone marrow 
toxicity caused by 5-FU is expected to be overcome by inhalation delivery of this 
anticancer agent loaded with LNPs (5-FU LNP). Also, a low release rate of this dosage 
form would provide a sustained-release delivery system for aerosolized drugs.[113] 
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Following this, investigation of influence of core diameter and lipid shell 
thickness suggested the latter to be the rate limiting step for the release of 5-FU. Based on 
this, the authors have developed a release model from polydispersed cores and shells 
consisting of a sequential zero-order/first-order kinetics. Accordingly, a delivery system 
consisting of 600 nm diameter poly-(glutamic acid):5-FU (4:1) cores and 200 nm thick 
tripalmitin:cetyl alcohol (2:1) shells was chosen for in vivo studies in hamsters. The 
particle size of this formulation measured by dynamic light scattering was 1.02 ± 0.26 
μm. From a diluted dispersion, an ultrasonic nebulizer (model not specified) generated 
aerosol droplets that were subsequently dried to the drug particle unit (reflux drying 
process). The formulation aerodynamic properties were then measured using an Andersen 
cascade impactor (airflow not reported). The MMAD was 1.15 μm with a GSD of 2.15 
and neither the reflux drying process nor the ultrasonic nebulization demonstrated an 
influence on the release rate. Hamsters in whole body aerosol exposure units presented 
estimated drug deposition in the lungs as high as 3.4 ± 0.3%, based on nebulizer output 
rate and respiratory minute volume.[115] 
Next, fluorescein isothiocyanate dextran (FITC-dextran) was added to the 
formulation and hamsters were exposed to a nose only aerosol chamber for an eight-
component pharmacokinetic modeling study. Separate HPLC analysis of FITC-dextran 
and 5-FU ensured distinction of entrapped and released 5-FU. LNPs demonstrated a 5-FU 
peak concentration of 0.13 μg/g at 1.02 hours. In addition, the half-life of LNPs in the 
lungs was 4.95 ± 0.38 hours with an almost complete clearance in 24 hours. Using 
pharmacokinetic modeling, the authors estimated that the effective dose (0.065 to 0.13 
μg/g, for DNA synthesis inhibition) would be maintained for up to 5.4 hours. The 
pharmacokinetic model used also predicted that, using this route of administration, lung 
levels would be 5.5 times higher than the systemic circulation.[116] In their conclusion, 
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the authors discuss that, when considering greater than 20% drug deposition (which can 
easily be achieved by modern medical aerosol devices) doses of about 100 mg can be 
translated to humans.  
This thorough 5-fluorouracil formulation study is a great illustration of how the 
dosage form may potentially improve the drug delivery to the lungs. Selection of 
excipients combined to careful assessment of drug characteristics and, consequently, well 
elaborated formulations are crucial to achieve performances that will indeed explore the 
full antineoplastic potential of each drug. However, further studies are warranted to 
confirm these predicted pharmacokinetic modeling data. 
 
1.1.3. Conclusions 
Lately, there has been a shortage in new drug discovery to aid more effective 
treatment for pulmonary malignancies, which has translated into a poor prognosis for 
lung cancer patients. Inhalation chemotherapy can noticeably target the disease site to 
treat lung malignancies. By delivering appropriate chemotherapeutic agents to the 
specific disease site, at the proper dose, at a convenient and appropriate interval may lead 
to better patient outcomes.  
Clinical studies have shown improved drug tolerability via pulmonary 
administration, consequently enabling higher MTDs to be achieved. Despite that, 
oncologists may decide to insist on continuing systemic chemotherapy due to the high 
dissemination profile of lung cancer. For this reason, improvements in the early diagnosis 
of the disease are highly desirable for the potential success of aerosol delivery of 
anticancer agents. To date, the results from the early clinical development with inhaled 
chemotherapeutics have not yet justified the choice of this type of therapy over systemic 
administration. Notably, this is in part due to the nature of patient selection in these early 
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phase clinical trials, where extensive disease patients that in general had previously failed 
treatments with similar compounds were enrolled. In addition, significant issues remain 
to be understood in order to facilitate properly designed aerosol formulations of 
anticancer agents: 
A. The traditional MTD methods clinically used may not be adequate to establish the 
required lung dose of inhaled chemotherapeutics. For instance, pulmonary toxicity 
may be confounded by disease progression. In addition, lung doses that require 
unreasonably long administration times may be considered “no-go” during early 
phases of pharmaceutical development; 
B. An appropriate parameter to correlate a pharmacokinetic profile and a 
pharmacodynamic response is yet to be determined (e.g. peak levels in the lungs, 
AUC or alternatively a minimum lung concentration akin to an IC50); 
C. Obstacles to drug penetration in solid tumors following pulmonary administration 
may impose significant barriers to treatment efficacy. For instance, the delivery of 
drug nanoparticles to the tumor vicinity may not be as effective as the beneficial 
EPR effect achieved when nanoparticles are systemically administered. Also, other 
characteristics of the particles, such as charge and shape, may also affect tumor 
penetration. If tumor penetration cannot be surpassed, neoadjuvant therapy may still 
benefit from inhalation chemotherapy, as well as the treatment of more diffuse 
forms of cancer, such as bronchoalveolar carcinoma; 
D. Targeting the aerosol delivery site within the respiratory system may impose 
increased complexity. As the aerodynamic particle size predominantly determines 
drug deposition, tumors located anywhere from the trachea/main bronchus to 
peripheral lung regions will require different challenges. The capacity to deliver the 
formulation to peripheral lung regions occupied by the disease is a different 
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challenge than that of avoiding the mucociliary clearance of particles when 
targeting tumors close to the trachea; 
E. An antineoplastic agent suitable for pulmonary delivery may need to be selected 
based on proper physicochemical properties (e.g. solubility, log P), and 
pharmacodynamic characteristics (e.g. required lung dose, sensitivity of cancer cells 
to drug, etc.). A balance of these factors may be added to the right choice of device 
and excipients used in the formulation to provide the proper pharmacokinetic 
profile (e.g. lung levels, pulmonary drug clearance, etc.) and therefore to achieve 
the desirable therapeutic efficacy. 
 
Even with these challenges, the formulation development of inhaled anticancer 
agents appears to be an exciting and emergent field that must be further and more 
extensively explored. As shown in this review paper, many dosage forms have been 
studied for the delivery of anticancer agents using pulmonary administration. Despite 
these attempts, in our opinion, the results are unsatisfying from a formulation standpoint. 
Before considering preclinical and clinical trials, a formulation scientist, as part of a 
multi-disciplinary team must consider the different formulation designs applied to the 
different routes of administration; each one with its own idiosyncrasies. In the same way 
that an oral formulation is not likely to be intravenously administered, a pulmonary 
dosage form should not be based on formulations for other routes of administration. An 
ideal dosage form depends highly on the physicochemical properties of the drug and the 
method of aerosolization that will be used. In addition, safety, tolerability and clearance 
of the excipients chosen must be considered. Therefore, the formulation for each 
antineoplastic agent should be carefully designed according to these aspects. 
Consequently, inappropriate or incomplete characterization of aerosolization performance 
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can mislead the results from inhalation chemotherapy studies. As a result, the formulation 
must be thoroughly characterized in order to ensure the expected dose is delivered to the 
lungs. Without considering the full aspects of formulation design and characterization, 
any conclusions made about the future of inhalation therapy are deprived of the potential 
that this type of therapy may render to treat lung malignancies. 
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1.2. INFLUENCE OF PARTICLE SIZE ON REGIONAL LUNG DEPOSITION – WHAT 
EVIDENCE IS THERE? 
 
Abstract 
The understanding of deposition of particles in the respiratory tract is of great 
value to risk assessment of inhalation toxicology and to improve efficiency in drug 
delivery of inhalation therapies. There are three main basic mechanisms of particle 
deposition based primarily on particle size: inertial impaction, sedimentation and 
diffusion. The regional deposition in the lungs can be evaluated in regards to the 
aerodynamic particle size, in which particle density plays a significant role. In this part of 
the review, we first introduce the available imaging techniques to confirm regional 
deposition of particles in the human respiratory tract, such as planar scintigraphy, single 
photon emission computed tomography (SPECT) and positron emission tomography 
(PET). These technologies have widely advanced and consequently benefited the 
understanding of deposition pattern, although there is a lack of lung dosimetry techniques 
to evaluate the deposition of nanoparticles. Subsequently, we present a comprehensive 
review summarizing the evidence available in the literature that confirms the deposition 
of smaller particles in the smaller airways as opposed to the larger airways.  
 
1.2.1. Introduction 
Particles are deposited in the respiratory tract when they are removed in a 
definitive fashion from the flow streamline generated by the breathing maneuver. 
Understanding this process and the factors influencing particles settlement in the surface 
of specific regions of the airway tree has implications to the development of 
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pharmaceutical inhalation products for aerosol therapy and to risk assessment of air 
pollutants that concerns toxicology. 
Besides pulmonary physiology of patients (e.g. breathing pattern and lung 
geometry), particle deposition is also known to be influenced by aerosol 
characteristics.[117, 118] Namely, the physicochemical properties of inhaled aerosols 
that can determine deposition are: size, size distribution, shape, charge, density and 
hygroscopicity.[119] In the field of aerosol medicine, particle size is a formulation design 
variable that can be engineered accordingly, aiming the development of pulmonary drug 
delivery systems.[35, 120] As we can examine from the mechanisms of deposition, 
particle diameter is the primary factor determining pulmonary deposition of aerosols in 
the various regions of the respiratory tract. Ultimately, inspiratory flow rate also plays an 
important role in the particle deposition following pulmonary administration.[121] 
In this section, the evidence available in the literature to confirm that smaller 
particles delivered to the lungs are deposited in the smaller airways as opposed to the 
larger airways is summarized (Figure 1.1). So, the mechanisms of particle deposition and 
the relevance of particle aerodynamic diameter for regional lung deposition are firstly 
presented. Following the description of particle deposition, experimental techniques that 
can be used to confirm regional deposition of particles in the respiratory tract are 
highlighted. Our focus herein is on evidence of deposition patterns applied to inhalation 
therapies in humans, based on available data about particle aerodynamic size. 
 
1.2.2. Mechanisms of Particle Deposition 
There are five different mechanisms by which particle deposition can occur in the 
lungs: inertial impaction, sedimentation, diffusion, interception, and electrostatic 
precipitation. The two latter mechanisms are related, respectively, to particle shape (e.g. 
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elongated particles) and electrostatic charges; and have been reviewed in detail 
elsewhere.[117, 118] The mechanisms of deposition directly (or inversely) related to 
particle size are presented in Figure 1.2. 
 
1.2.2.1. Inertial Impaction 
Inertial impaction occurs when airborne particles possess enough momentum to 
keep its trajectory despite changes in direction of the air stream, consequently colliding 
with the walls of the respiratory tract. The chances of deposition by impact are increased 
when the particles are more likely to travel longer distances, S, which is based on the 
particle mobility (velocity per unit force), B, mass, m, and velocity, v, according to 
Equation 1.1:[117] 
 
ܵ ൌ ܤ · ݉ · ߥ  (Equation 1.1) 
 
The dimensionless Stokes’ number, Stk, more specifically describes the 
probability of particle deposition in the airways via impaction. The higher the Stokes’ 
number, the more readily particles will be deposited by inertial impaction, according to 
Equation 1.2: 
 
ܵݐ݇ ൌ  ఘ೛·ௗమ·௏ଵ଼·ఎ·ோ    (Equation 1.2) 
 
Where ρp is the particle density, d is the particle diameter, V is the air velocity, η 
is the air viscosity and R is the airway radius. Therefore, considering the bifurcated 
architecture of the lungs, large particles travelling through the airways at high airflow 
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velocity are more likely to impact in the proximal portion of the respiratory tract (upper 
airways).[118] 
 
1.2.2.2. Sedimentation 
Sedimentation is a time-dependent process in which particles settle due to the 
influence of gravity. Hence, breathing maneuvers in which more time is allowed for the 
particles to sediment (e.g. breath-holding) may increase lung deposition.[118] The 
Stokes’ Law assumes that the relative velocity between the surface of the particle and the 
airstream is null. Considering unit density spheres of 1 to 40 µm, Stokes’ law can be used 
to predict the terminal settling velocity, Vts, according to Equation 1.3: 
 
௧ܸ௦ ൌ ൫ఘ೛ିఘೌ൯·ௗ
మ·௚
ଵ଼·ఎ    (Equation 1.3) 
 
Where ρa is the density of air (ρp > ρa) and g is the gravitational acceleration.[117] 
However, for particles smaller than 10 µm, a slip correction factor (Cc) derived by 
Cunningham should be applied to Stokes’ law, as described in Equation 1.4:[122] 
 
ܥ௖ ൌ 1 ൅ ܭ௡ · ቀܣଵ ൅ ܣଶି஺య ௄೙⁄ ቁ  (Equation 1.4) 
 
Where Kn is the Knudsen Number, and A1, A2 and A3 are constants. The size-
dependence of this equation is related to the balance between the downward force exerted 
by the particle and the resistant force for which Stokes’ law is valid. With increased air 
flow, the stream becomes turbulent and the deposition by impaction increases.[118] 
Therefore, this equation assumes laminar flow within the airways, as defined by the 
Reynolds number, Re (Equation 1.5). 
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ܴ௘ ൌ ఘೌ·௏·ௗఎ   (Equation 1.5) 
 
Interestingly, the effect of gravity on particle sedimentation has recently been 
evaluated by the National Aeronautics and Space Administration (NASA). Inhalation of 
lunar dust is a concern for potential toxicological effects to future explorers of the 
moon.[123] Six healthy subjects were administered aerosols with particle diameters of 
0.5 and 1.0 µm on the ground (1 g) and during short periods of lunar gravity (1/6 g). In 
this study, the researchers found that, although the deposition of fine particles is greater 
on earth, peripheral deposition was improved at low gravity for those particles that are 
actually deposited in the lunar environment. 
 
1.2.2.3. Diffusion 
Diffusion occurs when particles are sufficiently small to undergo a random 
motion due to molecular bombardment. This process, also known as Brownian motion, is 
correlated to particle size, according to Stokes-Einstein equation (Equation 1.6):[117] 
 
ܦ݂݅ ൌ  ௞·்ଷగ·ఎ·ௗ  (Equation 1.6) 
 
Where Dif is the diffusion coefficient, k is the Boltzmann's constant and T is the 
absolute temperature. Different from impaction and sedimentation mechanisms, 
diffusional deposition is therefore inversely related to particle size. 
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1.2.3. Particle Aerodynamic Diameter 
Aerosols for inhalation vary not only on geometric particle size and size 
distribution, but in a number of other factors that influence particle deposition: physical 
state (liquid or solid), density, shape and velocity. In addition, a dynamic system of forces 
is interacting with the airborne particles throughout the airways, namely: gravity, 
resistant force of the inspiratory air and inertial force. The balance between these forces 
and the aerosol properties ultimately determines the mechanism of particle deposition in 
the lungs.[39] 
The aerodynamic diameter, dae, is, by definition, the diameter of a sphere with 
unit density (ρ = 1), having the same terminal settling velocity in still air as the particle in 
consideration.[39] Considering the particle characteristics, this independent variable can 
therefore correlate the effect of geometric diameter and particle density, as described in 
Equation 1.7: 
 
݀௔௘ ൌ ݀ · ට ఘఘబ   (Equation 1.7) 
 
Where d is the actual diameter of the sphere, ρ is the spherical particle density and 
ρ0 is unit density. For non-spherical particles, which are more prone to deposition via 
interception, the particle shape also influences the aerodynamic diameter and therefore 
correction for shape factors is applied.[117, 118] 
The relationship between the geometric diameter and the particle density for 
aerodynamic diameter is illustrated by a study of large porous particles for pulmonary 
delivery.[124] In this investigation, Edwards et al.. have effectively delivered very light 
weight large particles (ρ = 0.1 g/cm3; d = 8.5 µm) to the deep lung. Therefore, 
aerodynamic diameter, as opposed to geometric diameter, must be used as independent 
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variable to relate to particle deposition governed primarily by inertial impaction.[33] In 
vitro determination of the aerodynamic size of inhalation products can be performed 
using cascade impactors, including: the Andersen Cascade Impactor, Multi-Stage Liquid 
Impinger, and the Next Generation Cascade Impactor.[39] This characterization is 
essential to evaluate the particle deposition in the lungs. Usually, the mass median 
aerodynamic diameter (MMAD) and the geometric standard deviation (GSD) are 
reported. MMAD is the cut off particle size in which 50% of the mass of the aerosol is 
smaller and the other 50% is larger than the referred parameter.[125] MMAD is a 
measure of central tendency while GSD indicates the magnitude of dispersity from the 
MMAD value.[126] 
During the inhalation process of pharmaceutical products, a specific device is 
positioned in the mouth of the patients and the drug particles are aerosolized. These 
particles travel throughout the airways with a number of factors determining its 
deposition in the respiratory tract, which can be anywhere from the oral cavity to the 
alveoli. There are a number of mathematical models and computational tools available in 
the literature that aids in predicting the deposition patterns of particles in the whole lung 
and in its specific regions, even considering different disease states. These topics have 
recently been reviewed and beyond the scope of this review.[127-130] 
 
1.2.4. Assessment of Regional Lung Deposition 
An overview of the commonly used techniques is presented in Figure 1.3. There 
are two basic methods to identify drug deposition in the lungs following inhalation: 
pharmacokinetic methods and gamma-scintigraphy techniques.[44] The former one can 
only provide information about total lung dose, based on plasma concentrations and/or 
urinary recovery.[45, 131] On the other hand, besides quantifying total lung deposition, 
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radionuclide imaging (or gamma-scintigraphy) is the primary technology used to 
differentiate between depositions into different zones of human lungs.[132] This in vivo 
imaging technology is greatly valued due to its ability to provide visual confirmation (and 
therefore convincing evidence) that the dosage form is functioning in the way it is 
designed to, by demonstrating that the drug particles are being deposited into the lungs 
following inhalation. Initially, two-dimensional gamma-scintigraphy was used as imaging 
technique for delivery of inhaled drugs. Lately, tridimensional imaging technologies have 
been applied for more accurate particle deposition in the human respiratory tract, 
including Single Photon Emission Computed Tomography (SPECT) and Positron 
Emission Tomography (PET). More recently, a new experimental technique based on 
Magnetic Resonance Imaging (MRI) has been published and is herein discussed briefly. 
 
1.2.4.1. Two-Dimensional Gamma Scintigraphy 
This planar imaging technique has been extensively used to assess the delivery 
efficiency of inhaled drugs,[133, 134] in which deposition patterns can be determined for 
different formulations and devices used for pulmonary administration. Usually, the 
radiolabelling process involves adsorbing the imaging agent to the surface of the drug 
particle[135] or adding the radionuclide to the nebulizer solution.[136, 137] The 
radionuclide Technetium-99m (99mTc, half life of 6 hours) has been widely utilized as 
radiolabelling agent for imaging of structure and function of different organs.[138] Other 
radionuclides include Indium-111 (111In), Iodine-123 (123I), and Gallium-67 (67Ga).[139] 
Mucociliary clearance, coughing and rapid permeability of the tracer through the airways 
limit the process to a short period of time when evaluating particle deposition 
patterns.[45] Despite this, accurate quantification of particle deposition in the lungs can 
be obtained, as long as drug and radionuclide distributions for comparative particle size 
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ranges are equivalent and the radiolabelling process does not affect the particle size 
distribution of the drug.[140] 
Gamma scintigraphy operates with either a single-headed or dual-headed gamma 
camera positioned to take static images. When fitted into a two-dimensional perspective 
these images can provide information about the distribution of the radiolabelling agent in 
the organ of interest.[141] To determine the specific region at which particles are 
deposited onto the lung using gamma scintigraphic methods, it is common practice to 
spatially divide the lungs into sections of interest (e.g. central, intermediate and 
peripheral) using computer tools. Based on the regions of interest, the Peripheral to 
Central (P/C) ratio (or, inversely, the Central to Peripheral C/P ratio) of particle 
deposition is widely used as planar index.[45, 139] In this image division, the peripheral 
zone refers mainly to the small airways (≤ 2 mm) while the central portion of the lung 
represents the larger airways. Hence, the P/C ratio correlates to the proportion of drug 
particles deposited in the respiratory bronchiole/alveolar region as compared to 
tracheobronchial regions of the lung. 
One of the main drawbacks of the planar scintigraphy though is the projection of 
the (three-dimensional) lung structure into a two-dimensional image. Relative particle 
deposition at different plane levels of the lungs may obscure the real deposition pattern 
when using this technique. Consequently, the lack of three-dimensional resolution can 
cause overestimation of deposition due to overlapping airways. Based on a coronal 
position image, this effect is considerably higher in the hilar region and gradually 
decreases towards the small airways in the periphery. Hence, it has been highly 
recommended to correct for attenuation of the radioactivity in the chest wall.[121, 142] 
To overcome this issue, SPECT and PET provide information about three-dimensional 
intrapulmonary deposition pattern that can reduce this source of error. 
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1.2.4.2. Single Photon Emission Computed Tomography (SPECT)  
With the gamma camera rotating through 360º, SPECT provides three-
dimensional image of the lungs.[45] Similar to gamma scintigraphy, the single-headed 
cameras rotate around the chest of the patient laid in supine position. However, with 
single detector cameras the scanning time can be unacceptably long (e.g. greater than 15 
min), since relative quantification can be erroneous due to significant absorption, 
mucociliary clearance (1 mm/min), or cough.[143, 144] For this reason, twin-headed or 
even triple-headed cameras have been used to boost analysis efficiency.  
Using the same radiolabelling method as in gamma scintigraphy, the obtained 
scans can be used to reconstruct the three-dimensional distribution of the particles in the 
lungs using an algorithm.[139] SPECT can then be used to determine regional lung 
deposition by differentiating between small and large airways.[145] As opposed to planar 
sections (based on pixels), the lung structure can be divided into volumes of interest, also 
known as voxels. For instance, in one of these techniques, the airway tree is arbitrarily 
divided into lung layers in the shape of concentric “shells” with the main bronchial 
bifurcation as the reference point.[146, 147] Based on gamma camera counts, these shells 
are further converted into spatial distributions that can consequently be used in the 
definition of Penetration Index (PI = P/C or C/P ratio). Given the arbitrary definition of 
this index established according to the research group, they should be analyzed on a case-
by-case basis.  
More recently, the development of 3D in silico models that can be superimposed 
on laboratory images of SPECT and PET may improve the interpretation of regional 
particle deposition in the lungs from clinical data.[148, 149] In this manner, the 
individual anatomy is preserved and, based on the airway dimensions of a lung model; 
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the airway generation contribution to each shell can be detailed. Unquestionably, such 3D 
in silico model is a powerful tool to better elucidate regional particle deposition patterns 
in the airways. 
 
1.2.4.3. Positron Emission Tomography (PET) 
While in SPECT the formulation is radiolabelled with surrogate markers like 
99mTc, PET incorporates positron emitters such as Carbon-11 (11C) and Fludeoxyglucose 
(18F) into the drug molecule.[45, 139, 150] Although the radiolabelling method in PET is 
considerably more elaborated, some drugs have been used for PET studies as aerosols, 
including: 11C-triamcinolone,[151] 11C-formoterol,[152] 18F-insulin,[153] 124I-insulin, 
and 125I-insulin.[154] Alternatively, the lung physiology can be studied by using aerosols 
of 18F-Fluorodeoxyglucose (FDG).[155] The need to formulate the radiolabelled drug 
into an inhaled dosage form (e.g. dry powder) and further load it into the respective 
delivery device (e.g. dry powder inhaler) requires consideration of the isotope decay from 
the time the radiolabelling process is finished. This procedure can be very challenging 
when considering the short half lives of these radionuclides: 20 min for 11C and 110 min 
for 18F.[156] 
In studying pulmonary deposition based on particle size, changes in the 
physicochemical properties of the particles due to the addition or incorporation of the 
radionuclide into the drug molecule or formulation may occur. Therefore, a verification 
that the particle size distribution after introduction of the tracer into the formulation has 
not changed significantly is required.[147] For instance, an investigation of budesonide 
delivered with pressurized Metered Dose Inhaler (pMDI), pMDI with Nebuhaler®, a large 
volume spacer, and Turbuhaler®, a dry powder inhaler (DPI) in eight asthmatic patients 
using gamma scintigraphy showed a P/C ratio of 1.24, 1.22 and 0.64, respectively.[157] 
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Despite the increased peripheral deposition of the pMDI device, however, the 
incorporation of 99mTc tracer to the formulation did not present similar sizes before and 
after the radiolabelling process. In this case, underestimation of particle deposition may 
have occurred.  
 
1.2.4.4. Magnetic Resonance Imaging (MRI) 
More recently, a MRI method of measuring regional lung deposition has been 
published based on superparamagnetic iron oxide nanoparticles.[158] The feasibility of 
this method was demonstrated in a study where mice were administered colloidal 
suspensions of the nanoparticles via a nose-only inhalation chamber. The MMAD of the 
aerosol droplets formed using a Pari LC Star® jet nebulizer was 5.6 ± 0.8 µm, with a 
geometric standard deviation (GSD) of 1.30 ± 0.03 (n=6), as measured by time-of-flight 
technique.[159] The longitudinal relaxation time of 12 axial slices of the lungs was 
analyzed using MRI and subsequently converted to iron concentration. The methodology 
showed potential for analysis of regional lung deposition, resulting in greater 
concentration of iron in central regions of the mice lungs. This is an expected result, 
based on MMAD value, as it is discussed in more details in the next section. As such, this 
technique has a potential as an alternative for scintigraphic methods for determining 
deposition patterns in the various regions of the lungs. Additionally, this experimental 
technique also shows considerable promise for evaluation of magnetic-based 
formulations for pulmonary drug delivery, in which particles are already loaded with iron 
oxide.[160] 
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1.2.5. Particle Deposition in the Lungs 
Stahlhofen and coworkers have previously studied the effect of particle size on 
lung deposition in a systematic experimental design with subjects inhaling monodisperse 
aerosols during tidal breathing.[161] With a tube inserted into the mouth, the 
oropharyngeal (mouth and throat) deposition for particles greater than 10 µm was more 
than 90% and 50% at 60 and 18 L/min, respectively. In their study, the smaller airways 
were differentiated by the larger airways according to the time of particle clearance from 
the lungs based on scintigraphic methods. A “fast-cleared” fraction was correlated to lung 
deposition at the tracheobronchial region (or larger airways), attributed to the known 
mechanism of mucociliary clearance in this area. Alternatively, a “slow-cleared” fraction 
was correlated to the absence of cilia in the terminal portion of the airway, indicating 
deposition in the lower airways and an expected particle clearance at approximately one 
day. By subtracting the slow-cleared fraction observed after a period of about 24 hours 
from the initial total lung dose, the regional deposition of particles is determined.[162] 
According to this experimental design and with particle aerodynamic diameter measured 
at an airflow rate of 30 L/min, it was found by Stahlhofen et al., that particles of 
approximately 6 and 3 µm are deposited predominantly in the larger and smaller airways, 
respectively. Notably a high intersubject variability was observed.[161] These results are 
in agreement with the particular mechanisms of deposition: inertial impaction and 
sedimentation. Interestingly, it was also found in this study that as particle sizes decrease 
to submicron dimensions the total lung deposition also decreased. With further decrease 
in particle size into the nanometric scale, the total lung deposition increased back to 
levels equivalent or greater than micronized particles[163] This minimum of total lung 
deposition may be attributed to a crossover between predominance of diffusion versus 
impaction/sedimentation mechanisms based on their particle sizes.[162]  
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Similar studies in terms of experimental design are reported in the literature.[164] 
However, there is evidence supporting that some particles depositing in the 
tracheobronchial region are actually cleared slowly and independent on their geometric 
diameters.[165] Therefore, the accuracy in determining regional pulmonary deposition 
from different particle sizes based on particle clearance should be evaluated with caution. 
Early on, evidence about the deposition of smaller particles in the smaller airways 
also emerged from related therapeutic response. According to the pathophysiology of 
asthma, inflammation may occur throughout the entire airway. Given the easy 
accessibility of the large airways, early studies related to this chronic inflammation had 
been done in the proximal central region, neglecting the occurrence in the distal 
airways.[166] In a series of studies, Zanen and coworkers demonstrated a significant 
improvement in lung function of stable asthma patients may be influenced by disease 
severity as well as particle characteristics. In the first study, monodisperse solutions of 
ipratropium bromide were aerosolized to mild asthma patients, with MMADs of 1.5, 2.8 
and 5.0 µm and GSDs smaller than 1.2.[167] Improvement in forced expired volume was 
observed for patients inhaling equivalent doses of aerosols with MMADs of 1.5 and 2.8 
µm only. Following this study, monodisperse salbutamol or ipratropium bromide 
solutions were administered in equal doses to asthma patients with severe 
obstruction.[168] For aerosols with the same aerodynamic characteristics as in the 
previous study, only particles with MMADs of approximately 3 µm presented 
improvement in the respiratory tract in this subset of patients. Not able to visualize the 
deposition patterns with imaging techniques, the authors were unable to explain why the 
aerosol with small particles (MMAD of 1.5 µm) presented similar lung function 
improvement as the solution aerosolized presenting larger particles (MMAD of 5.0 µm). 
These data suggest that aerodynamic diameter, geometric standard deviation and the 
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degree of underlying airway disease may all impact the delivery as well as the therapeutic 
response to inhaled medications. Finally, Zanen et al.. compared the monodisperse 
ipratropium bromide aerosol (MMAD 2.8 µm; GSD 1.1) with a polydispersed pMDI 
formulation of the same drug (MMAD 1.8; GSD 2.0).[169] The wide distribution of 
particle sizes of the pMDI formulation was found to be not as efficacious as the 
monodisperse delivery of the aerosol, based on lung function improvement. Subsequent 
studies have found that inflammation at distal portions of the lungs play a significant role 
in development and persistence of asthma symptoms.[170] 
More evidence for the deposition of smaller particles in the lower airways 
occurred after chlorofluorocarbons (CFC) were mandated to be removed from pMDIs, 
according to the 1987 Montreal Protocol on Substances that Deplete the Ozone 
Layer.[171] Gradually, the propellant CFC was being phased out and substituted by 
hydrofluoroalkanes (HFA), given its safety profile.[62] The need for reformulation 
provided the opportunity to produce solutions of inhaled corticosteroids (e.g. flunisolide 
and beclomethasone) with the propellant HFA, as opposed to the then available CFC-
based suspensions.[172, 173] The HFA-based formulation of beclomethasone 
dipropionate (QVAR®) was able to produce aerosols with MMADs of 1.1-1.2 µm, much 
smaller aerodynamic particle sizes than the CFC-based formulations with MMADs 
varying from 3.5 to 4.0 µm. Several studies comparing QVAR® and CFC-based 
formulations were performed for inhaled corticosteroids like beclomethasone and 
flunisolide.[172, 174, 175] The deposition patterns were based on percentage of 99mTc 
radiolabelled particles deposited in the oropharyngeal cavity (upper airways) versus the 
deposition in the deep lung (lower airways). The smaller aerodynamic particles of the 
HFA-based solution formulation were consistently deposited in the deep lungs in a 
considerably higher proportion than with the CFC-based suspension formulations. Such 
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findings have not been consistent with all HFA formulations though. Scintigraphic 
studies for beclomethasone and flunisolide HFA show dramatically increased lung 
deposition (50-70 %) when compared to CFC formulations (5-20 %).[170] The increased 
solubility in HFA for some drugs is likely the reason for smaller particle size. The 
importance of solubility on the particle size is illustrated by the scintigraphic studies of 
mometasone furoate HFA. Unlike the HFA-soluble drugs beclomethasone and 
flunisolide, mometasone furoate is currently delivered in an aerosol suspension. Studies 
by Pickering et al.. demonstrated lung deposition of mometasone furoate HFA of 
approximately 14% for a formulation presenting only approximately 20% of particles 
smaller than 5.8 µm.[176] Thus, in evaluating the reduction in particle size with HFA-
based formulations, one must take into account drug solubility. Therefore, the relatively 
low lung deposition of mometasone furoate HFA has been shown to be similar to the 
CFC-based suspension formulations. Importantly, both present larger particle sizes than 
the HFA-based solution formulations. 
pMDIs represent a high ballistic effect when actuated and therefore the particles 
are more prone to deposit via inertial impaction.[177] On the other hand, aerosols 
generated by nebulizers may be more dependent on the breathing pattern of patients.[178] 
Sangwan and coworkers have investigated the regional deposition patterns from aerosols 
generated by Misty-Neb® (MMAD = 3.1 µm) and AeroEclipse® (MMAD = 2.2 
µm).[179] The total lung deposition measured by two-dimensional scintigraphy was two-
fold smaller for the aerosols with larger particle size, and therefore presented a 
proportional increase in oropharyngeal deposition. The peripheral deposition though was 
higher for the aerosols generated from Misty-Neb®, with a C/P ratio of 1.5 as compared 
to 1.9 for AeroEclipse®. This controversial finding was attributed to the relatively 
extended time required for nebulization with the breath-actuated nebulizer AeroEclipse® 
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(20 minutes). As discussed earlier, the use of single-headed SPECT presents the 
disadvantage of long scanning times, allowing for particle clearance to occur. In the same 
manner, the effect of extended time due to aerosol generation may have hindered the 
evidence of small particles depositing in the alveoli. Nevertheless, the evidence that the 
larger particles were deposited in the upper airways was confirmed. 
Also using planar gamma-scintigraphy, an evaluation of the regional deposition of 
monodisperse particles was performed in twelve asthma patients in a more recent 
study.[180] Albuterol was radiolabelled with 99mTc and aerosolized using a spinning-disk 
aerosol generator able to provide a GSD smaller than 1.22. For regional deposition 
analysis, the lung images were divided in three different zones: central, intermediate and 
peripheral. The penetration index (P/C ratio) results for particles with MMADs of 1.5, 3.0 
and 6.0 µm were 0.79, 0.60 and 0.36, respectively. When considering central and 
intermediate zones together, the percentage of deposition in the peripheral lung zone 
compared to the total lung dose was still high for smaller particles: 44, 34 and 25%, 
respectively. The increase in penetration index values with decreasing particle sizes 
observed in this study clearly confirms the deposition of smaller particles in the smaller 
airways (peripheral lung region). On the other hand, larger particles are more likely to 
deposit in the upper airways that present a larger caliber. The deposition pattern of 
monodispersed particles with aerodynamic diameters of 1, 2.75 and 4.75 µm were 
reported likewise in another study.[181] In this investigation, 90% of the larger particles 
(MMAD 4.75 µm) were deposited in the upper airways. Also, increase in airflow rate 
demonstrated the effect of inertial impaction in larger particles, by increasing deposition 
in the upper respiratory tract. 
With the advances in SPECT instrumentation, multi-headed cameras have been 
used to decrease the image acquisition time and provide more reliable regional deposition 
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patterns in the lungs. Eberl and coworkers have introduced a dynamic SPECT technique 
in which acceptable image quality was obtained with 2-min frame using a triple-detector 
gamma camera.[181-183] In this study, the investigators compared the sensitivity of 
planar scintigraphy data with fast acquisition of three-dimensional images from SPECT. 
For the comparison, saline solutions containing 99mTc-DTPA tracer with different tonicity 
(hypertonic and normal saline) and droplet sizes (MMADs of 3.2 and 6.5 µm and span 
indices of 1.8 and 1.7, respectively) were aerosolized to six human subjects during tidal 
breathing. Using laser diffractometry, the span index was defined as the difference 
between the 90 and 10% cumulative volumes, divided by volume mean diameter: span = 
(Dv(90) – Dv(10))/Dv(50). The hypertonic saline aerosols were expected to undergo 
hygroscopic growth as the droplets travel through the humid airways. Though, due to 
insufficient time for growth coupled with effect of mass transfer, the increase in 
aerodynamic diameter by small hypertonic saline droplets was expected by the authors to 
reach an intermediate size between 3.2 and 6.5 µm. Consequently, it would be expected 
to demonstrate a pulmonary deposition pattern intermediate to the smaller and bigger 
airways. Based on the work by Fleming et al..,[146] the lung images from SPECT were 
likewise subdivided into concentric shells as previously explained and the regional 
deposition of the particles in the lungs was determined according to the penetration index 
(P/C ratio). However, only deposition in the right lung was considered, since the image of 
the left lung may include confounding factors from the stomach and cardiac shadow.  
In fact, the three-dimensional imaging technique proved to demonstrate a higher 
sensitivity than the planar scintigraphy. Not surprisingly, both techniques were able to 
detect the significant differences in penetration index that could be observed between the 
small normal saline and the large (both hypertonic and normal saline) droplets. However, 
the dynamic SPECT imaging was able to additionally identify significant differences in 
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intermediate particle sizes being deposited in intermediate regions of the airways that 
could not be achieved by the two-dimensional scintigraphic method. More importantly, 
the study was able to demonstrate that smaller particles are deposited more peripherally 
in the lungs. The mean (± SEM) penetration indexes as measured by SPECT for small 
normal saline, small hypertonic saline, large normal saline and large hypertonic saline 
droplets were, respectively, 0.501 ± 0.043, 0.432 ± 0.022, 0.358 ± 0.024, and 0.338 ± 
0.017. Interestingly, no significant difference in regional pulmonary deposition was 
found between the different tonicities of large droplets. This finding may be related to the 
already central deposition of these larger aerodynamic particles, with little further 
hygroscopic effect to the large hypertonic saline aerosol.  
A similar study has recently been published to confirm the deposition of small 
particles in the peripheral region of the lungs, following pulmonary administration using 
an Aeroliser® DPI device.[184] Eight healthy volunteers were dosed with powder 
aerosols of mannitol radiolabelled with 99mTc complexed to Diethylene Triamine 
Pentaacetic Acid (DTPA) prepared by co-spray drying. The incorporation of radionuclide 
to mannitol did not present difference in particle sizes. This indicates the validity of using 
this radiolabelling method to determine the mannitol deposition in the lungs by 
measuring the radioactivity. The three different formulations evaluated presented 
particles with MMADs of 2.7, 3.6 and 5.4 µm and GSDs of 2.6, 2.4 and 2.7. The lungs of 
the human subjects were analyzed using SPECT and the images were divided into 10 
concentric shells: central (5 innermost shells), peripheral (2 outermost shells) and 
intermediate (remaining 3 shells). An interesting finding from this study was that 
decreasing the particle aerodynamic diameter from 5.4 to 3.6 µm significantly increased 
the peripheral deposition. However, decreasing MMAD further from 3.6 to 2.7 µm did 
not improve significantly particle deposition in the lung periphery. With a greater 
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deposition of the smaller particles more diffusively throughout the lungs consequently 
provided a greater lung dose. Alternatively, the deposition in the upper airways was 
significantly higher for bigger particles (> 70%).  
In addition, Glover and coworkers investigated an intersubject variation in total 
lung dose based on individual subject flow patterns and inspiratory airflow rate. With 
peak inhalation flow greater than 90 L/min for all patients, no correlation could be drawn 
since no difference in in vitro deposition was found between airflow rates of 60 and 100 
L/min. Results of airflow rate and deposition patterns have been previously correlated, 
however using different DPI devices (InhalatorTM)[185] or the same device with different 
airflow rate ranges.[186] Although a consistent polydispersity characteristic was 
observed for the three different formulations of mannitol powder, the results obtained in 
this investigation using a more reliable imaging tool (SPECT) for regional lung 
deposition helps to support the evidence that aerodynamically smaller particles deposit in 
the smaller airways. 
While regional lung deposition of micronized aerosols is more frequently 
reported, the investigation of nanometer aerosols deposition in specific regions of the 
lungs is not available in the literature. Considering the late advances in nanotechnology, 
the regional dosimetry of nanoaerosols has been identified as a specific gap by the 
National Institute for Occupational Safety and Health.[187] More recently, Ruzer and 
Apte discussed the difficulties related to available experimental techniques for 
assessment of local deposition of nanoparticles (i.e. particles ranging from 1 to 100 nm) 
in humans.[188] The authors then go on to propose a potential method to be used for this 
purpose based on the unattached fraction of radon progeny. This marker forms naturally 
by decay of the inert radioactive gas radon and presents the smallest radioactive size, 1 
nm. Through diffusion mechanism, this marker can deposit onto the surface of particles 
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ranging from nanometer to micrometer dimensions and therefore has a potential for 
application in the regional dosimetry of nanoparticle aerosols. This approach has been 
previously used for determining extrathoracic deposition patterns in the human 
respiratory tract following nose- and mouth-breathing.[189] 
Nonetheless, a formulation of salbutamol with primary particles in the geometric 
nanosize range has been investigated for the local lung deposition.[190] The Quasi-
Elastic Light Scattering (QELS) results from this study showed that more than 70% of the 
particles prepared by spray-drying had a diameter smaller than 100 nm. The particle size 
results were confirmed by Scanning Electron Microscopy (SEM), which also 
demonstrated a well-defined round shaped morphology. The nanoparticles obtained were 
then compared to micronized particles of salbutamol in terms of aerodynamic diameter 
and regional deposition following inhalation with a Rotahaler® DPI device. The nano-
salbutamol formulation presented an MMAD of 1.6 µm, with the discrepancy to the 
geometric diameter attributed to a potential aggregation due to interparticle adhesion in 
the dry state. Despite of that, the distribution of particle deposition in the Andersen 
Cascade Impactor showed that approximately 20% of the formulation presented 
aerodynamic diameter smaller than 150 nm. The MMAD of the micronized drug was 
approximately 3.1 µm. The healthy volunteers were trained to retain the breath for 10s 
following deep inhalation and exhale into a collecting bag. Considering the diffusion 
mechanism related to ultrafine particles, an improvement in deposition of particles is 
expected with this breath-holding maneuver.[191] The planar scintigraphy imaging 
results, using the tracer 99mTc, showed a peripheral deposition of the nanoparticles greater 
than 2-fold higher than the micronized salbutamol and a minimal exhaled fraction (< 1% 
of the emitted dose).  
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Similarly to the results obtained with humans, the studies in animals have 
presented the same evidence for the deposition of small particles in the lower (smaller) 
airways, despite the differences in the structure of their respiratory tract and breathing 
characteristics (nose versus mouth breathing).[192] Intraspecies variability has been 
reported to be similar to that of humans in animal species that include: rodents, dogs, 
minipigs, and monkeys.[193-195] Besides the scintigraphic techniques generally used for 
studies in humans, more recently a fluorescent imaging method has been introduced to 
study deposition patterns in lungs of animals.[196] 
Age is a determinant factor in the airway caliber of humans, with both increasing 
gradually from the newborn to the adult phase. Considering this fact, formulations 
developed for inhalation therapy based on adults may not be appropriate or applicable for 
infants and young children. The relatively smaller airways of this subset of patients are a 
critical factor for the drug to reach the lower airways.[197, 198] 
Due to the focus on pulmonary delivery to adult populations, some studies have 
investigated specifically the importance of aerosol formulations with smaller 
aerodynamic particle sizes to be delivered to children. In certain studies, the distinction in 
particle deposition is based solely on the difference in radioactivity observed in intra- and 
extrathoracic regions. Although they lack distinctive information on more specific 
pulmonary regions (e.g. terminal airway region), these investigations provide valuable 
data from a different viewpoint, in which they are based on differences in particle 
deposition between oropharyngeal (larger airways) and deep lung (lower airways). 
Comparing deposition in the lower versus the upper respiratory tract, budesonide droplets 
radiolabelled with 99mTc presented MMADs of 2.5 µm (GSD of 1.25) and 4.2 µm (GSD 
of 2.0) after nebulization with eFlow® and Pari LC Plus® nebulizers, respectively.[199] 
Using planar gamma scintigraphy to analyze six asymptomatic three-year old children, 
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Schuepp and coworkers found that lung deposition was 36-38% and 5-8%, for children 
inhaling particles with MMADs of 2.5 and 4.2 µm respectively. In a similar study, jet 
nebulizers were used to produce aerosols with MMADs of 3.6 and 7.7 µm.[200] With 
twenty asymptomatic cystic fibrosis patients, ages 3- to 24-months old, lung deposition of 
nebulized small particles was also greater than large particles. The ideal size of particles 
and best method of delivery; however, have not been clearly established in infants and 
young children. 
 
1.2.6. Establishing Clear Relationships 
The respiratory tract is a complex anatomical structure in which the upper airways 
gradually decrease in diameter down to the small dimensions of the terminal airways and 
alveoli. The in vitro determination of aerodynamic diameters has long been explored as a 
parameter to correlate regional lung deposition with in vivo studies. For the development 
of inhalation products, the use of cascade impactors greatly benefits the fast screening of 
formulations. Hence, since the studies from Stahlhofen et al.., in the late 1980’s, the 
optimal particle sizes for inhalation products have been highly speculated. Consequently, 
rules-of-thumb have arisen. The most common one found in publications related to 
development of formulations for pulmonary delivery is that particles in the range of 1 to 
5 µm are deposited in the deep lungs; while those larger than 10 µm are generally 
deposited in the oropharyngeal region and the particles smaller than 1 µm are 
exhaled.[120, 201-203] In an attempt to determine a more consistent in vitro/in vivo 
relationship, Newman and Chan have evaluated the results available in the literature for 
DPIs and pMDIs.[38] Comparing the whole-lung deposition as a function of fine particle 
fraction, they found that the scattered data straddled the line of identity when particles 
were smaller than 3 µm. This may suggest an upper limit for particle size related to 
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deposition in the deep lungs. So far, this finding in conjunction with the published data 
summarized in this review paper may be the best guide to predict deposition in the small 
airways, although it does not present a high level of accuracy, since other factors 
influence deposition (e.g. particle shape and degree of airway inflammation). 
Just as it is important to define an upper limit of particle size distributed in 
various regions of the lung, it is also important to define the lower limit for each region. 
Considering the gradual, but not stepwise, decrease in the dimensions from the upper to 
the lower airways and the often polydispersed characteristic of orally inhaled products, it 
is reasonable to expect difficulties though in determining a specific cut off particle size 
range that translate into regional deposition in the lungs. One reason for that is the fact 
that the current available methods provide information on deposition via inertial 
impaction only, regardless of the other two significant mechanisms that can occur: 
sedimentation and diffusion.[33] Elutriation is the process by which particles are 
separated when moving upwards suspended in a fluid at a determined velocity. 
Elutriators have been developed to operate based on the principle of sedimentation; 
however they have not yet been widely applied to characterization of pharmaceutical 
formulations for inhalation therapy.[204] Specifically for the diffusion mechanism, not 
only methods for characterization of aerosols are not available, but also dosimetry 
techniques are yet to be developed, as discussed earlier. The lack of information on the 
determination of aerodynamic particle sizes based on the three possible mechanisms of 
deposition may be the gap to determine more specific ranges of MMAD that correlates to 
regional deposition in the lungs. The late advances in in vivo experimental techniques, 
mainly related to three-dimensional imaging, have certainly developed towards meeting 
this need. Even though the optimal particle size range is yet to be defined, the reports 
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available in the literature are evident about the deposition of smaller particles in the deep 
lungs, as opposed to deposition in the larger airways. 
 
1.2.7. Conclusions 
Despite the limitations in early imaging techniques used to determine particle 
deposition in specific zones of the lungs, the technological advances in imaging 
techniques are gradually improving the capability of differentiating the deposition 
patterns of particles with increasingly smaller differences in aerodynamic dimensions. 
With the advances in SPECT and PET, more confirmatory studies are being reported of 
the evidence of deposition of small particles in the smaller airways, as opposed to 
deposition in the larger airways. Nonetheless, the imaging techniques can also be used for 
less specific studies in the respiratory tract by comparing extrathoracic (upper airways: 
oropharyngeal cavity) versus intrathoracic (lower airways: lower trachea, bronchi, 
bronchioles and alveoli) particle deposition. This has been more frequently reported in 
studies with children.  
The desire to establish clear relationships between in vitro aerodynamic 
determination and in vivo particle deposition has led to comparisons between fine particle 
fraction and total lung deposition of particles. Results based on impaction studies indicate 
that particles smaller than 3 µm are more likely to deposit in the deep lungs. However, 
there is a lack of information about the regional lung deposition of particles affected by 
non-impaction mechanisms (e.g. sedimentation and diffusion), largely due to lack of 
applicable in vitro and in vivo experimental techniques; however, there is sufficient 
evidence reported in the literature showing that smaller aerodynamic particles deposit in 
the lower portion of the respiratory tract where the airways are gradually smaller. As 
imaging techniques advance, investigation of how particle size, shape, charge, and 
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composition affect deposition and movement through both the airway and the lung’s 
mucous gel layer. An overall understanding related to the fate of inhaled particles for a 
given formulation type will be required in order to optimize drug delivery using the 
pulmonary route of administration.   
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1.3. THE FUNCTION AND PERFORMANCE OF AQUEOUS AEROSOL DEVICES 
1.3.1. Introduction 
Commercially available technologies to transform a liquid dosage form into an 
aerosol for medical inhalation purposes have evolved significantly over the last century. 
Fundamentally, aerosol generation in the form of droplets has evolved from using 
human-powered techniques (manually compressed hand bulbs), followed by the advent 
of gas-powered devices (the air-jet stream principle), and through to electronic powered 
systems (using the ultrasound effect, including recent adaptations to create vibrating-
mesh micropumps). More recently, mechanical and electromechanical systems have been 
applied to develop novel aerosol production technologies (i.e. soft mist inhalers). The 
emerging technologies still include new nebulizing concepts involving mechanisms like 
electrohydrodynamic atomization and surface acoustic wave microfluidic atomization as 
well as capillary aerosol generators. Nebulizers are usually selected over other medical 
inhalers (e.g. pressurized metered dose inhaler (pMDI), or dry powder inhaler (DPI)) 
either due to the high drug deposition potential, or the negation of required patient 
training of complex inhalation maneuvers. Additionally, nebulizers have an innate 
capacity to aerosolize special formulations (e.g. recombinant human deoxyribonuclease 
(rhDNAse), or antibiotics not available as other inhalation dosage forms).[205] 
In addition to the progress of the basic principles of nebulization, the innovation 
has advanced further to encompass the so-called “smart” technologies with the objective 
to increase drug deposition to the lungs. Breath-enhanced nebulizer systems such as the 
Pari LC Star® and AeroEclipse® devices have an inspiratory flow rate to match that of the 
patient, increasing delivery of droplets, while going back to baseline during 
exhalation.[206] In addition, breath-actuated devices like the AeroEclipse® and Halolite® 
deliver aerosols after pre-profiling a patient’s breathing pattern. The I-neb Adaptive 
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Aerosol Delivery by Respironics® delivers aerosol only during the initial phase of 
inhalation.[207-209] And the AerXTM insulin Diabetes Management System (iDMS®) is a 
breath-activated inhalation system developed by Aradigm and Novo Nordisk that also 
allows for patient monitoring to ensure compliance to an adequate inhalation technique at 
optimal breathing conditions.[210, 211] Other technologies are available to monitor 
adherence of patients to MDI’s, like the SmartMist®, the Doser CT®, and the 
MDILog®.[212] 
Nebulization is the use of a particular device for the conversion of a liquid dosage 
form into fine droplets. Therefore, specific properties of bulk formulations in conjunction 
with the functional mechanism of a specific inhaler can dramatically influence the droplet 
characteristics and overall aerosol production. These droplet characteristics, together with 
patient dependent factors in turn determine the quality and extent of drug deposition to 
the lungs (Figure 1.4). 
Deposition throughout the respiratory airways of particles with different sizes is 
governed by different forces. Larger particles are highly affected by velocity, due to their 
relatively high mass, and therefore deposit by inertial impaction. Alternatively, 
sedimentation generally occurs to particles when gravitational forces are significant. 
Overall, larger particles are more likely to deposit in the upper airways while smaller 
sized particles tend to reach the deep lungs via sedimentation. At the smallest end of the 
scale, particles moving by Brownian motion are prone to be exhaled. More often than 
not, the droplets formed in most nebulizer systems present somewhat a heterogeneous 
size distribution. Thus, the dispersity of the size distribution is also an important 
parameter to be considered in deposition. Overall, it is generally accepted that particles 
with aerodynamic sizes between 1 and 5 µm may be deposited in the deep lungs.[213] 
69 
 
Essentially, two methods have become prominent in analyzing droplet sizes 
generated by nebulizers; these are cascade impactor (CI) and laser diffraction (LD). The 
first one relates to the drug concentration and is correlated to the hydrodynamic airflow 
and inertial impaction of droplets with specific sizes; the distribution of droplets is 
evaluated gravimetrically to determine a Mass Median Aerodynamic Diameter (MMAD). 
This parameter is the equivalent droplet size in which half (50%) of the droplets are 
smaller and 50% are larger than the specified cutoff diameter. The MMAD is calculated 
by following the evaluation of drug amount deposited in different stages of an inertial 
impactor. Commonly, the Geometric Standard Deviation (GSD) is reported to indicate 
the dispersity droplet size distribution around the MMAD. Laser diffraction is only 
applied to solution systems since it is derived from a volume-based measurement and is 
supported by the principle of homogeneous drug concentration of these dosage forms. 
For this technique, the MMAD is usually interchangeably referred to as Volume Mean 
Diameter (VMD) and the dispersity is sometimes given as span (10% percentile 
subtracted from 90% percentile and divided by VMD). 
A reduced nebulization time is always desired in order to boost patient 
compliance to treatment, and nebulizer systems capable of delivering relatively high 
amounts of drug are generally preferred. Therefore, measurement of aerosol output 
(amount and rate) is essential to establish nebulization performance. This analysis has 
been traditionally performed either by determining the difference in drug amount or by 
gravimetrical analysis (by simply weighing a nebulizer reservoir before and after 
nebulization). However, care should be practiced when relying on the gravimetric 
method. For instance, weight loss analysis can overestimate drug output due to 
evaporative effects of jet nebulizers[214, 215], or due to a heterogeneous nebulization of 
drug containing droplets (i.e. the generation of droplets that contain varying amounts of 
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drug) during aerosolization. These effects could potentially be exacerbated during the 
nebulization of dispersed systems like suspensions or liposomes.[216] 
In this section, the different mechanisms of aerosol generation are presented: the 
transformation of bulk liquids into droplets. Although some nebulizer systems are 
generally sub classified as “soft mist inhalers” (SMI) due to the slow velocity of their 
emitted aerosol, they were included herein from the standpoint of their functioning 
mechanism. The nebulization performance of different methods of aerosol generation 
were explored for solution and dispersed systems based on the bulk characteristics of 
liquids, with emphasis on the influence of changes in surface tension and viscosity on 
aerosol production. Additionally, the importance of density is recognized, but because the 
vast majority of the nebulizing formulations are based on aqueous systems overall 
changes might be small and its influence may be limited. Importantly, the nebulizer 
system comprises all components attached to the aerosol generation system, due to the 
fact that the nebulizer performance varies with respect to factors in addition to droplet 
formation, for example flow characteristics and airway connection tubing 
properties.[178]  
 
1.3.2. Jet nebulizers 
The basic functioning principle of jet nebulization is that a compressed gas (e.g. 
air) is forced through a tubing system which is in turn connected to a nozzle. As the air 
velocity increases with the decrease in the tubing cross-sectional area, a zone of low 
pressure is created around the nozzle (Venturi effect). As the high velocity jet passes 
tangentially or co-axially through the Venturi nozzle, the pressure drop created causes the 
liquid formulation to rise up on a feed tube from the liquid reservoir (Bernoulli effect). A 
primary droplet is then formed as an aerosol; a large droplet may subsequently impact on 
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baffles or onto the nebulizer walls, recycling into the reservoir. Droplets small enough 
circumvent these barriers (secondary droplets) and form the respirable aerosol generated 
from jet nebulizers.[217] Therefore, nebulizer design and dimensions greatly influence 
the characteristics of the secondary aerosol formation. This reason reinforces that 
nebulizers should be evaluated as a multicomponent system for the respirable aerosol 
generation, as opposed to characterization of the inhalation formulations based on 
isolating the single mechanism of aerosol production itself (primary aerosol generation). 
Although the influence of surface tension and viscosity on the size of primary droplets is 
well described, the secondary aerosol characteristic is a complex function of jet nebulizer 
systems.[217, 218] 
The performance of these nebulizer systems (compressor/nebulizer combinations) 
to produce water droplets has been compared extensively, with MMAD values measured 
using laser diffraction varying from 2.6 to 10.2 µm.[219] Treatment time reduction with 
these systems can be achieved by increasing airflow rate and by using a small initial fill 
volume, although these measures can slightly change the aerosol characteristics.[217, 
219] Overall, decrease in droplet size (with increased aerosol polydispersity) and increase 
in aerosol output can be expected for higher airflow rates and higher initial fill 
volumes.[220, 221] Irrespective of initial fill volume, this study with water clearly 
showed that output rate was not constant over time for the twenty three jet nebulizer 
systems investigated, varying anywhere from 0.05 to 0.29 mL/min at different time 
points within the same aerosolization event. This was an important study comparing the 
capacity of different nebulizer/compressor combinations to aerosolize a reference liquid 
(water). However, the fact that these systems promoted a device-specific variable 
decrease in temperature (4 to 8 °C)[222] does not allow us to evaluate the effect of the 
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important temperature-dependent properties (i.e. surface tension and viscosity) and their 
effect on nebulization performance. 
Nebulizer systems are capable of delivering high amounts of drug, and nebulizer 
formulations are primarily comprised of aqueous systems that can avoid damage to lung 
physiology. However, the presence of different excipients will almost certainly alter the 
physicochemical properties of liquids, even given the limited options for inhalation 
delivery due to potential toxicological effects of certain inactive ingredients.[119] For 
this reason, the characterization of the liquid formulation in conjunction with nebulization 
performance has been investigated in a number of recent studies. Very small droplet sizes 
(MMAD between 0.5 and 1 µm as measured by a 6-stage cascade impactor) were 
generated from jet nebulization of a simple hydroalcoholic solution (4% v/v ethanol in 
water) of Prostaglandin E1, aiming to treat neonatal hypoxemic respiratory failure.[223] 
The small ethanolic content was of a sufficient amount to decrease surface tension and 
viscosity values to approximately 61 mN/m and 0.982 cP, respectively. Cyclodextrin 
complexation of poorly-water soluble formoterol has provided solutions with surface 
tension and viscosity values of 54-56 mN/m and 1.16-1.18 cP, respectively.[215] Jet 
nebulization of these solutions has shown VMD values varying between 3 to 5 µm, with 
drug output rates of approximately 30-60 µg/min for four different nebulizer systems. 
Interestingly, the authors report that rate of formulation output is greater than rate of the 
formoterol emitted, indicative of the formation of aerosol droplets with varying drug 
concentration. 
The effect of surface tension on jet nebulization output of solutions was clearly 
illustrated when Ventolin® (albuterol sulfate) was added to a tobramycin intravenous 
solution supplied by Eli Lilly Canada.[221] The presence of benzalkonium chloride as 
preservative in the Ventolin® formulation caused the surface tension of the final mixture 
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to change from 66 mN/m (tobramycin IV solution diluted with saline) to 31 mN/m.[224] 
As a result, an increased drug output (10-50%) was observed for the lower surface 
tension solution. Similar results have been reported in another investigation that used 
three different jet nebulizer systems.[222] Importantly, authors from both studies 
highlighted the magnitude of increased drug output further related to differences in jet 
nebulizer systems and parameters (e.g. airflow rate) studied. Conversely, studies on 
solutions with increasing concentrations of heparin have shown a concomitant increase in 
kinematic viscosity, but no change in surface tension.[220] This increase in viscosity is in 
general translated into increased output rate and decreased droplet sizes when solutions of 
calcium, sodium, and low molecular weight heparin are jet nebulized. Interestingly, 
analysis of droplet size over time within a 15-minute nebulization run using a highly 
concentrated sodium heparin solution (19,900 IU/mL) displayed a decrease in MMAD 
from 2.5 to 1.9 µm, with no change in GSD. 
A drop in temperature caused by the latent heat of evaporation of the nebulizer 
solution is only one formulation attribute changing over time during jet 
nebulization.[225] According to Steckel and Eskandar, while studying the changes 
occurring within a 10-minute nebulization period, an increased drug concentration can 
also be expected as the water evaporates. This can be attenuated by the presence of buffer 
in saline solution, which causes a drop in the saturated vapor pressure. Moreover, the 
investigators found that while viscosity increases due to temperature drop of the nebulizer 
solution, surface tension decreases due to the increased nebulizer solution concentration. 
Most importantly, the authors explain that, within a 10-minute nebulization period, as jet 
nebulization occurs and water starts to evaporate, the temperature drop promotes an 
increase in viscosity and a reduction in saturated vapor pressure. Consequently, an initial 
increase in droplet size is observed. As the process continues and the nebulizer solution 
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concentrates, the reduction in surface tension provides droplets with smaller VMD 
values. 
As indicated, it is very valuable to have knowledge during formulation 
development with respect to an understanding of the influence of physicochemical 
properties of liquids (i.e. surface tension and viscosity) on aerosol droplet size and output 
for these inhaler devices.[81] The addition of surface active agents to water changes the 
secondary aerosol properties in a device-specific manner, with an overall inverse 
relationship relative to aerosol output.[226] However, a more intricate relationship 
between surface tension and droplet size can be expected. In some cases this relationship 
between surface tension and droplet size may be inversely related, and in other cases it 
may reach a peak value. Irrespective of the observed relationship, the size of the emitted 
droplets appears to be independent of the critical micelle concentration, and respirable 
output results overall agree with total output trends.[226] Viscosity effects are clearer, 
with jet nebulization being more efficient in terms of respirable output with liquids of low 
viscosity (1 to 6 cP). Thereafter and up to ceasing nebulization, increased viscosity 
increases MMAD as well as aerosol output, also in a device-specific manner.[81, 227] 
Jet nebulizers have been shown to be capable of aerosolizing protein solutions. 
Recombinant human deoxyribonuclease I (RhDNase I, also known as dornase alfa) has 
been tested and successfully delivered to the cystic fibrosis patient airways using jet 
nebulizer systems, to alleviate excessive mucus accumulation.[228, 229] In fact, there are 
only three different jet nebulizer systems approved for delivery of dornase alfa to treat 
cystic fibrosis patients and these are (nebulizer/compressor system): the Marquest Acorn 
II/DeVilbiss Pulmo-Aide; the Hudson T Up-draft/DeVilbiss Pulmo-Aide; and the Pari LC 
Jet Plus/Pari Inhalier Boy.[230, 231] However, studies to evaluate jet nebulization on 
protein degradation must always be considered. It is apparent that through different 
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mechanisms, the micellar properties of tween 80 and the hydrodynamic size as well as 
the influence of polyethylene glycol (PEG) on the conformational structure of protein in 
the air-water interface have shown to aid in protein stabilization during air jet 
nebulization.[232] Chitosan provides an additional protective effect, possibly via ionic 
interactions between its positive charge and the negatively charged enzyme[233]. 
Moreover, protein solutions are commonly freeze-dried to provide greater 
physicochemical stability.[234] When sodium polyphosphate, calcium chloride, or 
magnesium sulfate are used as cryoprotectants in a protein formulation (aviscumine), 
decreased surface tension and increased viscosity are seen.[235] The droplet size of jet 
nebulized formulations was observed to be slightly decreased when containing these 
excipients as compared to normal saline. Meanwhile, these components also provide 
protection to aviscumine destabilization caused by the air-jet process. For the treatment 
of emphysema, and potentially cystic fibrosis, the addition of antifoams such as span 65, 
or a mixture of cetyl alcohol and tyloxapol to protein solutions of α1 protease inhibitor 
also decreased surface tension without altering viscosity.[236] An overall increased 
amount of jet nebulized protein was observed while the cetyl alcohol/tyloxapol antifoam 
mixture provided an improved respirable fraction. 
Dispersed dosage forms can also be delivered to the lungs using jet 
nebulizers.[237] The aerosolization efficiency is highly device-dependent.[238, 239] For 
instance, thirty different jet nebulizer systems show respirable fractions of Pulmicort 
Respules® (budesonide suspensions) ranging from 15 to 50% but with very different 
output rates.[240] Reportedly, these suspensions present drug particle sizes of 2-3 
µm.[241] Nanoemulsions of budesonide (10.9 nm) prepared using ultrasonication 
presented improved aerosol characteristics for pulmonary delivery following jet 
nebulization. MMAD values were around 5.0-5.5 µm for the nanoemulsion compared to 
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7.0-8.0 µm for the standard suspension, additionally the nanoemulsion had better aerosol 
output, thus allowing for a much improved respirable fraction.[242] Jet nebulization of 
nanoparticle dispersions of deoxyribonuclease I (DNase I) show similar results, while 
greater than 50% activity of the protein is maintained.[243] Importantly, the nebulization 
performance of suspensions using jet nebulizers is also dependent on formulation 
properties, with different excipients and methods of preparation providing rather variable 
drug deposition patterns.[244] In addition, drug nanoparticle aggregation may also occur 
during jet nebulization.[245] 
Many liposomal formulations have been aerosolized with this method. Liposome 
components included soy (SPC) or egg phosphatidylcholine (EPC), cholesterol, and a 
variety of synthetic phospholipids, such as 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC).[95] With increased phospholipid concentration (1,2-
dilauroyl-sn-glycero-3-phosphocholine – DLPC), an increase in the Non-Newtonian 
apparent viscosity of budesonide and cyclosporine A liposomes has been observed, 
promoting reduction in drug mass output rate following jet nebulization.[246] 
Nevertheless, the differences in nebulizer design as well as lipid concentration (and 
therefore viscosity) are factors influencing secondary droplet sizes.[247] Ultimately, the 
type of phospholipid influences the jet nebulization performance differently for particular 
compounds.[248] 
Powders of phospholipid-coated particles (proliposomes) are ready for hydration 
to form liposomes and can be directly dispersed within the jet nebulizer reservoir for 
efficient aerosolization.[216] However, the shear effect of air-jet aerosolization can be 
expected to affect the physical stability of multi lamellar vesicles (MLV).[249] A slightly 
higher physical stability of liposomes to jet nebulization can be achieved when MLVs are 
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extruded through 1 µm polycarbonate filters.[68] Further reduction in particle size of 
MLVs by extrusion through 0.4 µm filters did not improve physical stability, in terms of 
retained entrapped drug following jet nebulization, but did provide an improved drug-to-
aerosol mass output. In vitro studies suggest that liposomal drug encapsulation with 
DPPC is beneficial for deposition to the deep lungs with air jet nebulization when 
compared to free drug, mainly for poorly-water soluble compounds.[250] Supposedly, 
the decrease in surface tension caused by this phospholipid can bring advantages to the 
adsorption kinetics of the liposomes to lung surfactants.[251] 
 
1.3.3. Ultrasonic nebulizers 
During the function of an ultrasonic nebulizer, acoustic waves are generated by a 
piezoelectric transducer that converts electrical signal into oscillatory mechanical 
movement. With frequencies of approximately 20 KHz, this mechanism creates 
oscillatory pressure disturbances that travel through a bulk liquid which is to be 
aerosolized. Cavitation occurs when pressure disturbances propagating through the liquid 
cause zones of low pressure, this creates vapor bubbles. At the collapse of these bubbles, 
shock waves conveniently close to the air-liquid interfacial region lead to surface 
destabilization creating the droplets. Alternatively, liquid excitation by ultrasonication 
causes capillary waves going outwards from the surface region up to a collapsing point in 
which droplets are generated. These two widely discussed possible mechanisms, for wave 
destabilization at the liquid surface are responsible for producing droplets, namely 
cavitation and capillary.[252]  
Conversely to air-jet systems, ultrasonic nebulizers promote an increase in 
solution temperatures to as much as 10°C above the starting temperature after a 5 to 7 
minute aerosolization period.[222] This phenomenon of increasing temperature is caused 
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by the high energy input of the piezoelectric crystal. Additionally a higher magnitude of 
increase in drug concentration within a 10-minute nebulization period is observed than 
that of jet nebulizers.[225] On the other hand, the addition of buffer salts or saline 
solution has also a relatively greater effect in decreasing drug concentration differences 
as well. Nonetheless, ultrasonic nebulizers are capable of maintaining a more constant 
VMD over time during the same nebulization event, while causing viscosity as well as 
saturated vapor pressure at the air-water interface to drop during aerosolization.[225] 
Increased concentration of buffer solution promotes increase in VMD caused by increase 
in viscosity, decrease in saturated vapor pressure and/or a surface tension drop. 
Considering the functioning mechanisms of aerosol generation, it is extremely 
important to independently evaluate formulations by comparison of different devices. For 
instance, for formulations of heparin with increased concentration (and therefore 
increased kinematic viscosity, but no variation in surface tension), aerosol characteristics 
were unsatisfactory for ultrasonic nebulizers, presenting variable MMADs from 5.5 to 7 
µm. This variation was not observed for air-jet nebulizers, as previously discussed.[220] 
The ultrasonic aerosolization of solutions containing macromolecules is another concern. 
For instance, activity of the protein aviscumine is highly affected by ultrasonic nebulizers 
compared to air-jet systems.[235] Notably, a device in which water was used as medium 
to propagate the ultrasonic waves presented less accentuated protein degradation in this 
study than when the protein solution was used as transducer medium. Nevertheless, this 
investigation also showed that salts used as cryoprotectants decreased surface tension and 
increased viscosity, but did not alter droplet size significantly. In addition, the salts were 
not as capable of providing protection to the protein solution during ultrasonic 
aerosolization as they were for jet nebulization, and could not be ruled out as a possible 
contributor to extensive protein instability. On the other hand, aerosolization of a protein 
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solution of α1 protease inhibitor (viscosity of 1.25 mPa and surface tension of 53 mN/m) 
using a variable frequency ultrasonic nebulizer (up to 2.4 MHz) provides adequate VMDs 
of approximately 1.6 µm at different vibration levels of the piezoelectric crystal.[253] 
More importantly, the protein molecular weight and antielastase activity are maintained 
despite the stress caused by the ultrasonic nebulization. As the protein is a thermo-labile 
compound, this stabilization is related to the heat absorption of a coupling liquid that is 
designed with the ultrasonic nebulizer to act as a buffer; avoiding excessive temperature 
increases in the formulation to be aerosolized. Therefore, it appears that the thermal and 
mechanical stresses caused by ultrasonic nebulization are potential reasons for the 
unsuitability of these devices to aerosolize large molecules. However, when studying 
nebulization of lactate dehydrogenase solutions, no simplistic evaluation could be 
inferred for the capability of different types of nebulizers (jet and ultrasonic) to 
effectively aerosolize this protein solution, as enzyme activity was maintained across the 
board.[254] This reinforces the need to specifically determine the effectiveness of a 
device to aerosolize protein solutions. 
Overall, ultrasonic nebulizers are incapable of generating aerosols from high 
viscosity liquids (i.e. greater than 6 cP).[81, 227] For less viscous liquids, an inverse 
relationship to the respirable output occurs. And comparing liquids with decreasing 
surface tension, peak values for VMDs outbalance the trough values of total output 
resulting in an optimal respirable output from ultrasonic nebulizers concurring with 
droplet size patterns generated.[81, 226] In general, ultrasonic nebulizers present a less 
heterodisperse aerosol than jet nebulizer systems.[81] 
Ultrasonic devices are well known for not being appropriate to deliver 
microparticulate dispersed dosage forms, such as budesonide suspensions, and MLV 
liposomes.[92, 95, 216] Radiolabelled solid lipid nanoparticles however have been 
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effectively delivered to the lungs using this aerosol generation mechanism to study 
lymphatic uptake.[255] Furthermore, recent studies show that ultrasonication does not 
rupture nor does it cause aggregation or agglomeration of drug particle size encapsulated 
in lipid nanocarriers.[256] Further investigations are warranted to determine nebulization 
performance of these formulations as well as whether this resistance of solid lipid 
nanoparticles to nebulization is related to particle composition or structure and size.  
 
1.3.4. Vibrating-mesh nebulizers 
Vibrating-mesh nebulizers can be classified as micropump systems because 
aerosol generation from this technology is a result of ultrasonic energy forcing liquid to 
flow through small apertures of a plate or membrane. There are two types of micropump 
nebulizers: passive or active vibrating-mesh systems. The passive vibrating-mesh 
nebulizer (e.g. Omron MicroAir®) is composed of a piezoelectric crystal which generates 
vibration from electrical force to a transducer horn that is in contact with the liquid 
formulation. The ultrasonic vibration then creates waves in the nebulizer reservoir that 
travel towards a perforated plate positioned in front of the transducer horn. Consequently, 
aerosol droplets are created once the fluid flowing through the membrane is enough to 
cause drop detachment. Alternatively, active vibrating-mesh nebulizers (e.g. Aerogen 
Aeroneb®, and Pari eFlow®) have a dome-shaped membrane directly connected to a 
vibrating piezo electric element. Following application of electric current, the liquid 
formulation is rapidly extruded through the mesh as a consequence of the downward and 
upward movements of said membrane, this action generates the droplets.[31, 257]  
These devices present the lowest change in temperature of the nebulizer solution 
among the inhalers discussed so far, with a small increase of about 3 °C over a 5-minute 
nebulization period.[222] This particular technological advance in functioning 
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mechanism offers the benefit of promoting its selection for clinical trials use of inhalation 
therapies.[258, 259] Both active and passive vibrating-mesh nebulizers are highly 
dependent on formulation characteristics. The influence of bulk liquid characteristics on 
aerosol generation of solutions has been systematically evaluated.[260, 261] Both 
systems have been demonstrated their ineffectiveness to produce aerosols from solutions 
that have viscosities of higher than 2 cP, with their total aerosol output being independent 
of physicochemical properties of liquids. The passive mesh technology yields slightly 
larger droplets than the active mesh system, but compensates to provide a similar 
respirable output by having a higher total aerosol output. An increased viscosity provides 
a decrease in droplet size, and a consequently higher respirable output from both mesh 
systems, but the overall output rate is compromised for passive mesh nebulizers. The 
influence of surface tension on aerosol properties are less clear, but it is known that fluids 
with low viscosity and low surface tension seem more desirable for greater nebulization 
performance.[260] A low ion concentration is crucial for providing less variable aerosol 
generation.[260-262] It should be noted that not all available apertures produce droplets 
all of the time though, this is highly dependent on the interactions between the bulk liquid 
formulation and the vibrating membrane.[261] 
Importantly, the orifices of a mesh can get clogged over time, despite 
emphasizing cleaning instructions to patients that aerosolize solutions.[263] As a result of 
clogging, dramatic variations in output rate and subsequent delivered dose can be 
problematic. In extreme clogging situations the device may even be caused to switch-off 
automatically. For these reasons, thorough cleaning of the vibrating-mesh must be 
conducted and the membrane should be periodically evaluated for clogging. In a clinical 
setting, timely replacement of the membrane as well as dedication of device to specific 
formulations should be considered to avoid cross contamination. 
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Active vibrating-mesh nebulizers more efficiently deliver solutions than jet 
nebulizers, while passive devices present comparable performance.[264-266] On the 
other hand, passive vibrating-mesh nebulizers more efficiently deliver protein solutions 
than the air-jet systems.[208, 229, 267] Vibrating-mesh nebulizers can successfully 
deliver poorly-water soluble drugs to the lungs from dispersed systems, such as 
nanosuspensions.[28, 268, 269] Active devices have been shown to be capable of 
delivering liposomal formulations of water-soluble drugs as well,[270] demonstrating a 
superior performance when compared to air-jet and ultrasonic systems (greater physical 
stability and output rate).[216, 249] Manufacturer customization of the active vibrating-
mesh with larger aperture sizes (8 µm as opposed to the commonly available 4 µm) have 
been shown to provide a lower extent of MLV liposome disruption than that of air-jet 
nebulization, but no significant difference when compared to the normal aperture size 
vibrating-mesh.[68, 249] Extrusion of MLV liposomes through 1 µm membrane filters 
improved drug output from large mesh aperture nebulizers, but further decrease in 
lamellarity (using a 0.4 µm filter) was not deemed beneficial.[68] Despite being able to 
better aerosolize drug suspensions than jet nebulizers, the delivery of nanoemulsions of 
budesonide demonstrates an even more pronounced improvement, with better drug output 
and fine particle fraction.[242] The drug particle size of nanosuspensions can be 
maintained for this particular aerosolization, including nanoparticles prepared using 
freeze-drying with different lyoprotectants.[271, 272] 
Reconstitution of liposomal formulations with various hydration media provides 
differences in aerosolization performance of active vibrating-mesh nebulizers, based on 
the physicochemical properties of the medium.[273] Interestingly, the drug particle size 
increases have been observed in the nebulizer reservoir. This increase could indicate that 
aggregation and/or accumulation can occur due to a cutoff size of liposomes that may be 
83 
 
extruded through the mesh during aerosolization. Thus, formulation properties highly 
influence the nebulization performance of these devices. Therefore, it is imperative to 
evaluate many of the properties of the dispersion (e.g. drug particle size distribution, zeta 
potential, rheology, etc.) when considering aerosolization of this dosage form. 
 
1.3.5. Colliding jets (Respimat®) 
A compressed coiled spring positioned in the bottom of a liquid reservoir serves 
to store the energy necessary to operate this system. When the spring is released, the 
formulation is pushed through two precisely engineered nozzles (uniblock) positioned in 
a specific pre-set angle that allows liquid jets to converge and thus collide against each 
other. The uniblock is comprised of finely engineered microchannels that filter the 
solution prior to jet formation in the outlet nozzle. As a result, aerosols are generated at a 
slow speed. Hence, the name soft mist inhaler (SMI), which, based on the definition of 
conversion from liquid to aerosol droplet, can be considered a subcategory of nebulizers. 
It has been recently found that a high deposition of small particles in the mouthpiece 
occurs with the current Respimat® design, due to a zone of recirculation created around 
the nozzle outlet.[274, 275] 
The rationale for developing this system was to overcome the disadvantages of 
other inhalers. The aerosol cloud lasts longer and travels slower (10 m/s for aqueous drug 
solutions) than aerosols generated by pressurized metered dose inhalers (pMDI) (50 
m/s).[276] Other comparisons show that the mist generated from Respimat® can be up to 
ten times slower than pMDIs and last 1.2 to 1.6 seconds in the air.[277] The characteristic 
slow velocity mist avoids high drug deposition in the oropharynx and negates the need 
for patient synchronization as seen with all pMDI devices.[278] Mixing the concepts of 
the functional mechanism of nebulizers with the advantage of having a portable inhaler, 
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Respimat® is currently available for clinical use in Europe, but not approved for the 
United States yet.[279] It provides a multidose of 120 actuations that are precisely 
delivered[280] using this mechanical-powered platform. In addition to being independent 
on inspiratory effort (as observed in some dry powder inhaler systems), it is portable and 
user-friendly to patients.[32, 281] 
Respimat® is designed to deliver drug solutions, but not dispersed systems.[282] 
Successful clinical trials in asthma patients with an aqueous solution containing 
ipratropium bromide and fenoterol hydrobromide led to the approval of Berodual®.[283, 
284] Follow up studies demonstrated its efficacy and safety, despite the presence of 
benzalkonium chloride and EDTA in the formulation.[285, 286] In fact, Berodual® was 
shown to provide better efficiency in drug delivery to the lungs, and the nominal dose of 
the active ingredients could be decreased by 2- to 4-fold when using this device, 
compared to conventional DPI or pMDIs (with or without the use of spacers).[275, 287, 
288] Similar results were found when treating Chronic Obstructive Pulmonary Disease 
(COPD) patients.[289-292] Inhalation solutions of tiotropium have been shown to be safe 
in asthma patients,[293] but an increased risk of mortality has been reported for COPD 
patients using Respimat®.[294] The high efficiency of this device also allows for the 
delivery of acidic solutions with pH values as low as 2.7, as well as ethanolic solutions, 
to be safely delivered to asthma patients without causing adverse events.[295, 296] The 
flexibility of this platform has allowed the use of a novel β2 agonist solution (olodaterol) 
to be evaluated for pulmonary delivery using this technology in a hydroalcoholic 
mixture.[297] 
Although, to our knowledge, there is no report on a systematic investigation, 
surface tension and viscosity of liquids may also play a role in the performance of this 
device. Analysis of an ethanolic solution of the steroid flunisolide showed a higher fine 
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particle fraction and slower aerosol cloud speed (7.5 m/s) than that of an aqueous solution 
of β2 agonist fenoterol containing also benzalkonium chloride and 
Ethylenediaminetetraacetic acid (EDTA).[276] The physicochemical properties that 
result from the components utilized in each of the aforementioned formulations are likely 
to have been responsible for the apparent differences in nebulization performance. 
Finally, device handling is considered safe, with unintentional misuse being likely to 
show no harmful or unwanted side effects due to facial and/or ocular deposition.[298]  
 
1.3.6. Extruded jets (AerXTM and Medspray®) 
A three-layer laminate strip is assembled to form the unit dose package of this 
technology for the pulmonary delivery of aqueous formulations. The first layer contains a 
microvolume liquid reservoir blister that is heat sealed to the second (lid) layer. A nozzle 
array completes the third layer where micrometer holes are laser drilled. Index holes align 
the multilayer system, which is then connected to a handle to form a final assembled 
package (strip) fit to the device accordingly. During operation, a piston forces the first 
layer of the strip towards the nozzle array, a minimum pressure, dependent on the surface 
tension, is needed to impart the necessary velocity to the liquid jet stream. As the liquid 
ruptures the lid layer and rapidly extrudes through the microholes, liquid break up occurs. 
This break up is dependent on the liquid viscosity that generating the aerosol 
droplets.[299] This functioning mechanism produces a slow velocity mist and is 
commercialized as AerXTM.  
This technology is capable of aerosolizing solution dosage forms, including 
testosterone[300] and opioids[301, 302] (e.g. morphine[303-306] and fentanyl[307]) . An 
ethanolic formulation containing a poorly-water soluble prodrug candidate for pulmonary 
delivery was also successfully delivered using this device.[308] The prodrug had an 
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MMAD of 3 µm and a GSD of 1.3, with a pharmacokinetic study showing systemic 
absorption following pulmonary delivery comparable to that of intravenous 
administration. Patient posture, and breathing maneuver were not shown to influence the 
diffuse pattern in lung distribution of aerosols generated using this technology.[144] 
Despite its usual small volume reservoir (e.g. 45 µL), AerXTM is capable of delivering 
high doses of therapeutic agents in solution. Two inhalations from this system were twice 
as effective in delivering an inhaled drug candidate to the lungs as up to 15 minutes of 
aerosolization using conventional air-jet nebulizers. The superior performance can be 
attributed to the improved aerosol output (higher respirable dose) that the soft mist 
inhaler provides.[309]  
Furthermore, protein solutions can also be aerosolized using the extruded jets 
mechanism. When an interleukin-4 receptor drug was aerosolized to the lungs, together 
with a radiolabelling compound in a saline solution, a higher peripheral deposition was 
found when compared to air-jet nebulization.[310] The higher peripheral deposition 
could be explained by differences in aerosol properties that showed MMAD values of 2.0 
and 3.5 µm, and GSDs of 1.35 and 2.5, for the AerXTM and air-jet nebulizer respectively. 
Importantly, AerXTM delivered five times faster, three to four times more drug (relatively 
to their initial protein charge) than the air-jet system. Similar results were found when 
compared to a pMDI device for the deposition profile of a radiolabelling solution.[311] 
Importantly, bolus inhalation of dornase alfa using this extruded jets mechanism to treat 
cystic fibrosis patients may in the future be a possible alternative to the currently 
approved jet nebulizer systems.[312] 
However, the possibility of macromolecule degradation must always be 
considered on a case-by-case basis. DNA-based drug products can be prone to 
degradation following extruded jet nebulization.[313] Plasmid DNA protected by 
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encapsulation in cationic lipids (lipoplexes) can avoid such degradation when this 
nonviral gene therapy formulation is aerosolized to the lungs using AerXTM. Ion 
concentration plays an important role in production of aerosols via this mechanism due to 
suppression of electrostatic charges.[314] And the addition of sodium chloride to lipoplex 
formulations has shown an improved emitted dose.[313]  
The possibility of delivering insulin to diabetes patients via the lungs is a subject 
that has been widely investigated.[315] Insulin solutions have also been delivered with 
this technology.[302, 316] In particular, this has been the only system used for inhaled 
insulin in liquid dosage form when most of the other attempts are with formulations in 
dry powder form.[210, 317] Recently, a long term study comparing prandial inhaled 
insulin compared to subcutaneous administration showed encouraging results.[318] In 
this insulin study using the iDMS technology, the authors concluded that, after one year, 
both routes of administration of insulin were comparably safe and efficacious, although 
further optimization was needed to avoid risk of nocturnal hypoglycemia with the inhaled 
dosage form.  
When drug particles are in the nanoscale size range, this technology can also 
produce aerosol from dispersed systems. Solid lipid nanosuspensions of ketoprofen and 
indomethacin were prepared via supercritical fluid extraction of emulsions. 
Aerosolization using AerXTM and AerXTM Essence (electronically and mechanically 
controlled) produced fine particle fractions of 60-80% and emitted doses of 50-60%, 
which resulted in fine particle doses of approximately 40%.[319, 320] Importantly, 
suspensions of a few hundred nanometers were not as effectively delivered using micron-
sized nozzle extruders as those suspensions with drug particle sizes below 100 nm.[319, 
321] Sub-micron sized nozzle extruders are also being considered for development, in 
which viscosity and drug particle size of dispersions are expected to have a greater 
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impact on the aerosolization profile.[320] In addition, a miniaturized version of AerXTM 
has been developed and is due to be used in large animals (e.g. dogs).[322] This system 
might bring great value to future proof-of-concept studies for safety and tolerability of 
drug candidates for inhalation therapy. 
Medspray® is a recently developed technology that applies the extruded jets 
principle from the Rayleigh break-up theory to produce aerosols.[323, 324] It is a hand-
held, liquid metered dose inhaler in which lithography (wafer stepper and etching 
techniques) is used to engineer different micron sized spray nozzles. Following actuation 
by the patient, a loaded spring mechanically controls the release of the drug solution 
contained in a metering valve. As the liquid formulation is extruded through the spray 
nozzle, the patient’s inspiratory flow pulls the formed droplets from a Venturi-like 
mouthpiece channel into the lungs. The device therefore requires some synchronization, 
with the patient pushing the drug release button a few seconds after initializing the 
inspiratory maneuver. On the other hand, since the aerosol production rate is controlled 
by the device (spring), it avoids dose emission variability that could be caused by 
differences in pressure and speed of actuation by a patient. A slow mist (4 m/s) is created 
at an inspiratory flow of 30 L/min by a patient. Weber further considered the influence of 
liquid viscosity on Rayleigh’s basic analysis of jet instability to describe a relationship 
between water aerosol droplets and nozzle diameters.[323, 325] During the development 
phase of the Medspray® inhaler, nozzles of 1.5, 2.0, and 2.5 µm in diameter generated 
droplets with aerodynamic diameters of 4.0, 5.0, and 6.0 µm, respectively. Further studies 
showed that the larger droplets (6.0 µm) are more effective for improving the pulmonary 
function in asthmatic patients.[326] 
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1.3.7. Electrohydrodynamic mechanism (MysticTM) 
A liquid is slowly fed to a positive potential, electronically-controlled capillary 
nozzle surrounded by a gas flow sheath. An electric field is then created between the 
nozzle and a counter-electrode; also positively charged, independently from the capillary 
nozzle. A Taylor cone-jet is formed between the capillary nozzle and the counter-
electrode once the electrical stress outbalances the surface tension, generating charged 
droplets. Subsequently, a corona discharge controls the droplet charge generating a 
monodisperse aerosol.[327] This functioning mechanism is called electrohydrodynamic 
atomization (EHDA) or electrospray and has been recently adapted for pulmonary 
delivery of drugs.[328] Under the trade name MysticTM, it is currently being developed 
by the Battelle Memorial Institute.[329] This technique is also widely used in 
pharmaceutical applications for ionization in mass spectroscopy,[330] thin film 
formation[331, 332] and particle engineering.[333-336] Particularly, this technique can 
consistently produce highly monodisperse aerosols (with GSD values between 1.2 and 
1.4).[337] 
Control of certain variables during EHDA can greatly benefit the aerosol 
generation for inhalation purposes. Flow rate is directly related to droplet size while 
surface tension presents an inverse relationship.[327, 337] The surrounding gas sheath 
influences the electric breakdown threshold, preventing corona discharge at the tip of the 
nozzle. Utilization of a small concentration of carbon dioxide (0.5%) in the gas sheath 
helps stabilize the electrospray in cases when fluids of high surface tension (e.g. pure 
water) require a voltage greater than the electric breakdown threshold. Ion concentration 
can also help stabilize the electrospray and produce smaller droplet sizes. When adding 
low concentrations of sodium chloride (0.005% w/w) to pure water, increased water 
conductivity can be achieved while not affecting surface tension. Thus, electrical current 
90 
 
can flow more effectively, producing smaller particle sizes.[337] However, higher 
concentrations of NaCl can increase polydispersity, which can be a problem for 
pulmonary delivery of certain pharmaceutical preparations (e.g. isotonic solutions).[327] 
Viscosity also appears to influence aerosol generation with this mechanism, although 
systematic investigation is warranted.[337] Droplet charge control through the corona 
discharge system can avoid deposition in the oropharynx despite droplet size.[327] An 
increase in drug concentration can increase droplet size and polydispersity, but does not 
change MMAD and GSD values significantly over time for the same aerosolized 
system.[337] 
Clinical trials using EHDA aerosol generation have shown the feasibility of 
delivering ethanolic solutions of beclomethasone dipropionate.[338] Interestingly, 
evaluation of monodisperse aerosols (GSD < 1.2) shows bioavailability of larger droplets 
(MMADs of 2.5 and 4.5 µm) to be greater than that of small droplet aerosols (MMAD of 
1.5 µm). Additionally, this technology can produce aerosols from dispersed dosage 
forms.[339] Electrospraying of negatively charged nanoliposomes of DPPC, 1,2-
Dipalmitoyl-sn-Glycerol-3-[Phospho-rac-(1-glycerol)] sodium salt (DPPGNa) and 
cholesterol presented a bimodal size distribution (35 and 100 nm) caused by different 
agglomeration patterns inside the capillary nozzle during aerosolization.[340] Head-to-
tail and side-by-side juxtaposition were identified during aerosolization of suspensions 
with high lipid mass concentration. Notably, the characteristics of the dispersed system 
(i.e. drug particle size of nanosuspension) can influence the jet break-up 
characteristics.[341] Nevertheless, EHDA is a gentle technique that can be successfully 
used in the ionization of macromolecules for analysis with mass spectroscopy.[342, 343] 
Not surprisingly, large biomolecules are aerosolized with this mechanism without 
suffering thermal degradation, even at high concentrations of protein solutions.[344] 
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Very importantly, this technology has shown to be more effective for aerosol delivery of 
gene therapy than jet, ultrasonic, and vibrating-mesh nebulizers.[345] 
 
1.3.8. Surface Acoustic Wave Microfluidic Atomization 
Much like the traditional ultrasonic nebulizers, this novel technology uses 
propagating waves to generate aerosols. However, it is designed in a way that, instead of 
millimeter order wavelengths propagating through the bulk liquid, the nanometer 
amplitude Raleigh waves travel on the surface of a piezoelectric substrate at a much 
higher frequency (10-20 MHz).[346-348] The Surface Acoustic Wave (SAW) is 
therefore a highly efficient method to drive fluid motion. With a microsyringe pump 
continuously delivering a solution on top of the lithium niobate (LiNbO3) substrate, the x-
propagating acoustic waves generate aerosol from the formed capillary waves.[346] With 
a significantly more efficient energy transfer, a considerably lower energy input is 
required (1-3 W). A lower energy input results in the feasibility of a portable hand-held 
device.[349]  
The droplet diameter during SAW atomization is directly proportional to surface 
tension and inversely proportional to the viscosity of liquids.[350] Due to the higher 
surface tension and lower viscosity, water produces larger droplets when compared to 
fluids like ethanol and octanol.[349] Ethanol and octanol have similar surface tensions 
(22-27 mN/m) but the latter presents a greater viscosity of 7.3 cP, compared to 1.1 cP. 
Aerosolization of octanol using SAW results in smaller droplets than with ethanol. 
Further development of this system could therefore be an alternative to jet nebulizers for 
aerosolization of highly viscous fluids due to the limitations described above for other 
nebulizer types (e.g. ultrasonic and vibrating-mesh). Of equal importance, the aerosol 
output is directly related to the power input, but its increase compromises droplet size and 
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dispersity.[351] In general, an optimal power input to produce aerosols for delivery to the 
deep lung at a reasonable rate has been shown to be around 1.5 watts.[349]  
The delivery of large molecules is expected to be feasible since proteins have 
been shown to maintain their activity.[352, 353] Insulin solutions have been successfully 
aerosolized.[351] The SAW microfluidic process may be unsuitable for atomization of 
dispersed systems (i.e. suspensions) due to concentration of particles via nucleation 
templating.[354, 355] But this a priori disadvantage has further found an application in 
the production of pharmaceutical nanoparticles.[352, 356, 357] 
 
1.3.9. Capillary Aerosol Generator (CAG) 
In this aerosolization process, a liquid solution is pumped into one end of a heated 
micro-capillary. Once inside the tube, the formulation vaporizes before it exits from the 
other end where it mixes with the cooler surrounding air. This cooling causes the vapor to 
supersaturate and therefore initiate nucleation. A subsequent increase in droplet size 
occurs due to condensation of the surrounding vapor onto the formed nuclei, generating 
the desired aerosol for pulmonary delivery.[358, 359] The appropriate particle size can be 
achieved by controlling droplet coagulation using reservoir chambers.[360]  
The surface tension and the viscosity of liquids appear to greatly influence the 
production of aerosols from CAG. Using a variety of vehicles, the values found for 
MMAD varied greatly, up to ten times.[361] Furthermore, both concentration and the 
physicochemical characteristics of solutes influence the aerosol generation.[362] 
Importantly, by dissolving benzil in propylene glycol, it has been shown that both 
evaporate and condensate simultaneously.[360] The aerosol droplet is also dependent on 
energy input, with trough in MMAD at about 40 Joules.[363] It is not feasible to 
aerosolize thermolabile substances using CAG, since the vapor jet temperature reaches 
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between 150 to 200 °C.[363] Studies with the antiemetic perphenazine dissolved in 
propylene glycol required a higher energy input (84-95 J), but still showed acceptable 
stability of this substance with the CAG aerosolization process.[364] 
 
1.3.10. Characterization of Nebulizer Formulations  
In spite of the great significance of nebulization therapy in clinical practice, very 
little has been done to standardize the characterization of nebulizer formulations. 
Assessment of the nebulizer device itself is available under a European Standard[365] 
and the European Respiratory Society presents guidelines on nebulization therapy.[205] 
Nebulizers were not covered, in the United States Pharmacopoeia (USP) General Chapter 
<601> Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers. Only 
very recently, the first supplement of USP 34 – NF 29 brings the standardization of 
characterization tests for nebulizer products. 
The General Chapter <1601> Products for Nebulization – Characterization Test 
of the USP now establishes, based on the dose delivered to a patient intrinsic to the 
formulation characteristics in conjunction with the device chosen (nebulizer system), two 
analyses for assessment of nebulization performance: 
 
• Drug Substance Delivery Rate and Total Drug Substance Delivered 
(TDD); and 
• Aerodynamic Assessment of Nebulized Aerosols. 
 
The first test determines the rate and total amount of drug delivered. A breathing 
simulator is recommended to be used at specific airflow rates, established depending on 
the targeted patient population (neonates, infants, children or adults).[179] Instead of 
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continuous delivery, breathing patterns more appropriately measure drug mass output 
from nebulizers. In this analysis, a volume of formulation specified for therapy is filled to 
the nebulizer reservoir. The device, positioned as intended to use, is connected to a filter 
enclosed in a holder, which is then connected to the breathing simulator. The nebulization 
is started and, at regular intervals, the filter is substituted for a new one. The drug mass 
deposited in each filter is then suitably analyzed and used to calculate the results as 
follows: 
 
ܴ௜ ൌ  ௠೔௧೔   (Equation 1.8) 
 
ܶܦܦ ൌ  ∑ ݉௜௡௜ୀଵ   (Equation 1.9) 
 
Where Ri, mi, and ti are the rate, the drug mass and the time interval used for 
collection at the ith interval, respectively, and n is the total number of filters collected. 
Among various cascade impactors, the Next Generation Impactor (NGI) is the 
apparatus recommended by the USP for assessment of aerodynamic droplet sizes from 
nebulizer systems, because it is a direct measurement of drug mass deposited based on 
aerodynamic droplet sizes.[33, 366-370] Alternatively, laser diffractometry is accepted 
for droplet size measurement specifically for homogeneous solutions, but not for 
dispersed systems or when significant droplet evaporation occurs.[39, 371] The test 
should be performed at airflow of 15 L/min and with a cooled impactor to avoid droplet 
evaporation.[110, 372, 373] The seven stages of the NGI therefore present the following 
cutoff diameters: 0.98, 1.36, 2.08, 3.30, 5.39, 8.61, and 14.1 µm. Besides the micro-
orifice collector (MOC) plate, an external filter is also recommended to collect very small 
droplets. Plate coating to avoid droplet bounce and re-entrainment, and the use of a pre-
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separator are unnecessary. Impactor stage overloading should be avoided by adequately 
establishing a feasible time interval for drug deposition during the test, a balancing 
capability with that of sensitivity of the analytical method employed to determine drug 
mass.  
If a normal distribution of the deposited drug is observed, the MMAD and GSD 
can be determined from the log cutoff size versus probability scale (probit) of cumulative 
mass, starting at the MOC/external filter. Intercept of this curve identifies MMAD, since 
probit of 50% is equal to zero. GSD can be determined from the slope of the linear 
portion of the curve or as follows: 
 
ܩܵܦ ൌ  ටௌ௜௭௘ ௥௘௟௔௧௜௩௘ ௧௢ ଼ସ.ଵଷ% ௗ௘௣௢௦௜௧௜௢௡ ௌ௜௭௘ ௥௘௟௔௧௜௩௘ ௧௢ ଵହ.଼଻% ௗ௘௣௢௦௜௧௜௢௡   (Equation 1.10) 
 
The mass fraction of drug deposited in each plate should also be presented, 
including the deposition in the induction port. 
Nevertheless, the characterization of the physicochemical properties of the 
formulations is very important to help determine the factors influencing droplet formation 
from nebulization systems with different functioning mechanisms. There are innumerous 
methods available to measure surface tension, including the Capillary Rise and the Du 
Noüy ring methods.[374, 375] As described earlier in this chapter, our group has 
developed a simple and quick method using a texture analyzer.[376] Likewise, viscosity 
can be measured using various techniques such as: capillary (or Ostwald-Cannon-Fenske) 
viscometer, falling-sphere viscometer, and rotational (cup-and-bob, and cone-and-plate) 
viscometers.[377, 378]  
When dispersed systems (e.g. suspensions, liposomes, etc.) are to be nebulized, it 
is very important to characterize the drug particles in bulk liquid in order to better 
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understand the nebulization performance based on the different mechanisms of aerosol 
generation from the appropriate devices.[379] Among the different methods, 
measurement of drug particle size and charge should be considered. Particle size and 
particle size distribution can be analyzed via laser diffraction or dynamic light 
scattering.[159] Measurement of zeta potential based on the principle of dynamic 
electrophoretic mobility can inform the magnitude of attraction or repulsion between 
particles.[380, 381] Very importantly, it should be considered that the rheology of 
dispersions (i.e. suspensions and emulsions) is much more complex than the simple 
measurement of viscosity for Newtonian fluids.[382, 383] Non-Newtonian behavior of 
fluids may be a factor influencing the nebulization performance of these systems 
depending on the type of nebulizer used. In addition, the aerosol output from these 
systems, based on gravimetrical analysis, may be misleading with respect to the real drug 
mass that is being aerosolized. 
 
1.3.11. Conclusions 
The technology to produce aerosols from liquid formulations for inhalation 
therapy has greatly evolved in a continuous manner from the traditional jet and ultrasonic 
nebulizers to emerging technologies based on techniques like surface acoustic waves, 
electrohydrodynamic atomization, and capillary aerosol generation. And smart 
technologies have further improved success through monitoring of patient adherence to 
therapy. The recent establishment of compendial characterization tests for nebulization 
products will greatly favor in vitro comparison of devices, which should ultimately 
translate into better in vivo efficiency. The physicochemical properties of the 
formulations in conjunction with the nebulizer design and mechanism of function greatly 
determines the aerosolization performance. Overwhelmingly it is surface tension and 
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viscosity that can highly influence these results and a greater understanding of their role 
in nebulization performance is a large part of the puzzle towards improved nebulization 
therapies. 
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1.4. TABLES 
 
Drug Use and Dosage Regimen[54] Log P Water Solubility[54] 
Cisplatin 
SCLC and NSCLC. Combination therapy: 75-100 mg/m2; IV infusion once every 3-4 
weeks. 
-2.19 [384] 
Soluble 
Doxorubicin (HCl) 
ED-SCLC. Monotherapy: 60-75 mg/m2 single dose at 21 days interval; or 20 mg/m2 once 
weekly; or 30 mg/m2 daily on 3 successive days every 4 weeks. Combination therapy: 
40-60 mg/m2 single IV dose and repeated at 21- to 28-days intervals. 
0.65 [385] 
Gemcitabine (HCl) 
Advanced NSCLC and metastatic disease. Optimum dosage regimen not established. 
Commonly, for monotherapy: 1 or 1.25 g/m2 30-min IV infusion once weekly for 3 
weeks followed by 1 week of rest. Combination therapy: 1 g/m2 once weekly for 3 weeks 
on 4-week cycle; or 1.25 g/m2 once weekly for 2 weeks on 3-week cycle. 
-1.24 [75] 
Etoposide 
Not preferred chemotherapy for NSCLC. For SCLC, combination therapy: IV infusion 
ranging from 35 mg/m2 daily for 4 consecutive days to 50 mg/m2 daily for 5 consecutive 
days every 3-4 weeks. Alternatively, oral administration: twice the IV dosage rounded to 
the nearest 50 mg. 
0.60 [384] 
Sparingly soluble 
5-Fluorouracil Not a conventional treatment -0.89 [384] 
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Drug Use and Dosage Regimen[54] Log P Water Solubility[54] 
Farnesol Not a conventional treatment 5.31 [88] Very Slightly Soluble 
Methotrexate Recurrent SCLC and squamous cell type NSCLC. Not preferred chemotherapy option. 0.54 [385] 
Practically insoluble 
Docetaxel Advanced NSCLC: 75 mg/m2 1-hour IV infusion once every 3 weeks 4.10 [386] 
Paclitaxel 
For NSCLC, combination therapy: 135 mg/m2 24-hour IV infusion or 175 mg/m2 3-hour 
IV infusion with cycles repeated every 3 weeks. For SCLC, no survival benefits of 
adding paclitaxel to standard combination regimens (platinums and etoposide). Phase II 
studies presented only partial responses with monotherapy of 250 mg/m2 24-hour IV 
infusion every 3 weeks or combination therapy of 175 mg/m2 3-hour IV infusion every 3 
weeks. 
3.50 [387] 
Celecoxib Not a conventional treatment 3.68 [61] 
Nimesulide Not a conventional treatment 2.60 [384] 
ED: extended disease; IV: intravenous; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer. 
Table 1.1 - Use, dosage regimen and physicochemical properties of selected drugs to treat lung malignancies. 
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Drug Dosage Form Formulation Device MMAD test 
specification 
MMAD 
(µm) / GSD 
Cell Line Medication 
Delivery (µg/shot) 
Respirable 
Fraction (%) 
Methotrexate 
[58] 
Suspension 
0.66% w/w in 10% w/w 
ethanol/HFA 134a. 
Drug co-milled with Poloxamer 217 
(3:1). 
pMDI 
Six-stage viable 
Andersen Cascade 
Impactor at 28.3 
L/min 
2.2 to 3.2 / 
2.7 to 3.7 
HL-60 
(leukemia) 
29 to 52 14 to 17 
Nimesulide 
[59] 
Solution 
0.1% w/w in 15% w/w ethanol/HFA 
134a 
Proventil 
HFA 
Eight-stage Mark II 
Andersen Cascade 
Impactor at 28.3 
L/min 
1.1 ± 0.3 / 
2.8 ± 0.6 
A549 (lung 
cancer) 
51.1 ± 3.3 42.4 ± 4.2 
Celecoxib 
[60] 
Solution 
0.25-0.45% w/w in 10-15% w/w 
ethanol/HFA 134a or 227 
Qvar80 
Eight-stage Mark II 
Andersen Cascade 
Impactor at 28.3 
L/min 
1.3 to 1.4 / 
1.9 
A549 and 
H460 (lung 
cancer) 
72 to 117 35 to 53 
Doxorubicin 
[77] 
Dry Powder 
Drug loaded 
poly(butylcyanoacrylate) 
nanoparticles: 1.39 µg per mg 
powder. Carrier: lactose 
Passive 
DPI 
Mark II Andersen 
Cascade Impactor at 
60 L/min 
3.41 ± 0.22 / 
N/A 
A549 and 
H460 (lung 
cancer) 
N/A N/A 
Farnesol [90] Emulsion 
10.5 mg/mL of drug and polysorbate 
80 (0.5 mg/mL) in 20% v/v 
ethanol/water 
Pari LC 
Star® and 
Pari LC 
Plus® jet 
Phase Doppler 
Anemometer 
coupled to breath 
simulator (airflow: 
4.96 / 1.48 
6.87 / 1.67 
A549 and 
H460 (lung 
cancer) 
N/A N/A 
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Drug Dosage Form Formulation Device MMAD test 
specification 
MMAD 
(µm) / GSD 
Cell Line Medication 
Delivery (µg/shot) 
Respirable 
Fraction (%) 
nebulizers 18 L/min; tidal 
volume: 0.75 L) 
Paclitaxel 
[101] 
Liposomes 
Drug-fullerene (C60) conjugation in 
DLPC 
N/A N/A N/A 
A549 (lung 
cancer) 
N/A N/A 
Docetaxel 
[103] 
Solution 
0.25% w/w in 15% w/w 
ethanol/HFA 134a 
Proventil 
HFA 
Eight-stage Mark II 
Andersen Cascade 
Impactor at 28.3 
L/min 
1.58 ± 0.4 / 
3.2 ± 0.5 
A549 (lung 
cancer) 
80.0 ± 2.3 42.2 ± 3.2 
5-Fluorouracil 
[113] 
Liposomes 
Combinations of DPPC, HSPC, 
cholesterol, DPPA and DPPG. 
N/A N/A N/A N/A N/A N/A 
Polymer 
Microspheres 
Combinations of PLGA, PLCL and 
PLA 
N/A N/A N/A N/A N/A N/A 
Lipid Coated 
Nanoparticles 
Combinations of: 
Core: poly-(glutamic acid), poly-
lysine, or lactose; 
Shell: tripalmitin, tristearin, cetyl 
alcohol, and stearyl alcohol. 
N/A N/A N/A N/A N/A N/A 
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MMAD: mass median aerodynamic diameter; GSD: geometric size distribution; HFA: hydrofluoroalkane; pMDI: pressurized metered dose inhaler; DPI: dry powder 
inhaler; DLPC: dilauroylphosphatidylcholine; DPPC: dipalmitoylphosphatidylcholine HSPC: hydrogenated soy phosphatidylcholine; DPPA: dipalmitoyl phosphatidic 
acid; DPPG: dipalmitoyl phosphatidylglycerol; PLGA: poly-(lactide-co-glycolide); PLCL: poly-(lactide-co-caprolactone); PLA: poly-(lactide); N/A: not available or not 
applicable. 
Table 1.2 - Summary of in vitro studies of anticancer agents for pulmonary delivery. 
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Drug Dosage Form Formulation Device MMAD test 
specification 
MMAD 
(µm) / GSD 
Specie Tumor 
Model 
Dosing 
Method 
Drug Deposition 
Estimative Method 
Celecoxib 
[64] 
Emulsion 
5 mg/mL 
dissolved in 
ethanol and PEG 
400. 
Emulsification 
with molten 
vitamin E TPGS 
Jet nebulizer 
(Pari LC® Star) 
Mercer Cascade 
Impactor (airflow 
rate not reported) 
1.68 / 1.36 Mice 
Human 
orthotopic 
NSCLC 
xenograft 
Nose only 
inhalation 
chamber 
Estimated dose 
Gemcitabine 
[70-74] 
Solution 
Gemzar® (Eli 
Lilly) 
Microsprayer + 
high pressure 
syringe 
N/A 18 / 3 Mice 
Human 
orthotopic 
NSCLC 
xenograft 
Endotracheal 
spray 
Scintigraphic 
images 
Jet nebulizer 
(AeroTech II®) 
Andersen Cascade 
Impactor (airflow 
rate not reported)  
0.8 / 2.1 Mice 
Osteosarcoma 
lung 
metastases 
Unrestrained 
chamber 
Estimated dose 
Not specified 
Andersen Cascade 
Impactor at 10 L/min  
0.8 / 2.1 Dogs 
Osteosarcoma 
lung 
metastases 
Unrestrained 
outdoors 
Not specified 
Microsprayer + 
high pressure 
syringe 
N/A 18 / 3 Rats N/A 
Endotracheal 
spray 
Scintigraphic 
images 
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Drug Dosage Form Formulation Device MMAD test 
specification 
MMAD 
(µm) / GSD 
Specie Tumor 
Model 
Dosing 
Method 
Drug Deposition 
Estimative Method 
Jet nebulizer 
(Atomisor 
NL9M®) with 
Atomisor 
Abox+ 
compressor 
Ten-stage cascade 
impactor (IMPAQ 
GS-1) operated at 1 
L/min 
3.7 / 0.8 Baboons N/A 
Inhalation 
cabin 
Scintigraphic 
images 
Doxorubicin 
[80] 
Solution 
16 mg/mL in 20% 
ethanol 
Jet nebulizer 
(Pari LC®) 
N/A N/A Dogs 
Spontaneously 
occurring 
primary or 
metastatic 
lung tumors 
Endotracheal 
tube 
(anesthesia) 
Estimated dose 
(time, body surface 
area and minute-
volume of 
respiration) 
Paclitaxel 
Solution [80] 
75 mg/mL in PEG 
200 and ethanol 
Jet nebulizer 
(Pari LC®) 
N/A N/A Dogs 
Spontaneously 
occurring 
primary or 
metastatic 
lung tumors 
Endotracheal 
tube 
(anesthesia) 
Estimated dose 
(time, body surface 
area and minute-
volume of 
respiration) 
Polymer 
Microspheres 
[94]  
poly-(L-glutamic 
acid) (PGA) were 
loaded with 20% 
(w/w) paclitaxel 
Jet nebulizer 
(8900, Salter 
Labs, USA) 
Seven-stage cascade 
impactor (In-Tox 
Products) at 5 or 9 
L/min 
Not 
calculated 
Mice 
Human 
orthotopic 
NSCLC 
xenograft 
Intratracheal 
injection 
N/A 
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Drug Dosage Form Formulation Device MMAD test 
specification 
MMAD 
(µm) / GSD 
Specie Tumor 
Model 
Dosing 
Method 
Drug Deposition 
Estimative Method 
(PGA-PTX) 
Liposomes 
[96] 
10 mg/mL with 
DLPC (1:10 w/w) 
Jet nebulizer 
(Aeromist®) 
Andersen Cascade 
Impactor at 10 L/min  
2.2 / 1.9 Mice 
Renal 
carcinoma 
lung 
metastases 
Whole body 
inhalation 
chamber 
Not reported 
Camptothecin 
and Rubitecan 
(9NC) [47, 
105, 106] 
Liposomes 
10 and 100 mg/mL 
with DLPC (1:50 
w/w), respectively 
Jet nebulizer 
(AeroTech II®) 
Six-stage Andersen 
cascade impactor at 
10 L/min 
0.8 to 1.6 / 
1.8 to 2.6 
Mice 
Human 
orthotopic 
NSCLC 
xenograft 
Whole body 
and nose 
only 
inhalation 
chambers 
Estimated dose 
Rubitecan 
(9NC)  
Liposomes 
[107] 
DLPC (1:50 w/w) 
Jet nebulizer 
(AeroTech II®) 
Six-stage Andersen 
cascade impactor at 
10 L/min 
1.41 ± 0.29 / 
2.37 ± 0.15 
(average ± 
SD measured 
weekly over 
53 days) 
Beagle 
dogs 
N/A N/A Estimated dose 
Liposomes 
[109] 
soybean lecithin 
and cholesterol 
N/A N/A N/A 
Mice 
Rats 
N/A 
Intratracheal 
injection 
N/A 
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Drug Dosage Form Formulation Device MMAD test 
specification 
MMAD 
(µm) / GSD 
Specie Tumor 
Model 
Dosing 
Method 
Drug Deposition 
Estimative Method 
5-Fluorouracil 
[115, 116] 
Lipid Coated 
Nanoparticles 
Core: 600 nm 
diameter poly-
(glutamic acid):5-
FU-FITC dextran 
(3:1:1 wt); 
Shell: 200 nm 
thick 
tripalmitin:cetyl 
alcohol (2:1 wt). 
Ultrasonic 
nebulizer 
(model not 
specified) 
Eight-stage Mark II 
Andersen cascade 
impactor (airflow rate 
not reported). 
Formulation droplets 
pre-evaporated. 
1.15 / 2.15 
0.95 / 1.57 
Hamster N/A 
Intratracheal 
injection; 
and whole 
body and 
nose only 
inhalation 
chambers 
Estimated dose 
MMAD: mass median aerodynamic diameter; GSD: geometric standard deviation; SD: standard deviation; PEG: polyethylene glycol; PGA: poly-(L-glutamic acid); 
DLPC: dilauroylphosphatidylcholine; 5-FU: 5-fluorouracil; FITC: fluorescein isothiocyanate; N/A: not available or not applicable. 
Table 1.3 - Preclinical (in vivo) studies of anticancer agents for pulmonary delivery. 
  
 107
Drug Dosage 
Form 
Study 
Phase 
Formulation Device Population Dose 
Calculation 
Dose and 
Regimen 
Outcomes 
Doxorubicin 
[82] 
Solution I 
16 and 24 mg/mL 
in ethanol:water 
1:4 (pH 3).  
Jet nebulizer (Pari LC 
Plus®) with 
OncoMystTM model 
CDD-2a 
Metastatic 
Tumors 
(n = 53) 
Technetium 
99m 
deposition 
test and 
scintigraphy 
0.4 to 9.4 
mg/m2 every 3 
weeks 
No systemic toxicity; Dose limiting 
pulmonary toxicity: 7.5 mg/m2 
every 3 weeks; 1 partial response 
(spindle cell sarcoma) after 6th 
cycle of 1.9 mg/m2; 8 stable disease 
patients (2 bronchoalveolar 
carcinoma, 2 soft tissue sarcoma, 1 
endometrial carcinoma and 3 
thyroid cancer) after 5-15 cycles. 
Rubitecan 
(9NC) [108] 
Liposomes I 
0.2 mg/mL in 
DLPC (1:50 w/w) 
Jet nebulizer (Aeromist®) 
with mouth breathing-
only face mask and 
HEPA-filtered airborne 
scavenging tent 
Primary or 
metastatic 
tumors (n = 25) 
N/A 
6.7 to 26.6 
µg/kg/day, 5 
days per week 
for 8 weeks 
Dose limiting toxicity: 13.3 
µg/kg/day, 5 days per week during 
8 weeks; 2 partial remissions 
(uterine cancer); stable disease in 3 
patients (primary lung cancer). 
Cisplatin Liposomes 
I 
[111] 
SLIT CPT (1 
mg/mL), DPPC 
(1:16 w/w) and 
cholesterol (1:7.5 
w/w) in 0.9% 
Jet nebulizer (Pari LC 
Star®) with Pari filter® in 
Demistifier Canopy 
model 2000® tent  
NSCLC 
(n = 16) and 
SCLC  
(n = 1) 
Body 
Surface Area 
Escalation from 
1.5 mg/m2 until 
DLT for 1-4 
consecutive 
days every 1-3 
Dose Limiting Toxicity not 
reached: increasing dose level 
(inhalation time: up to 8h), 
reducing interval between cycles, 
increasing number of nebulization 
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Drug Dosage 
Form 
Study 
Phase 
Formulation Device Population Dose 
Calculation 
Dose and 
Regimen 
Outcomes 
NaCl. weeks sessions per day, and increasing 
amount of drug inhaled; stable 
disease in 12 patients. 
Ib/IIa 
[112] 
SLIT CPT 
(concentration not 
disclosed) 
Nebulizer (not specified) 
Relapse 
osteosarcoma 
metastasis  
(n = 14) 
Body 
Surface Area 
24 and 36 
mg/m2 every 2 
weeks 
Cumulative doses of 840 to 1020 
mg per year in heavily pre-treated 
patients. Two patients with 
pulmonary disease free after 1 year. 
DLPC: dilauroylphosphatidylcholine; DPPC: dipalmitoylphosphatidylcholine; SLIT: sustained-release lipid inhalation targeting; CPT: camptothecin; 9NC: 9-
nitrocamptothecin or rubitecan; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; HEPA: high efficiency particulate arresting; DLT: dose limiting 
toxicity; N/A: not available or not applicable. 
Table 1.4 - Clinical studies of anticancer agents via inhalation. 
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1.5. FIGURES 
 
 
Figure 1.1 – Schematic diagram representing particle deposition in the lungs according to 
different mechanisms related to particle size: inertial impaction, 
sedimentation and diffusion. The diagram presents the smaller particles 
depositing in the lower airways as opposed to the larger airways. The GI 
tract is omitted in this diagram.  
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Figure 1.2 – The influence of particle size on deposition. d: particle diameter; Stk: Stokes 
number; ρp: particle density; V: air velocity; η: air viscosity; R: airway 
radius; Vts: terminal settling velocity; ρa: air density; g: gravitational 
accelaration; Dif: diffusion coefficient; k: Boltzmann’s constant; T: absolute 
temperature; dae: aerodynamic diameter; ρ0: unity density. 
  
 111
 
Figure 1.3 – Commonly used methods for assessment of regional lung deposition. 2D: 
two-dimensional; 3D: three-dimensional; SPECT: Single Photon Emission 
Computed Tomography; PET: Positron Emission Tomography. 
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Figure 1.4 – Factors influencing lung deposition from nebulizer formulations. 
 
  
Liquid formulation: 
dosage form (solution 
or dispersion); surface 
tension; viscosity, 
hygroscopicity.
Nebulizer functioning 
mechanism: 
jet (stream, colliding or 
extruded), ultrasonic, 
vibrating-mesh, etc.
Aerosol properties: 
droplet – size, shape, 
density, and charge.
Patient factors: 
airways anatomy and 
pathophysiology, 
respiratory pattern, etc.
Lung 
deposition
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Chapter 2: Research Outline 
 
2.1 OVERALL OBJECTIVES 
The primary goal of this work, presented in this dissertation, was to develop 
formulations of Coenzyme Q10 (CoQ10) with the potential to be delivered at high doses 
via inhalation, for the purpose of treating lung carcinomas in future work. Development 
of a pulmonary drug delivery system capable of carrying high drug amounts may provide 
flexibility in dosing strategies during treatment of lung cancer patients for either primary 
or supportive care. Nebulization was selected as the delivery mode of inhaler device to 
attain the desired high doses. Being a poorly-water soluble compound, it naturally 
presented formulation technology challenges for the delivery of aqueous dispersions of 
CoQ10 using the nebulization strategy. Consequently, it was most pertinent to investigate 
the physicochemical properties influencing the aerosolization profile of these dispersions. 
The research presented encompassed the definition of an appropriate manufacturing 
process, in vitro characterization and in vivo investigation. These studies were performed 
to identify the potential to deliver high doses of CoQ10 through the pulmonary route. 
 
2.2 SUPPORTING OBJECTIVES 
 
2.2.1. Measurement of Surface Tension of Liquids from the Maximum Pull on a 
Disk Theory using a Texture Analyzer 
The surface tension of liquids has been shown to influence the aerosolization 
profile from nebulizers. There are several methods available to measure this 
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physicochemical property in bulk liquid matter. The DuNoüy ring is the most common 
method utilized to determine this interfacial phenomenon and employs analytical 
microbalances for the measurement of the detachment force of a platinum-iridium ring 
from the surface of the bulk liquid. Using a disk geometry probe, an increase in the 
detachment force leads to the substitution of the microgravimetric system by a texture 
analyzer. By extrapolating the previously published work from the maximum pull on a 
rod, the objective of the study presented in Chapter 3 was to develop a precise, accurate 
and reproducible analytical method based on the maximum pull on a disk using a texture 
analyzer to determine the surface tension of the liquids. 
 
2.2.2 Development and Characterization of Phospholipid-Stabilized Submicron 
Aqueous Dispersions of Coenzyme Q10 Presenting Continuous Vibrating-Mesh 
Nebulization Performance 
CoQ10 is a poorly-water soluble compound that is being investigated for the 
treatment of lung malignancies. In this study, the aim was to develop a suitable 
formulation of CoQ10 for pulmonary delivery. The rationale for the selection of 
excipients and vibrating-mesh nebulizer device are presented in Chapter 4, in conjunction 
with preformulation characterization of the drug limited to the intended purpose. High 
pressure homogenization was chosen as an appropriate manufacturing process based on 
the production of submicron drug particles in aqueous dispersions and potential scale up 
capabilities. Soybean lecithin was used as a model excipient to stabilize CoQ10 
dispersions and analysis of the adequate number of passes in the microfluidization 
process was performed. It is known that the pores of vibrating-mesh nebulizers can clog, 
causing variations in the aerosol generation (i.e. intermittent mist). Therefore, in 
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conjunction with analysis of physicochemical properties, the nebulization performances 
of the CoQ10 formulations were also investigated. 
 
2.3.2 Prediction of In Vitro Aerosolization Profiles Based on Rheological Behaviors 
of Aqueous Dispersions of Coenzyme Q10 
Phospholipids comprise the majority of the components in the human alveolar 
surfactants. Dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine 
(DPPC) and distearoylphosphatidylcholine (DSPC) are among these phospholipids and 
can be synthetically produced. Soybean lecithin is a mixture of phospholipids. The 
objective of the study presented in Chapter 5 was to determine the nebulization 
performances and in vitro particle deposition profiles of formulations of CoQ10 stabilized 
with synthetic phospholipids and compare them with that of lecithin dispersions 
presented in Chapter 4. The nebulization steadiness, aerosol output, and deposition 
profiles were evaluated. In addition, the physicochemical properties of these formulations 
were further investigated and compared to identify those that may have the greatest 
influence on the aerosolization profile. Particle size distribution, zeta potential, surface 
tension, and rheological behavior were all studied. 
 
2.4.2 Pulmonary Deposition and Systemic Distribution in Mice of Inhalable 
Formulations of Coenzyme Q10 
Based on the in vitro characterization data, unprecedentedly high doses were 
observed with potential to reach the lungs based on their aerodynamic properties. 
Following-up, in vivo studies were performed to confirm the in vitro data. The goal of 
this investigation, presented in Chapter 6, was to determine the lung and nasal 
depositions as well as the systemic distribution of CoQ10 following nebulization of 
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formulations stabilized with DMPC, DPPC or DSPC. An estimated dose at which mice 
were to be exposed to was calculated for each formulation to be delivered. Mice were 
exposed to the drug aerosol for 15 minutes into a nose-only inhalation chamber, and the 
dosed and control groups were compared with respect to the estimated doses. 
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Chapter 3: Measurement of Surface Tension of Liquids from the 
Maximum Pull on a Disk Theory using a Texture Analyzer 
Abstract 
The intrinsic property of liquids serves as a vital indicator of formulation 
performance and stability. Therefore, investigation of the interfacial phenomenon of 
surface tension is a routine procedure in the development of products in a wide variety of 
areas including foods, pharmaceuticals, cosmetics, and painting technologies. In this 
work, it is hypothesized that studies related to the maximum pull on a rod can be 
extrapolated to disk geometry for application to measure surface tension using a texture 
analyzer. A glass disk probe was attached to the arm of a texture analyzer and pulled 
from the liquid surface. The maximum force of detachment was used to calculate surface 
tension extrapolated from the theory of maximum pull on a rod. The surface tension of 
water, ethanol and a hydroalcoholic solution were measured and compared to literature 
values to validate this hypothesis. The calculated values of surface tension for the liquids 
studied were within 5% of reported values. Probe diameter appears to have an important 
role on surface tension accuracy as compared to literature values. Slight discrepancies 
can be attributed to temperature control and leveling of the liquid surface, although still 
in accordance with reported values of surface tension measured using different methods. 
This study presents a simple, precise, and quick method to determine the surface tension 
of liquids from the maximum pull on a disk. Further studies are necessary to determine 
the optimum glass disk probe diameter for better accuracy. 
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3.1 INTRODUCTION 
Interfacial phenomena are important aspects in the formulation development 
process of liquids in the pharmaceutical, cosmetics, consumer product, painting, and food 
industries. Particularly, this physicochemical property is critical in pharmaceutical 
formulation development of microemulsions, suppositories, topical and transdermal 
delivery systems, eye drops and nasal aerosols, as the presence of surface active agents in 
formulations aid in the stability of suspensions, emulsions, and foams.[1, 2] Surface 
tension properties can be affected by the addition of ingredients to a liquid. Of particular 
importance to the development of inhalable pharmaceutical product, the surface tension 
of liquids has been shown to influence the aerosolization performance of nebulizers.[3-5] 
Numerous methods exist for the determination of liquid surface tensions, and can be 
either dependent or independent of contact angle.[6, 7] Considering their widely 
established use and acceptance, the DuNoüy ring and the capillary rise methods are the 
most noteworthy techniques applied to the evaluation of surface tension.  
Several types of probe geometries, including rings, cones and rods, have been 
used for the pull technique to measure surface tension from the menisci at a free liquid 
surface.[8-10] To date, there have been limited publications on the pull on a disk method 
after this technique was deemed not to offer applicable solutions for the measurement of 
surface tension.[7] According to Nietz and Lambert, disk geometry “presents complex 
problems” due to the exponential increase in force as a function of probe diameter. 
Ultimately, it was determined that the linear relationship found for rings, reasoned probe 
ring geometry to be the most suitable method for measurement of surface tension. 
However as an alternative approach, Padday and coworkers had previously determined 
the physical aspects governing the maximum pull on a rod.[11] They found that the 
maximum force to suspend the liquid underneath the rod, expressed as volume, is a 
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characteristic property of the system that can be numerically correlated to the probe 
radius for determination of surface tension.  
In order to rapidly determine the suspension force of a liquid, the inclusion of a 
force measurement apparatus is essential in the evaluation of surface tension. 
Traditionally, analytical balances are the predominant apparatus used to measure force 
exerted, by raising the liquid above a general level.[12] The DuNoüy method requires a 
microbalance to measure the detachment force of the liquid surface from platinum –
iridium ring. The texture analyzer is a force measurement instrument with a high force 
sensitivity and measurement range, although not capable of measuring the very small 
detachment force for a ring probe. The texture analyzer has in recent years become a 
standard for force measurement applications and has been widely used as a research tool 
in the pharmaceutical as well as the food industries.[13-16] With measurement time, arm 
speed and displacement distance as parameters that can be finely controlled, this versatile 
equipment offers the tools needed to investigate a variety of formulation aspects 
including material hardness, adhesiveness, stickiness, swelling, and penetration, 
properties.[17-19] 
The larger relative diameter of disks, as compared to rods and rings, is capable of 
suspending a greater volume of liquid underneath the probe, therefore requiring a greater 
maximum force to be measured. This increase in the measured detachment force is 
sufficient to fall within the measurement range of the texture analyzer. Previous work has 
not focused on disk geometry due to the reasons described above. In this study, it is 
hypothesized that the work performed by Padday et al. on the theory of maximum pull on 
a rod, can be extrapolated to the application of disks as the probe geometry due to their 
similarities in shape. However, the large differences in dimensions may alter the 
dynamics of static interfacial phenomenon measurement by modifying the magnitude of 
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maximum detachment force. The objective of this study was to explore the feasibility of 
using a glass disk probe in conjunction with a texture analyzer instrument to develop an 
accurate, precise and reproducible analytical method for the determination of the surface 
tension of liquids. The novelty of this work is in exploring the disk geometry capability 
of suspending significant volume of liquid underneath its leveled surface, making the 
force measurement to fall within the range of measurement of the texture analyzer. 
Therefore, eliminating the need of an extremely sensitive instrument to measure force, 
like the analytical microbalances commonly used to measure surface tension. Given its 
versatile and widespread application in a variety of laboratory settings, expanding the 
capabilities of this instrument would greatly benefit the fast screening of formulations for 
diversified industries. 
 
3.2 EXPERIMENTAL 
3.2.1. Materials 
A texture analyzer from Texture Technologies, model TA.XTPlus (Scarsdale, 
NY, USA) was used for all experiments in this study. A PYREX® 150 x 75 mm 
crystallizing dish (Product #3140-150) (Lowell, MA USA) was used as the liquid 
reservoir, and Alconox® Powdered Precision Cleaner (White Plains, NY, USA) was used 
as the cleaning agent. The ethanol used was procured from Fisher Science Education 
(Hanover Park, IL, USA) and the deionized water was obtained from a central reverse 
osmosis/demineralizer system commonly found in research laboratories. Duco® Cement 
from ITW Performance Polymers, Devcon (Danvers, MA, USA) was used to assemble 
the probes. 
 155
Two commissioned machine-made aluminum probes were constructed at the 
University of Texas at Austin department of Chemistry and Biochemistry machine shop. 
For each probe, an aluminum rod of radius 3.2 mm with thread on both ends was screwed 
perpendicularly into the probe housing of the texture analyzer on one end, and to a 
circular aluminum plate of radius 3.12 cm on the other. Two hand-made borosilicate 
glass disks were made by the University of Texas at Austin Chemistry Glass Shop, and 
the glass disks were adhered to the bottom of the aluminum plates with Duco® Cement 
(Figure 3.1). The small and large probes consisted of a radius of XS = 2.53860 ± 0.00402 
cm and XL = 2.97375 ± 0.00403 cm; and a width of WS = 6.571 ± 0.0547 mm and WL = 
6.684 ± 0.060 mm, respectively, using a caliper and average of 8 points about the 
circumference. 
 
3.2.2. Methods 
3.2.2.1. Preparation 
Prior to testing, all probes and liquid containers were cleaned with concentrated 
detergent (Alconox®), rinsed with deionized water, sprayed with ethanol, allowed to air 
dry, and followed by a thorough drying with compressed air. Additionally, an internal 
height calibration was performed on the texture analyzer as reference prior to each series 
of tests, as well as weight calibration check.  
 
3.2.2.2. Procedure 
Surface tension was measured by attaching the probe to the texture analyzer arm 
and lowering the probe until the bottom surface of the glass probe contacted the surface 
of a test liquid contained in a reservoir (Figure 3.1). At the start of test, the probe was 
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raised from the surface of the liquid at a constant speed to a specific height, while the 
texture analyzer registered force as a function of time or distance. The maximum force 
represents the force of detachment of the probe from the surface of the liquid, which was 
used to calculate the surface tension as explained later. The settings on the texture 
analyzer were as shown in Table 3.1. 
In this protocol, the probe was set to descend at a set speed until a trigger force 
was reached; this subsequently initiated the pre-programmed ascending movement to the 
return distance. The small trigger force of 0.20 mN was intentionally set to prevent the 
creation of disturbances on the liquid surface, from any descending movement. 
Therefore, contact time with liquid was maintained for a set period of time before the 
probe started its ascent.  
 
3.2.2.3. Calculation of Surface Tension 
Padday and coworkers have thoroughly investigated the surface tension 
measurement of liquids from the maximum pull on a rod.[11] Our study for calculation of 
surface tension from the maximum pull on a disk is derived from their work. The 
rationale for using specific equations developed by Padday and coworkers is described 
below. 
By raising a probe from the free surface of a liquid, the maximum force, Fmax, 
observed before meniscus breakaway is the result of hydrostatic pressure and surface 
tension contributions: 
 
ܨ௠௔௫ ൌ ߨܺଶܼߩ݃ ൅ 2ߨܺߛݏ݅݊ߠ  (Equation 3.1) 
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Where X is the probe radius, Z is the distance above the free surface of a liquid, ρ 
and γ are respectively the density and surface tension differences between the liquid and 
the surrounding fluid, g is the gravitational acceleration and θ is the angle between the 
vertical longitudinal axis and the meniscus angle at the junction of the disk. Therefore, 
the determination of surface tension is based on the following relationship: 
 
ߛ ൌ ி೘ೌೣିிೇ௅·௖௢௦ఏ  ቀ݅݊ 
௠ே
௠  ݋ݎ
ௗ௬௡
௖௠ ቁ  (Equation 3.2) 
 
Where FV is the force related to the hydrostatic pressure created by the volume of 
liquid lifted by the probe, L is the probe perimeter and θ is the contact angle. The 
commonly used DuNoüy ring is made of platinum, a material that presents a zero contact 
angle with water, similar to glass.[20, 21] 
 
In their work, Padday et al. express the maximum force as volume, V, according 
to the following equation: 
 
ܸ ൌ ி೘ೌೣఘ·௚   (Equation 3.3) 
 
By introducing a meniscus coefficient, k: 
 
݇ ൌ ටቀ ఊఘ·௚ቁ
మ   (Equation 3.4) 
 
The relationship between volume, probe radius and meniscus coefficient is 
established as: 
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௑
௞ ൌ ܽ଴ ൅ ܽଵ · ቀ
௑య
௏ ቁ ൅ ܽଶ · ቀ
௑య
௏ ቁ
ଶ
൅ ܽଷ · ቀ௑
య
௏ ቁ
ଷ
   (Equation 3.5) 
 
According to the mathematical analysis made by Padday et al., at different 
domains of X3/V, different coefficients, an, of Equation 3.5 are defined. In general, the 
greater the probe radius, the fewer the degrees of the polynomial equation above, are 
necessary to determine surface tension. In their work, Padday and coworkers present an 
extensive table of coefficients focusing on the lower range of X3/V to fit values from the 
maximum pull on a rod. A rod of small radius and capable of suspending a low volume of 
liquid from the surface justifies the focus of this work on the low range of X3/V. Since the 
ratio X3/V is largely determined by probe radius, and because our probe is significantly 
larger than a rod, the surface tension of liquids in this study was calculated using the 
coefficients related to the upper range of X3/V as determined by the envelope construction 
technique used by Padday and coworkers. The studied equations are presented in Table 
3.2. 
More recently, Christian and coworkers have synthesized all 18 polynomial 
expressions developed by Padday et al. into one cumbersome formula (Equation H, 
presented below), regardless of the range of X3/V: 
 
௑
௞ ൌ 2.48573 · ቀ
௑య
௏ ቁ
଴.ହ
൅ 0.70985 · ቀ௑య௏ ቁ ൅ 4.21654 · ቀ
௑య
௏ ቁ
ଵ.ହ
െ 1.94468 ·
ቀ௑య௏ ቁ
ଶ
൅ 2.30285 · ቀ௑య௏ ቁ
ଷ
െ 2.77894 · ቀ௑య௏ ቁ
ସ
൅ 1.65453 · ቀ௑య௏ ቁ
ହ
െ 0.420300 · ቀ௑య௏ ቁ
଺
൅
0.0129372 · ቀ௑య௏ ቁ
଼
  (Equation H) 
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In this work, Equation H was also analyzed for accuracy in measuring surface 
tension from the maximum pull on a disk. 
 
3.2.2.4. Validation Design 
To validate this test, surface tensions of 300 mL of distilled water, ethanol 
(EtOH), or 10% w/w ethanol in distilled water (10% EtOH/H2O), were analyzed for each 
of the two probes (n=5). These three liquids were chosen to cover a broad range of 
surface tensions according to their literature values (approximately, 22 to 72 mN/m). The 
liquid temperature was registered prior to each test. To compare with literature values, 
accuracy was measured according to Equation 3.6: 
 
ܣܿܿݑݎܽܿݕሺ%ሻ ൌ ቂቀఊ೎ೌ೗೎ఊ೗೔೟ ቁ െ 1ቃ ൈ 100  (Equation 3.6) 
 
Where γcalc and γlit are the calculated and literature values of surface tension of 
liquids, respectively.  
 
3.2.2.5. Statistical Analysis 
The data is presented as average ± standard deviation. Samples were analyzed in 
quintuplicate and evaluated for statistical differences with t-test for significance when p < 
0.05 using NCSS/PASS software Dawson edition.[22] 
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3.3 RESULTS AND DISCUSSION 
Force increases as a function of time when considering the distance moved by the 
texture analyzer arm at a constant speed. A typical graph of the measurement of surface 
tension of liquids using this method is shown in Figure 3.2. 
The peak (Fmax) represents the force of probe detachment from the surface of the 
liquid. The Fmax values measured for water, 10% w/w ethanol in water and ethanol and 
their respective calculated X3/V are shown in Table 3.3. Considering the radius of the 
probes and the maximum force, the majority of the X3/V values for liquids evaluated in 
this study do not fall within the ranges provided in the work from Padday and coworkers, 
namely: 0.01 – 1.85. Interestingly, both probe sizes presented very precise results, with 
coefficients of variation smaller than 1%, indicating the high reproducibility of this 
method. Nevertheless, Fmax (and consequently X3/V) was more precise for the large probe 
diameter. Based on the study from maximum pull on a rod, the equations related to the 
upper range of X3/V (Table 3.2) were empirically used to calculate the surface tension 
values of the referred liquids for comparison with the literature values.[23] The results of 
X3/V to Equation H as previously described were also fitted. The accuracy results are 
presented in Figure 3.3 for small and large diameter probes.  
The surface tension of water, ethanol and the hydroalcoholic solution calculated 
using Equations A to H) presented overall underestimated values compared to literature 
data. Regardless of probe size, similar patterns were observed for the equation groups 
B/D and C/E/F/G. Besides more precise results, the large diameter probe presented more 
accurate values than the small probe. This may indicate that accuracy and precision may 
be dependent on an optimum probe diameter. Figure 3.4 helps to elucidate this trend. 
Considering the differences in accuracy of surface tension according to the probes 
investigated (radius of approximately 2.5 and 3.0 cm), it is believed that increasing the 
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probe radius to about 3.5 to 4.0 cm may provide even more accurate results. Further 
studies are warranted for verification of this relationship, but it is noteworthy to highlight 
that with increased radius, a wider container is necessary to maintain the infinite interface 
configuration later discussed, consequently requiring a greater sample volume. 
Nevertheless, using the large probe and Equation E, for instance, provided results with 
accuracy that was less than 5% from literature values for water (69.55 ± 0.34 mN/m), 
10% w/w ethanol in water (45.20 ± 0.13 mN/m) and ethanol (21.40 ± 0.05 mN/m). 
Interestingly, Equations C, E, F and G, which provided similarly better accuracy results 
with the large probe, are either first or second order polynomial forms of X3/V. This 
indicates that an exponential function does not necessarily model an increase in force as a 
function of disk diameter, as previously described by Nietz and Lambert.[7] Finally, 
Equation H appears to be unfeasible for use in the calculation of surface tension from 
maximum pull on a disk, since it is equally accurate compared to Equations C, E, F and G 
when X3/V is below 2.0 but largely deviates from the literature values when this 
parameter increases. 
Any slight discrepancy between the calculated values of surface tension measured 
by the large probe (e.g. using Equation E) and the literature values may be explained by a 
number of factors that could be considered limitations of this method. Most importantly, 
the probe and liquid surfaces must be in full and close contact throughout the 
measurement. To ensure this, probe and container surfaces were thoroughly cleaned prior 
to experiments with an abrasive detergent, adequately dried to remove any dust, and 
followed by careful handling to avoid particle settling. Additionally, our in-house 
constructed glass probe is prone to present a non-ideal edge roughness, as well as micro-
chips and micro-cracks despite careful handling and storage. A glass probe produced and 
stored under strict specifications in terms of edge roughness, radius measurement, and 
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storage container, may potentially provide even more accurate results. Moreover, 
considering the large surface area of the probes, any tilt in probe position in relation to 
the surface of the liquid, must be avoided. In this study, leveling was performed by 
placing a level instrument on the texture analyzer platform and adjusting the legs of the 
equipment. Lastly, the operator must certify that any bubble underneath the probe is 
removed prior to starting the test. This has been performed in this study purely based on 
visual observation. When a high volume of sample is being analyzed (e.g. 300 mL as 
initially tested), the operator can easily identify the presence of bubbles by looking 
upwards at the liquid-probe contact point from a low eye position. In the case of opaque 
liquids (e.g. suspensions, emulsions) and low volume samples, the configuration in 
Figure 3.5 with a mirror positioned underneath the sample container is very useful. 
Frequently, a series of upward and downward movements with the texture analyzer arm 
is necessary to ensure that no bubbles are impeding the direct contact between glass 
probe and liquid surface. A container equipped with ultrasonication capability is an 
alternative option to help remove bubbles, both dissolved in the liquid and generated by 
the contact of the probe with the surface of the liquid.  
Furthermore, temperature is highly influential in the determination of liquid 
surface tension and should be strictly controlled. In our proof-of-concept experiments, the 
liquid temperature was registered using an ordinary alcohol lab thermometer. 
Alternatively, a thermal cabinet adequately adapted to enclose the container (and possibly 
the texture analyzer arm) could provide improved temperature control. Furthermore, there 
must be sufficient distance between the probe and container walls to eliminate cross-
interference in the measurement of surface tension of liquids (infinite interface).[24, 25] 
For this reason, and considering probe diameter, a wide circular container was used in our 
study, necessitating a sample volume of a few hundred milliliters. Further studies to 
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determine the minimum sample volume for this setup have also been performed. Using 
50 mL, the surface tension of water analyzed at 24 °C was calculated using Equation E of 
this method and found to be 69.79 ± 0.24 mN/m. This is not statistically different from 
the measurement made with 300 mL of water. With smaller sample volumes, stricter 
temperature control is even more important because heat transfer to the liquid mass turns 
the sample more prone to temperature variation. Lastly, any difficulty in measuring the 
surface tension of surfactant solutions due to rise of liquid against the glass probe wall, 
may be circumvented via careful control of the ascending arm speed of the texture 
analyzer. This would allow adequate time for the liquid to drain down as the peak force is 
approached.  
Remarkably, uncertainty in absolute values of surface tension of liquids using 
different methods has been widely described. For instance, the surface tension of water at 
25°C has been reported between 71.82 and 73.0 mN/m.[26, 27] Therefore, our method 
presents an acceptable accuracy. Particularly, the method presents excellent precision, 
with coefficients of variation below 0.5% for the large probe (1.4% for the small probe). 
During our studies though, it was observed that more precise measurements were 
obtained at the end of a series of analysis. Studies on the dehydration of glass surfaces 
indicate an increase in contact angle as a function of water drying time.[28] These 
findings may indicate that the glass probe needs to be in contact with aqueous solutions 
for a certain period of time prior to analysis of surface tension.  
 
3.4 CONCLUSION 
A glass probe disk with radius of approximately 3 cm attached to the arm of a 
texture analyzer can be used to measure the detachment force from a liquid surface. This 
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maximum force can be extrapolated to equations previously developed to calculate 
surface tension from the maximum pull on a rod. Using this method, calculated absolute 
values of surface tension of selected liquids are within 5% from literature values. With 
this setup, sample volumes as low as 50 mL can be analyzed. Using a texture analyzer to 
determine surface tension provides an additional feature for this versatile equipment 
already used in a multitude of testing procedures and therefore widely available in such 
research laboratories. This experiment provides a precise, simple and quick method to 
determine the surface tension of liquids from the maximum pull on a disk. Further studies 
are necessary to ensure the optimal probe diameter necessary to improve accuracy in the 
values of surface tension compared to the literature.
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3.5 TABLES 
 
Parameter Value 
Texture analyzer protocol: Adhesive test 
Speed of descent: 0.5 mm/s 
Trigger force: 0.20 mN 
Contact time: 5 s 
Return distance: 10 mm 
Return speed: 0.05 mm/s 
Data acquisition: 5 points per second 
Table 3.1 – Settings on texture analyzer for measurement of surface tension of liquids 
from the maximum pull on a disk. 
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Equation Range of X3/V Formula 
A 0.50 – 0.60 
ܺ
݇ ൌ 0.378 ൅ 5.8 · ቆ
ܺଷ
ܸ ቇ 
B 0.60 – 0.80 
ܺ
݇ ൌ 0.57211 ൅ 5.15631 · ቆ
ܺଷ
ܸ ቇ ൅ 0.533894 · ቆ
ܺଷ
ܸ ቇ
ଶ
 
C 0.80 – 1.00 
ܺ
݇ ൌ 0.299048 ൅ 5.8626 · ቆ
ܺଷ
ܸ ቇ ൅ 0.0783455 · ቆ
ܺଷ
ܸ ቇ
ଶ
 
D 1.00 – 1.20 
ܺ
݇ ൌ 0.676415 ൅ 5.16281 · ቆ
ܺଷ
ܸ ቇ ൅ 0.401204 · ቆ
ܺଷ
ܸ ቇ
ଶ
 
E 1.20 – 1.40 
ܺ
݇ ൌ 0.0408687 ൅ 6.20312 · ቆ
ܺଷ
ܸ ቇ െ 0.0240752 · ቆ
ܺଷ
ܸ ቇ
ଶ
 
F 1.40 – 1.60 
ܺ
݇ ൌ 0.253174 ൅ 5.90351 · ቆ
ܺଷ
ܸ ቇ െ 0.0814259 · ቆ
ܺଷ
ܸ ቇ
ଶ
 
G 1.60 – 1.85 
ܺ
݇ ൌ െ0.013 ൅ 6.2 · ቆ
ܺଷ
ܸ ቇ 
Table 3.2 – Relation of X/k as a function of X3/V for the calculation of surface tension of 
liquids from the maximum pull on rods with different diameters.[11] 
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Liquid Fmax (mN) X3/V 
XS XL XS XL 
Water 101.44 ± 0.65a 
(0.64%) 
142.57 ± 0.36 
(0.25%) 
1.577 ± 0.010a 
(0.64%) 
1.804 ± 0.005 
(0.25%) 
10% w/w ethanol 
in water 
81.79 ± 0.16 
(0.20%) 
113.71 ± 0.16 
(0.14%) 
1.923 ± 0.004 
(0.20%) 
2.223 ± 0.003 
(0.14%) 
Ethanol 50.25 ± 0.17 
(0.33%) 
69.78 ± 0.08 
(0.11%) 
2.506 ± 0.008 
(0.33%) 
2.901 ± 0.003 
(0.11%) 
a The liquid temperature during measurement was 24 °C. Fmax: maximum detachment force; X: probe radius; V: 
volume; S: small; L: large. 
Table 3.3 – Values of measured Fmax for three different liquids and their respective 
calculated X3/V at 25°C, unless specified. Results are expressed as mean ± 
standard deviation (coefficient of variation) for 5 replicates. 
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3.6 FIGURES 
 
Figure 3.1 – Schematic diagram of texture analyzer used to measure the surface tension 
of liquid. Details of the probe appear in the zoomed-in area. X and W 
represent radius and width of the glass disk probe, respectively.  
 169
 
 
Figure 3.2 – A typical graph from the maximum pull on a disk using the present method 
for small and large probes. 
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Figure 3.3 – Accuracy in measurement of surface tension of three different liquids based 
on extrapolation on the theory of maximum pull on a rod to the application 
of disks as probe geometries. Results are expressed as mean ± standard 
deviation (n = 5). Equations A to G are shown in Table 3.2 and Equation H 
is presented in section 3.2.2.3. A: small probe (XS); B: large probe (XL). 
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Figure 3.4 – Comparison with literature values of surface tension of water (dotted), 10% 
ethanol in water (diagonal) and ethanol (empty columns); based on 
extrapolation on the theory of maximum pull on a rod to the application of 
disks as probe geometries. Results are expressed as mean ± standard 
deviation (n = 5). Equations A to G are shown in Table 3.2 and Equation H 
is presented in the section 3.2.2.3. A-C: small probe (XS); D-F: large probe 
(XL). Measurements were performed at 25°C (except graph A: 24°C). 
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Figure 3.5 – Setup for measurement of surface tension of opaque liquids, such as 
suspensions and emulsions, and/or low volume samples for better 
visualization of the presence of bubbles between the liquid surface and the 
glass disk probe. The stand is a cube shaped structure with open walls in all 
faces. Therefore, the movement of the texture analyzer arm should be 
controlled to avoid breaking the glass container. 
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Chapter 4: Development and Characterization of Phospholipid-
Stabilized Submicron Aqueous Dispersions of Coenzyme Q10 Presenting 
Continuous Vibrating-Mesh Nebulization Performance 
Abstract 
Coenzyme Q10 (CoQ10) is a poorly-water soluble compound that is being 
investigated for the treatment of carcinomas. The aim of this research was to develop a 
suitable formulation for pulmonary delivery of this anticancer agent. An appropriate 
selection of excipients (phospholipids) and a suitable device (Aeroneb Pro® vibrating-
mesh nebulizer) were selected initially after reviewing the literature. Initial 
characterization of the bulk drug using X-ray diffraction (XRD), Differential Scanning 
Calorimetry (DSC), Laser Diffractometry (LD) and Scanning Electron Microscopy 
(SEM) was performed. High shear mixing, high pressure homogenization or 
ultrasonication was then evaluated as feasible manufacturing processes to obtain small 
particle size dispersions of CoQ10. Following selection of an appropriate process, the 
parameters affecting drug particle size were studied. Using LD and gravimetrical 
analysis, nebulization was evaluated to assess the performance of the inhalation system 
triad: drug-excipients-device. CoQ10 powder studied was crystalline with a melting point 
approximately at 51 °C with a particle size of 30 µm. Therefore, particle downsizing was 
deemed necessary for pulmonary delivery. Microfluidization was found to be a suitable 
method to prepare submicron drug particles in aqueous dispersions. The number of 
passes and type of phospholipids (lecithin or Dipalmitoyl Phosphatidylcholine – DPPC) 
used strongly affected final drug particle size of the dispersions. Nebulization 
performance of lecithin-stabilized CoQ10 dispersions varied according to number of 
passes in the microfluidizer. Most importantly, the rheology of these dispersions 
appeared to play a significant role in the aerosol generation from the active vibrating-
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mesh nebulizer used. In conclusion, aqueous dispersions of CoQ10 were adequately 
produced using a microfluidizer with characteristics that were suitable for pulmonary 
delivery with an Aeroneb Pro® nebulizer. 
 
4.1. INTRODUCTION 
Coenzyme Q10, also known as CoQ10, ubiquinone or ubidecarenone, is a vitamin-
like compound in that it is similar in structure to vitamin K. CoQ10 is absorbed in a 
similar fashion to vitamin E; this becomes enhanced in the presence of lipids.[1] 
Naturally found in the body, therefore not considered a vitamin, this compound primarily 
participates in electron transport and proton transfer in mitochondrial respiration.[2] It 
follows that altering the levels of this antioxidant may have an impact on aging, 
neurodegenerative and cardiovascular diseases, diabetes and cancer.[3] Endogenous 
CoQ10 has shown to be a prognostic factor for melanoma progression by observing that 
patients with higher levels presented a lower risk of metastasis.[4] Therapy using 
exogenous CoQ10 has long been reported in cases where a number of cancer patients were 
effectively treated against a variety of different types of carcinomas.[5, 6] Reports 
include survival ranging from 5 to 15 years for pancreas, rectum, breast, prostate, 
larynges, or lung cancer patients. Recent findings indicate that chemotherapeutic drugs 
(e.g. camptothecin, etoposide, doxorubicin, methotrexate) can increase levels of CoQ10 
following treatment of cancer cell lines.[7] Further studies have shown that this 
endogenous compound may act against melanoma and other malignancies through 
modulation of the BCL-2 protein family.[8-10] Although improved survival rates for end 
stage cancer patients treated with CoQ10 have lately been confirmed in a pilot study, no 
rigorous trials have been carried out to substantiate these findings.[11] This anticancer 
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agent is a poorly-water soluble compound presented as a yellow or orange crystalline 
powder.[12] 
The pulmonary delivery of such compounds has been attempted in dosage forms 
of nanosuspensions and liposomes where vibrating-mesh nebulizers have been used.[13-
19] These devices generate aerosol by vibrating a mesh following application of electrical 
current to a piezoelectric membrane.[20] Studies have shown that surface tension, 
viscosity, and ion concentration play a significant role in the aerosol output from these 
devices.[21] Since droplet sizes of 1 to 5 µm generated from nebulizers are expected to 
reach the deep lungs following inhalation,[22] it is crucial to select appropriate excipients 
and a suitable delivery device. 
The highest plasma concentration of CoQ10 reported in the literature is 10.7 
µmol/L (approximately 9 µg/mL) from a solubilized formulation among several oral 
formulations available on the market as dietary supplements (nutraceutical).[23] 
Nevertheless, the maximum tolerated dose (MTD) has yet to be determined. We 
hypothesize that formulations of CoQ10 can be developed for pulmonary delivery with a 
satisfactory pharmacokinetic profile that will improve the pharmacodynamic response to 
treat lung malignancies. By delivering a high amount of drug to the disease site, a lower 
dose may be necessary compared to intravenous or oral administration. Additionally, 
systemic distribution from the lungs may favor treatment of carcinoma in different body 
organs. However, the systemic absorption from the lungs is unknown.  
The main objective of this study was to develop an inhalable formulation of 
CoQ10. We start by introducing the rationale for selection of the main elements of this 
formulation: device and excipients for pulmonary delivery. We then present 
preformulation characterization of bulk CoQ10 limited to our intended purpose. Next, we 
selected an appropriate manufacturing process with scale up potential. Finally, we 
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determined the nebulization capacity of this dispersion and investigated the possible 
physicochemical properties of the formulation that may be indicative of nebulization 
performance. We discovered out that rheology may play a significant role in the 
hydrodynamics of aerosol production using a vibrating-mesh nebulizer with CoQ10. 
 
4.2. RATIONALE FOR FORMULATION DESIGN 
The intended purpose of this formulation is to deliver CoQ10 to treat lung 
malignancies via inhalation therapy. The formulation design of this poorly-water soluble 
compound is extremely important to ensure the safe delivery to patients. For this reason, 
consideration of the bulk physicochemical properties of this drug and an adequate 
selection of excipients and device ensures an appropriate formulation design. In turn, a 
feasible manufacturing process guarantees the development of the final dosage form for 
pulmonary delivery. 
In general, a nebulizer is selected for inhalation therapy over pressurized Metered 
Dose Inhalers (pMDIs) and Dry Powder Inhalers (DPIs) by virtue of their capability of 
delivering high amounts of drugs via passive breathing.[24] Therefore, patients with 
impaired pulmonary function (e.g. lung cancer patients) are not expected to experience 
difficulty in using this type of device. Based on previous studies confirming the 
capability of this device in delivering poorly-water soluble drugs as a dispersed dosage 
form, we have designed the delivery of CoQ10 to the lungs using the Aeroneb Pro® 
micropump nebulizer (Aerogen Ltd, Galway, Ireland).[13-15] This autoclavable device, 
designed for mechanically ventilated patients in hospital settings, is an active vibrating-
mesh nebulizer.[25] This functioning mechanism generates aerosol from aqueous-based 
formulations, including liposomes.[17-19] The device has a mesh placed on the bottom of 
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the nebulizer reservoir (medication cup capacity: 10 mL) that actively vibrates (frequency 
of nebulizer unit: 128 KHz) generating an aerosol from the liquid that is available in the 
reservoir (low residual volume in medication cup minimizes drug waste)[26]. 
Importantly, the performance of this nebulizer can be affected by mesh clogging, 
resulting in changes in the performance and ultimately automatic switch off of the 
device.[27] Therefore, thorough cleaning of the membrane must be ensured prior to 
performing each test run. 
A very limited number of excipients are available for safe delivery of drugs via 
nebulization, which complicates the selection process.[28] Phospholipids are the main 
constituents of the human alveolar surfactant (90%), and there is a predominant 
occurrence of phosphatidylcholine (PC – 73% of phospholipids). Among the different 
saturated and unsaturated lipidic chains of PC, dipalmitoyl phosphatidylcholine (DPPC) 
is the main component (81% of PC), while dimyristoyl phosphatidylcholine (DMPC) and 
distearoyl phosphatidylcholine (DSPC) each comprise 3% of PC.[29] We have chosen to 
stabilize our formulations with phospholipids given their physiological occurrence in the 
lungs. 
Lung surfactants are used for the treatment of Respiratory Distress Syndrome 
(RDS) in premature infants.[30] Survanta is an intratracheal suspension (25 mg/mL of 
phospholipids) of pulmonary surfactant extracted from natural bovine lungs. Other 
pulmonary surfactants include: Curosurf, from porcine extract (80 mg/mL of 
phospholipids); Exosurf, a synthetic phospholipid mixture of DPPC (13.5 mg/mL) with 
cetyl alcohol (1.5 mg/mL) and tyloxapol (1 mg/mL); and Infasurf, from calf lung lavage 
(35 mg/mL of phospholipids).[31] We have chosen 2.5% w/w to be the maximum 
phospholipid concentration in our formulations, which is the same as in the approved 
drug product Survanta®. DPPC is one of the components of the mixtures of phospholipids 
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that comprise soybean lecithin, with concentrations varying widely depending on the 
source and extraction method.[32, 33] Given that it is already in approved drug products 
for inhalation and available at a low cost, lecithin has been selected as a model 
phospholipid. DPPC was also selected and analyzed as a purified PC choice. 
Figure 4.1 presents our vision of the pulmonary delivery of CoQ10 based on our 
formulation design. The bulk drug is formulated into a phospholipid-stabilized aqueous 
dispersion with small (drug) particle size that is aerosolized using the vibrating-mesh 
nebulizer into droplets containing small drug particles. For definition purposes, “particle” 
is referring the internal phase of the aqueous dispersion and “droplet” is referring the 
result of becoming aerosol generated. Ideally, each droplet contains a certain number of 
drug particles. The physicochemical characterization of bulk CoQ10 for our intended 
purposes and the selection of a manufacturing process are presented next. 
 
4.3. MATERIALS AND METHODS 
4.3.1. Materials 
Coenzyme Q10 was supplied by Asahi Kasei Corp. (Tokyo, Japan). Lecithin 
(granular, NF) was purchased from Spectrum Chemical Mfg. Corp. (Gardena, CA, USA). 
Genzyme Pharmaceuticals (Liestal, Switzerland) provided 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC). Sodium chloride (crystalline, certified ACS) was acquired from 
Fisher Chemical (Fisher Scientific, Fair lawn, NJ, USA) and the deionized water was 
obtained from a central reverse osmosis/demineralizer system commonly found in 
research laboratories. The dispersant 1,3-propanediol (98%) was purchased from Sigma-
Aldrich (St. Louis, MO, USA). Ethanol 200 proof USP was purchased from Decon 
Laboratories (King of Prussia, PA, USA). 
 182
 
4.3.2. Bulk Characterization of CoQ10 
4.3.2.1. X-ray diffraction (XRD) 
Testing was performed using a Philips Model 1710 X-ray diffractometer (Philips 
Electronic Instruments Inc., Mahwah, NJ, USA) with primary monochromated radiation 
(CuKα1, λ = 1.54056 Å) emitting at an accelerating voltage of 40 kV and 30 mA. The 
CoQ10 powder was placed into a stage and the sample was scanned for diffraction 
patterns from 5º to 50º at 0.05º intervals of 2θ angles, with dwell time of 3 seconds. 
 
4.3.2.2. Differential Scanning Calorimetry (DSC) 
DSC testing was performed using a 2920 Modulated DSC (TA Instruments, New 
Castle, DE, USA) and analyzed using TA Universal Analysis 2000 Software. Powder of 
CoQ10 was weighed (10.5 mg) into aluminum pan (kit 02190041, Perkin-Elmer 
Instruments, Norwalk, CT, USA) and crimped. At a heating rate of 10 °C/min, the 
thermal behavior of the sample was analyzed from 10 to 120 °C. 
 
4.3.2.3. Laser Diffraction (LD) 
Bulk CoQ10 powder was dispersed in 20% (v/v) 1,3-propanediol in deionized 
water for analysis of particle size distribution. This dispersed sample was then added to a 
small cell apparatus in a Malvern Mastersizer S® instrument (Malvern Instruments, 
Worcestershire, UK) equipped with a 300 mm lens until 5-10% obscuration was attained. 
The internal phase and dispersant refractive indexes were 1.45 and 1.33, respectively.  
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4.3.2.4. Scanning Electron Microscopy (SEM) 
Analysis of physical appearance and estimation of particle size of bulk CoQ10 
were performed using SEM. An aluminum stage with adhesive carbon tape held the 
powder sample. Coating was carried out in a rotary-planetary-tilt stage with platinum-
iridium using a Cressington Sputter Coater 208 HR (Cressington Scientific Instruments, 
Watford, England) under argon atmosphere. The SEM pictures were captured using 
SmartSEM® graphical user interface software in a Carl Zeiss Supra® 40VP Scanning 
Electron Microscope (Carl Zeiss AG, Oberkochen, Germany) operated at a working 
distance of 19 mm and at 5 kV of Electron High Tension (EHT). 
 
4.3.3. Determination of Manufacturing Process 
We have tested three different manufacturing processes with the objective of 
obtaining an aqueous dispersion with a small drug particle size. A phospholipid 
dispersion containing 6% w/w of lecithin in water was added to the molten CoQ10 (1% 
w/w) at 55 °C. The lecithin concentration is above the critical micellar concentration 
(depending on soybean seed type and processing method, CMC varies from 1.3 to 5.5 
mg/mL[33]). The formulation was then processed as follows. 
 
4.3.3.1. High Shear Mixing 
One hundred milliliters of formulation was stirred at 300 rpm and high shear 
mixed at 10,000-12,000 rpm for 45 minutes using an Ultra-Turrax® TP 18/10 
Homogenizer with 8 mm rotor blade (IKA-Werke, Staufen, Germany). 
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4.3.3.2. High Pressure Homogenization 
 The microfluidization process works by having two jet streams in opposite 
directions. Each pass represents one chance that the drug particles have to collide against 
each other, breaking apart and becoming smaller. The formulation was predispersed 
using probe sonication for 2 minutes, followed by 30 passes at approximately 13,000 psi 
using an M-110Y High Pressure Pneumatic Microfluidizer® (Microfluidics, Newton, MA 
USA). 
 
4.3.3.3. Ultrasonication 
The formulation was ultrasonicated at 125W for 60 minutes using an Omni Sonic 
Ruptor-250® Ultrasonic Homogenizer with 5/32" (3.9mm) with a micro-tip probe (Omni 
International, Kennesaw, GA, USA). 
 
4.3.4. Formulation Development 
After selection of the manufacturing process, formulations were prepared with 
high pressure homogenization to determine the effect of the selected parameters and type 
of phospholipid on the particle size distribution of the drug dispersion. During 
preliminary studies, it has been observed that the high solute concentration of 
formulations containing 6% w/w of lecithin was not able to produce aerosol from the 
Aeroneb Pro® vibrating-mesh micropump nebulizer. Further preliminary studies have 
also shown that formulations containing a reduced concentration of lecithin (1% w/w, at 
1:1 drug-to-lipid ratio) have presented sufficient stability for evaluation of nebulization 
performance following preparation. Therefore, reduction of phospholipid concentration 
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was necessary while simultaneously keeping the concentration of CoQ10 constant at an 
adequate drug-to-lipid ratio. 
Following hydration, a phospholipid dispersion containing 1% w/w of 
phospholipid (lecithin or DPPC) in water was added to the molten CoQ10 (1% w/w) at 55 
°C. The formulation was then predispersed using high shear mixing (Ultra-Turrax® TP 
18/10 Homogenizer with 8 mm rotor blade, IKA-Werke, Staufen, Germany) for up to 5 
minutes at 20,000 rpm. Subsequently, the formulation was passed through an M-110P 
Bench-top Microfluidizer® (Microfluidics, Newton, MA USA) up to 100 times at 
approximately 30,000 psi while maintaining the temperature between 50 and 60 °C. 
In testing the effects that the type of phospholipid and number of passes have on 
particle size distribution of the formulations, phospholipid dispersions were hydrated for 
approximately 1 hour without stirring (Table 4.1, Formulations A and B). Formulations 
were then passed through a microfluidizer 10, 20, 30, 40 and 50 times when comparing 
different phospholipids; 20, 50, 70 and 100 times when evaluating the effect from 
number of passes. For nebulization performance tests, the phospholipid dispersions were 
hydrated overnight with stirring and 0.9% w/v of sodium chloride was added to the final 
formulation (Table 4.1, Formulation C). 
The particle size distributions of the formulations were then analyzed using Laser 
Diffraction (LD) and/or Dynamic Light Scattering (DLS). The surface tension, zeta 
potential and rheology were also evaluated. For nebulization performance, aerosol output 
was performed using LD and gravimetrical analysis. Unless otherwise stated, samples 
were characterized following preparation. 
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4.3.5. Formulation Characterization 
4.3.5.1. Particle Size Distribution 
Particle size distribution testing of the dispersed formulations was performed with 
LD using a wet sample dispersion unit stirring at 1,000 rpm coupled to a Malvern 
Spraytec® (Malvern Instruments, Worcestershire, UK) equipped with a 300 mm lens. The 
dispersed formulations were added to distilled water (dispersant) until approximately 5% 
laser obscuration was attained. The internal phase and dispersant refractive indexes were 
set as 1.45 and 1.33, respectively, based on reports related to lecithin in the literature.[34] 
A timed measurement was performed for 45 seconds with 1 second sampling periods (a 
total of 45 measurements). Results are presented as Dv(X) and span, where X is the 
cumulative percentile of particles under the referred size (e.g. Dv(50) corresponds to the 
median volume of the particles). Span is a measurement of particle size distribution 
calculated as [Dv(90) – Dv(10)]/Dv(50)]. Therefore the higher the span, the more 
polydisperse the particle size distribution was. 
In addition, the nanoparticle hydrodynamic diameter of the dispersed formulations 
was characterized with DLS using a Malvern Zetasizer Nano S® (Malvern Instruments, 
Worcestershire, UK) at 25°C and pre-equilibrated for 2 minutes. The intercept of the 
correlation function was between 0.5 and 1.0. Dilution of the dispersion was done with 
distilled water.  
 
4.3.5.2. Surface Tension 
Surface tension testing was performed using a TA.XT.plus Texture Analyzer 
(Texture Technologies, Scarsdale, NY, USA) from the maximum pull on a disk as 
described in the previous chapter. Briefly, the container and glass disk probe were 
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thoroughly degreased, cleaned with ethanol and allowed to dry. The probe was attached 
to the texture analyzer arm, and lowered until the bottom surface of the probe contacted 
the surface of the liquid formulation contained in the reservoir. The temperature of the 
liquid was measured and recorded. At the start of testing, the probe was raised from the 
surface of the liquid at a constant speed (0.05 mm/s) for 10 mm, while the texture 
analyzer registered at 5 points per second the force exerted as a function of either time or 
distance. Using the maximum (detachment) force the surface tension was calculated 
using the equation below: 
 
௑
௞ ൌ 0.0408687 ൅ 6.20312 · ቀ
௑య
௏ ቁ െ 0.0240752 · ቀ
௑య
௏ ቁ
ଶ
  (Equation 4.1) 
 
Where X is probe radius, V is volume and k is the meniscus coefficient. For more 
details, see Chapter 3. The density values used to calculate surface tension were assumed 
to be the same as the density of water at the measurement temperature. 
 
4.3.5.3. Zeta Potential 
Electrophoretic light scattering was used to perform zeta potential testing with a 
ZetaPlus Zeta Potential Analyzer (Brookhaven Instruments Corp., Holtsville, NY, USA). 
The samples were analyzed at a constant temperature of 25°C and constant (neutral) pH. 
Samples were diluted with distilled water to conductance values of 300 to 550 µS. Each 
sample was subjected to 10 runs each, with a 5 second interval between measurements.  
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4.3.5.4. Rheology 
Rheological behavior of the dispersed formulations were tested using a AR-G2 
rheometer (TA Instruments, New Castle, DE, USA) equipped with a cone-and-plate 
geometry (cone diameter: 40 mm; truncation: 54 µm). Zero-gap and rotational mapping, 
respectively, were performed prior to testing. All measurements were executed with fresh 
sample dispersion at a constant temperature of 25°C with no pre-shear. Excess sample 
around the edge of the probe was trimmed and water added to the solvent trap 
compartment. The samples were measured at steady state flow step over a range of shear 
rates (300 to 10 s-1) decreasing logarithmically (10 points per decade). The upper limit of 
shear rate was determined by hydrodynamic limitations (high probe speed will cause the 
liquid sample to spill away from the measurement zone). The sample period was 10 
seconds and considered in equilibrium after 2 consecutive analyses within 5% tolerance, 
not exceeding a maximum point time of 2 minutes. The results were evaluated using 
Rheology Advantage Data Analysis software (TA Instruments, New Castle, DE, USA). 
  
4.3.5.5. Nebulization Performance 
Based on previous experience, the performance of vibrating-mesh nebulizers can 
be affected by mesh clogging, resulting in variable aerosol emission (i.e. intermittent 
mist), since this formulation is a dispersed system.[27] To analyze the nebulization 
performance of these formulations, we evaluate the changes in transmission over time 
from LD technique measurements. The nebulization performance of the dispersions was 
evaluated using the “open bench” method with a Malvern Spraytec® instrument (Malvern 
Instruments, Worcestershire, UK) equipped with 300 mm lens.[35] The nebulizer 
reservoir was positioned with the membrane at 25 mm above the upper edge of the laser 
beam and a distance of 25 mm between the lens and the center of the aerosol cloud. Air 
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suction was positioned 10 cm beneath the laser beam. The device and air suction 
apparatus positions were maintained still throughout the whole measurement period. The 
internal phase and dispersant refractive indexes were 1.33 (water) and 1.00 (air), 
respectively. Formulation (10 mL) was added to the nebulizer reservoir. At the start of 
nebulization, aerosol characteristics were continuously measured every second for 15 
minutes. The slope of the transmission-time curves (transmittograms) were considered 
when comparing the different phospholipid formulations. 
In addition, the Total Aerosol Output (TAO) was gravimetrically measured for 
each of the formulations studied. Before aerosolization, the nebulizer was weighed after 
each formulation was dispensed into the reservoir. The remaining formulation in the 
nebulizer reservoir was re-weighed after undergoing 15 minutes of nebulization. The 
difference in weight before and after nebulization results in the calculated TAO. The 
weight of the nebulizer mouthpiece was not considered during the measurements. 
Importantly, neither transmittogram nor TAO provide information regarding drug 
output from the nebulizer. Information is limited solely to total mass output (droplets 
emitted over time). In the aerosolization of these dispersions, droplets not containing drug 
particles (empty droplets) are potentially generated. However, our purpose with this test 
is to investigate the capability of the Aeroneb Pro® nebulizer to continuously and steadily 
aerosolize the aqueous dispersions of Coenzyme Q10 over time. Intermittent mist can be 
identified in the transmittograms while TAO elucidates the magnitude of total mass being 
aerosolized. Saline solution (12 mL of 0.9% w/v NaCl in water) was used as the control. 
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4.3.6. Statistical Analysis 
The data is expressed as mean ± standard deviation with the exception of surface 
tension and zeta potential results, which were expressed as mean ± standard error. For 
rheology studies, standard errors were provided by the software used to analyze the best 
fit of the results to the rheological models. Samples were analyzed at least in triplicate 
and evaluated for statistical differences with One-Way ANOVA for significance when p 
< 0.05 using NCSS/PASS software Dawson edition.[36] Post hoc comparisons were 
performed to identify statistically significant differences among groups using Tukey-
Kramer method. A paired t-test was performed to analyze statistical differences (p < 
0.05) within the same formulation for stability of drug particle size over time and to 
analyze the effect of different phospholipids processed at the same microfluidization 
conditions. 
 
4.4. RESULTS AND DISCUSSION 
In this study, the feasibility in the development of a suitable formulation of CoQ10 
for pulmonary delivery has been explored. Following selection of excipients and 
nebulizer, the step starting the process was to perform a characterization analysis of the 
bulk powder for our intended purpose. The need to identify a suitable manufacturing 
process to prepare a colloidal dispersion of the drug was soon evident upon analyzing the 
powder characteristics. The selection for the manufacturing process consisted of 
formulating drug particles with small diameters in dispersion. This was suitably achieved 
with the microfluidizer, notably at different magnitudes of particle size according to type 
of phospholipid used and the number of passes. The ultimate purpose was to identify how 
the different physicochemical properties of the CoQ10 dispersions were influencing the 
nebulization performance of the Aeroneb Pro® vibrating-mesh nebulizer. Considering the 
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functioning mechanism of this type of nebulizer, surface tension and viscosity of 
formulations were expected to influence aerosol output. Most importantly, transmission 
data from LD and gravimetrical analysis of nebulizer output rendered a feasible method 
to evaluate steady aerosolization over time. 
The XRD pattern of bulk CoQ10 shows two high intensity peaks (2θ) at 
approximately 18.65 and 22.80, indicating the crystalline structure of this drug (Figure 
4.2). An endothermic peak at approximately 51°C in the DSC thermogram indicates the 
low melting point of this physiologically occurring compound (Figure 4.3). Most 
importantly, the drug particles are unsuitable for pulmonary delivery as presented in the 
bulk material, with Dv(50) of 29.87 µm and span value of 2.051. The magnitude of the 
particle dimensions were also confirmed by SEM pictures (Figure 4.4). The first 
approach to reduce particle size was performed with ball milling for 18 hours; however, 
the fluff appearance of the drug turned into a cluster of drug mass. This visual 
observation was confirmed by an increased particle size (Dv(50) = 29.87 µm, span = 
2.282). Due to the low melting point of CoQ10, heat generated during the process and 
mechanical impact may have both contributed to this outcome. Similar results were found 
when bulk powder was cryomilled. 
A more elaborate approach to engineer the particles for pulmonary delivery then 
turned out to be mandatory. Therefore, high shear mixing, high pressure homogenization 
and ultrasonication were subsequently tested. The results shown in Figure 4.5 indicate 
that formulations prepared using shear force presented drug particles in dispersion with 
nearly a bimodal distribution, confirmed by a higher span value and Dv(50) around 1 µm 
(Table 4.2). Both microfluidization and ultrasonication presented a monodisperse, 
unimodal distribution with a Dv(50) value in the submicron range, so each method is 
capable of preparing a formulation with small drug particle size. However, considering 
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the availability of in-line commercial scale-up equipment, we have chosen to pursue 
further studies using microfluidization. Similar results have been previously reported for 
phospholipid-stabilized nanodispersions of CoQ10 for intravenous administration forming 
supercooled unilamellar liposomes.[37] Nevertheless, the Fraunhofer theory applied in 
LD is limited only to cases when the particle size is greater than 0.5-2.0 µm (i.e., poor 
accuracy below one micron).[38, 39] Thus, DLS is included in further studies.  
Once the manufacturing process was selected, Formulation A was processed to 
determine the influence relating the number of passes in the microfluidizer to drug 
particle size stability (Table 4.1). We can observe from LD results that, following 
preparation, all formulations presented particle size distribution in the submicron range 
(Figure 4.6). After 7 days, the formulations similarly presented larger particles regardless 
of the number of passes. We observed from the DLS results that increasing the number of 
passes above 50 does not appear to provide smaller hydrodynamic diameters or more 
monodisperse systems (Figure 4.7). A trough in particle size as function of number of 
passes has been previously reported and attributed to a secondary particle growth due to 
fusion or Ostwald ripening during repeated homogenization.[40] Nevertheless, no 
statistical difference was found for drug particle sizes between days 0 and 7 for any 
individual preparation with any different number of passes. 
Reduction in number of passes and evaluation of different phospholipids were 
investigated using Formulation B (Table 4.1). Analysis using DLS show that drug 
particle sizes significantly decrease for increased number of microfluidization passes (up 
to 50 passes) for both lecithin and DPPC dispersions of CoQ10 (Figure 4.8). The DPPC 
formulation presented significantly smaller particle sizes than the lecithin dispersions of 
CoQ10 at the same microfluidization conditions (e.g. number of discrete passes), with Z-
averages in the ranges of 50-120 nm and 120-170 nm, respectively. Although the DPPC 
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colloidal dispersion presented smaller PdI values than lecithin-stabilized formulations, 
both presented high polydispersity (PdI > 0.2). This result indicates that no more than 50 
passes are needed to obtain formulations with small particle sizes; the final colloidal 
system will depend on the phospholipid utilized. 
Once a small drug particle dispersion of CoQ10 was feasibly prepared, we 
investigated the capability of the Aeroneb Pro® device to steadily nebulize these 
formulations as well as the physicochemical properties of the aerosolized liquid 
influencing nebulization performance. As previously mentioned, intermittent mist can 
occur when vibrating-mesh nebulizers generate aerosols from suspended dosage forms. 
Therefore, formulations should be evaluated for a lack of intermittent mist, indicating 
aerosolization continuity throughout the nebulization event. In this study, we primarily 
used the Malvern Spraytec® to analyze transmission as a function of time in order to 
select dispersed formulations that are continuously aerosolized using the Aeroneb Pro® 
nebulizer. Alternatively, a method capable of evaluating change in concentration over 
time of nebulized droplets could also be used, as suggested by the recently published 
General Chapter <1601> of the United States Pharmacopoeia (USP) on the 
characterization of nebulizer products.[41] The ease of prescreening a number of 
formulations over a limited nebulization time with Malvern Spraytec® was instrumental 
in formulation selection.  
Before setting up the Malvern Spraytec® with the “open bench” method, we 
attempted numerous times to perform these tests using the inhalation cell accessory 
provided by Malvern (Figure 4.9). In this system, a laser beam is projected from the left 
side of the instrument towards a detector positioned at the right side. In its trajectory, the 
laser beam crosses the inhalation cell coupled to this Spraytec®. At the rear of the 
inhalation cell setup a vacuum line is connected, while a nebulizer is positioned in front 
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of the inhalation cell. A set of tubes in the mid section of the inhalation cell creates an air 
sheath to help direct the aerosol droplets from the nebulizer towards the vacuum source. 
In order to best evaluate the nebulizer output of the dispersions, this setup was arranged 
with the inhalation cell in the horizontal position (90º angle) to measure aerosol 
generation as close as possible to the vibrating-mesh. The suction airflow rate was set to 
30 L/min and the sheath airflow rate was set to 15 L/min (30 – 15 L/min = 15 L/min) to 
obtain a final airflow rate of 15 L/min. This airflow rate was selected to match that 
required to analyze nebulizer formulations in the Next Generation Impactor (NGI) for 
comparison reasons.[42] 
However, a technique artifact could not be avoided due to the inhalation cell 
design. An inefficient air sheath was created in the Malvern Spraytec®, causing the 
aerosol cloud to “invade” the detector lens compartment, continuously increasing 
obscuration and consequently reducing transmission. During standard operation of the 
inhalation cell a HEPA membrane filter of 0.45 µm is positioned in-line with the vacuum 
source, both to avoid damaging the vacuum source and prevent potential exposure to the 
operator. However, in using the filter, the formulation gradually clogs the filter pores and 
a back pressure is created which overcomes the air sheath and directs the droplets 
towards the detection lens chamber. Once the inhalation cell windows are fogged the 
transmission values do not return to 100% and bogus data gives the appearance that the 
nebulizer operated uninterruptedly throughout the measurement. Despite testing different 
configurations and parameters (e.g. changing vacuum filter from membrane to cartridge 
type, changing suction level and sheath airflow rates, etc.), a feasible measurement using 
this setup was not possible. It was recognized that the amount of aerosol produced during 
each 15-minutes nebulization event was enormous when compared to pMDI and DPI 
devices, which the inhalation cell was primarily designed for. This accessory may be 
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more useful in characterizing aerosol generation from those other devices, and not for use 
with nebulizers for extended periods of time.  
To overcome the technique artifact, we decided to use the “open bench” method. 
The position of the nebulizer reservoir was appropriately chosen to avoid vignetting 
(wide angle scattered light misses the detector field) while also avoiding recirculating 
droplets by positioning the air suction source properly for a continuous exhaustion of the 
generated droplets.[35, 43] The transmittograms presented in Figure 4.10 show a 
nebulization event of 15 minutes for Formulation C (Table 4.1). At the end of this 
duration the transmission values go back up to 100% for all formulations, indicating that 
the measurement was properly performed with no fogging of the detector lens. The three 
formulations presented a steady nebulization for the initial 5 minutes. After this time 
point, the transmission related to the formulation of the 10 pass runs were increased at a 
different rate than formulations of the 30 and 50 pass runs. To evaluate the nebulization 
performance of these formulations, the transmittogram was fitted to a linear regression in 
order to analyze the slopes of the rate curves. By comparing their slopes, we can infer 
about how steady a nebulization event was.  
The slope values and TAO of Formulation C (Table 4.1) with different numbers 
of passes in the microfluidizer are presented in Figure 4.11. We observe a significantly 
lower slope value for formulations that were run at 10 passes compared to 30 and 50 
passes; this is in agreement with the higher TAO values. These results indicate that 
Formulation C processed with 10 passes in the microfluidizer was able to present a 
steadier nebulization over time than if it was prepared with increased processing. Next, 
we evaluated the physicochemical properties of Formulation C with 10, 30 and 50 passes 
to identify how they may be influencing the nebulization performance of these 
dispersions of CoQ10.  
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Upon analysis of the hydrodynamic size in the dispersions (Figure 4.12), we 
observe from LD results that the particle size appeared to be increasing slightly over time 
with most particles holding in the nanometric scale. When comparing formulations 
analyzed at day 0 for LD and DLS, we conclude that LD is not a suitable technique for 
the same reasons described earlier, based on the Fraunhofer theory. The DLS results then 
show that all formulations presented a Z-average of approximately 260 nm. After 7 days, 
Dv(50) is still below range of measurement for LD technique whereas Z-average did not 
vary significantly for the 30 and 50 passes. From the particle size distribution results we 
can conclude that the formulations with the higher number of passes were stable for about 
1 week. PdI was between 0.2 and 0.3 following preparation and showed some level of 
polydispersity after 7 days. 
The results indicate that a greater hydrodynamic diameter was formed for these 
lecithin dispersions (approximately 260 nm) than was formed with the previous 
formulation analyzed (Formulation B: 120-170 nm). These differences can be explained 
by the difference in electrolyte concentrations of the formulations. Addition of 0.9% w/v 
of sodium chloride to Formulation C serves two purposes: to provide normal 
physiological osmolarity and to reduce variability in aerosol generation from this active 
vibrating-mesh nebulizer.[21] Other than the reduced variability factor, Ghazanfari and 
coworkers have demonstrated increased aerosol output and smaller droplet sizes with 
solutions containing low ion concentrations. The low electrolyte content helps to 
overcome drop detachment resistance from the vibrating-mesh due to an improved 
electrical conductivity that works to suppress the high electrostatic charge of water,[44] 
which in turn favors aerosol generation. However, the addition of sodium chloride may 
also cause colloid instability, according to the Derjaguin-Landau-Verwey-Overbeek 
(DLVO) theory of interactions of electrolytes on phospholipid surfaces.[45] In this case, 
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a nonspecific adsorption based solely on electrostatic forces (no chemical interactions) 
may occur driven by the presence of monovalent cations (i.e. Na+). A decrease in zeta 
potential caused by the presence of the ions increase the flocculation rate, which can be 
analyzed by turbidimetry.[45] In fact, based on visual observation, the addition of the 
aforementioned salt following microfluidization changed the dispersion color from dark 
orange to bright yellow. Despite extensive discussion concerning the mechanism of this 
colloid stability, current theories in colloid science are unable to fully explain this 
phenomenon.[46] Despite that, the differences in drug particle size in dispersion from 
Formulations B and C can be supported by DLVO theory. Drug particle size distribution 
of the aqueous dispersion alone does not appear to be influencing the nebulization 
performance, since the dispersions had similar diameters following preparation but 
different aerosolization behavior.  
Analysis of zeta potential supports the dispersion stability previously discussed 
based on changes in drug particle size distribution over time. Increasing the number of 
passes increases both the surface tension and the module of zeta potential, which was 
statistically significant when comparing formulations processed with 10 or 50 
microfluidization passes (Figure 4.13). When evaluating surface tension and zeta 
potential results together, Kawaguchi and coworkers hypothesized that a higher number 
of passes aids encapsulation.[47] Hence, less surfactant is available in “solution” than is 
needed to cause decrease in surface tension. The role of surface tension in aerosol 
generation from active vibrating-mesh nebulizers is still unclear.[21] No similarity has 
been found between the results of zeta potential and surface tension seen in Formulation 
C that correlates the different number of passes in the microfluidizer and their respective 
nebulization performance. 
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Finally, we evaluated the rheology of the dispersions. After plotting the shear 
stress as a function of shear rate, the results were fitted to their best rheological model. It 
was found that the Herschel-Bulkley was the model that best represented these three 
formulations: 
 
ߪ ൌ  ߪ௬ ൅  ߢ · ߛሶ ௡  (Equation 4.2) 
 
Where σ is shear stress, σy is yield stress, κ is consistency index or viscosity, γ is 
shear rate and n is flow index (n = 1: Newtonian fluid; n < 1: shear-thinning; n > 1: shear-
thickening). Standard errors are 32.74 ± 3.58, 31.62 ± 2.04, 35.92 ± 3.57 for dispersions 
of CoQ10 prepared with 10, 30 and 50 microfluidization passes, respectively. The three 
elements of the Herschel-Bulkley model are presented in Figure 4.14. Although the 
values of each element are not statistically different, the similarity between the rheology 
results and the results of nebulization performance previously seen is more evident. 
Formulations of 30 and 50 passes presented a similar rheological behavior and 
nebulization performance, which were different from formulations of 10 passes. 
Interestingly, all formulations presented shear-thickening behavior (n > 1). It is well 
known that particle characteristics like size, size distribution, shape, charge, and the 
interactions between particles and the surrounding fluid play significant roles in the 
rheological behavior of these systems.[48] Therefore, it is not surprising that the 
rheological behavior of the formulations are more in agreement with the nebulization 
performance, since it considers the interactions of all the other physicochemical 
characteristics together due to interparticle forces acting on flow-induced structures. 
To our knowledge, this is the first study investigating the capability of vibrating-
mesh nebulizers to steadily nebulize dispersions in which fluid rheology is analyzed as 
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opposed to performing simpler kinematic viscosity measurements. Previous works have 
focused on the viscosity of the dispersion media per se, without considering the 
interactions between the dispersed particles with the surrounding fluid.[19, 49] The 
nebulizer used in this study (Aeroneb Pro®) functions by imparting a high vibration 
frequency (128 KHz) on a perforated membrane to generate the aerosol droplets. This 
high frequency mechanical stress is directly transferred to the liquid formulation. 
Therefore, analysis of rheology parameters at higher shear rates may better translate to 
what is actually occurring in the vicinity of the vibrating membrane. From the theory of 
rheology of suspensions, a shear thickening event may be expected at high shear rates 
depending on the particles’ deformability, besides the aforementioned factors. In our 
studies, the upper limit of shear rate was established based on the hydrodynamic 
characteristics of the formulations. Increasing shear rates ad infinitum, although desirable 
for this purpose, is impossible in practice. Nevertheless, analysis of the rheological 
behavior of the dispersions based on flow index (shear thickening or shear thinning 
event) may dictate how the system will behave under the stress imposed to the drug 
particles and the surrounding fluid by the vibrating-mesh. Further studies investigating 
non-Newtonian fluids are warranted to better understand how rheology of dispersed 
systems can influence nebulization performance from vibrating-mesh nebulizers. 
 
4.5. CONCLUSIONS 
Aqueous colloidal dispersions of CoQ10 can be suitably produced using 
microfluidization, and formulations of this poorly-water soluble anticancer agent can be 
effectively nebulized using vibrating-mesh devices. Proper selection of phospholipids 
was found to be crucial since it profoundly influenced the final drug particle size. 
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Moreover, processing can further influence other physicochemical properties; increasing 
the number of microfluidization passes increased surface tension and the module of zeta 
potential. Evaluation of the 1:1 lecithin:CoQ10 formulation in conjunction with the active 
vibrating-mesh nebulizer Aeroneb Pro® showed that the nature of aerosolization event 
could be elucidated as either a continuous or intermittent process. By analysis of the 
aerosolization event, formulation performance of dispersed dosage forms can be 
effectively evaluated. Importantly, the rheological behavior of the dispersions appeared to 
best represent the interparticle interactions at the microscopic level in the vicinity of the 
vibrating membrane. Further studies are warranted to expand the understanding of how 
dosage forms behaving as non-Newtonian fluids can influence the droplet formation from 
nebulizers. This would help pave the way to promote development of other compounds 
with similar, poorly-water soluble properties for use in inhalation therapy. 
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4.6.  TABLES 
 
Formulation Test 
Phospholipids 
Number of passes Characterization 
Type(s) Hydration 
A Number of passes; 
stability 
Lecithin ~ 1 hour, no 
stirring 
20, 50, 70 and 100 Particle size distribution 
B Number of passes; 
type of phospholipids 
Lecithin and 
DPPC 
~ 1 hour, no 
stirring 
10, 20, 30, 40 and 50 Particle size distribution 
C* Nebulization 
performance 
Lecithin Overnight, stirring 10, 30, and 50 Particle size distribution, 
surface tension, rheology, 
zeta potential, and TAO. 
*0.9% w/v added to final formulation following processing with microfluidizer. DPPC: dipalmitoylphosphatidylcholine; TAO: Total Aerosol Output. 
Table 4.1 – Formulations investigated for effect of processing parameters and type of phospholipids on the particle size 
distribution and nebulization performance.  
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Manufacturing Process Dv(50) (µm) Span Value 
Shear Force 1.03 2.076 
Microfluidization 0.63 0.367 
Ultrasonication 0.71 0.459 
Table 4.2 – Dv(50) and span values of dispersions prepared with different manufacturing processes. 
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4.7. FIGURES 
 
 
Figure 4.1 – Schematic diagram of aerosolization of CoQ10 dispersions using a vibrating-
mesh nebulizer.  
Vibrating-mesh
 204
 
Figure 4.2 – X-Ray Diffraction pattern of bulk powder of CoQ10. 
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Figure 4.3 – Differential Scanning Calorimetry thermogram of bulk powder of CoQ10. 
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Figure 4.4 – Scanning Electron Microscopy picture of bulk powder of CoQ10.
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Figure 4.5 – Particle size distributions of CoQ10 dispersions prepared using different 
manufacturing processes.
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Figure 4.6 – Particle size distributions from Laser Diffraction technique of aqueous dispersions of CoQ10 following preparation 
in the microfluidizer and after 7 days (Formulation A, Table 4.1).
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Figure 4.7 – Z-average and PdI values of aqueous dispersions of CoQ10 following preparation in the microfluidizer and after 7 
days (Formulation A, Table 4.1). Statistical differences were not found for drug particle size distribution 
characteristics (Z-average and PdI) neither in formulations prepared with different number of microfluidization 
passes and analyzed following preparation nor when the same formulations were compared at days 0 and 7.
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Figure 4.8 – Hydrodynamic diameters and polydispersity of aqueous dispersions of 
CoQ10 (Formulation B, Table 4.1) following preparation in the 
microfluidizer using lecithin (top) or DPPC (bottom). (* P ≤ 0.05 when 
compared to 10 passes; § Not statistically different when compared to the 
lecithin dispersion prepared with same number of microfluidization passes)
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Figure 4.9 – Malvern Spraytec® coupled with inhalation cell.
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Figure 4.10 – Transmittograms of lecithin dispersions of CoQ10 (Formulation C, Table 4.1). Results are expressed as means (n 
= 3) of percentage transmission relative to nebulization of CoQ10 dispersions for15 minutes. The slope values from 
the linear regression analysis of the curves are evaluated as measurement of steadines in aerosol production.
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Figure 4.11 – Slope of transmittograms (top) and Total Aerosol Output (TAO – bottom) 
for nebulization of lecithin dispersions of CoQ10 (Formulation C, Table 4.1) 
during 15 minutes. (* P ≤ 0.05 compared to other formulations)
15.00*
25.97 25.99
0
5
10
15
20
25
30
35
10 30 50
Sl
op
e 
x 
10
-3
 (%
/s
)
Number of Discrete Passes
66.9*
53.2
48.2
0
10
20
30
40
50
60
70
80
10 30 50
TA
O
 (%
)
Number of Discrete Passes
 214
 
 
 
 
Figure 4.12 – Particle size distributions analyses of aqueous dispersions of CoQ10 
(Formulation C, Table 4.1) following preparation in the microfluidizer using laser 
diffraction (left) and dynamic light scattering (right). (* P ≤ 0.05 compared to 
formulations analyzed following preparation; § P ≤ 0.05 compared to other formulations 
at day 7).
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Figure 4.13 – Zeta potential and surface tension values related to formulations of CoQ10 
processed at different number of microfluidization passes (Formulation C, 
Table 4.1). Columns and error bars represent means and standard errors, 
respectively (n = 10 for zeta potential and n = 5 for surface tension). The 
temperature during surface tension measurement was 25ºC. (* P ≤ 0.05 
when compared to 10 passes, § Not statistically different) 
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Figure 4.14 – Elements of Herschel-Bulkley model for aqueous dispersions of CoQ10 
processed at different number of microfluidization passes (Formulation C, 
Table 4.1). No statistical differences were found. 
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Chapter 5: Prediction of In Vitro Aerosolization Profiles Based on 
Rheological Behaviors of Aqueous Dispersions of Coenzyme Q10 
Abstract 
Coenzyme Q10 (CoQ10) is a poorly-water soluble compound that is being 
investigated for the treatment of carcinomas. The final drug particle size in dispersions 
when using microfluidization preparation methods is highly influenced by the number of 
passes and type of phospholipid used in the process. The aim of the research work 
presented in this chapter is to investigate the feasibility of preparing phospholipid-
stabilized dispersions of the anticancer agent for pulmonary delivery using a vibrating-
mesh nebulizer. We determined the physicochemical properties and compared the 
nebulization performance of dispersions of CoQ10 prepared with dimyristoyl 
phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), or distearoyl 
phosphatidylcholine (DSPC) to the formulation previously prepared with lecithin. The 
phospholipid formulations were characterized for drug particle size distribution in 
dispersion, zeta potential, surface tension, and rheology. An evaluation was performed on 
the aerosolization profile of the inhalation system triad: drug, excipients, and device, for 
nebulization performance (using laser diffractometry (LD) and gravimetrical analysis) 
and for the aerodynamic drug deposition of the formulations (using Next Generation 
Impactor – NGI). The Total Emitted Dose (TED) was characterized using both NGI and a 
Dose Uniformity Sampling Apparatus (DUSA) for Dry Powder Inhalers (DPIs) adapted 
for use with nebulizers. The hydrodynamic sizes of the drug particles in dispersion were 
primarily in the submicron range with the synthetic phospholipids presenting some larger 
particles. The lecithin dispersion presented a significantly large module of zeta potential 
(60 mV) while the synthetic phospholipids had values close to zero. The surface tension 
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of the formulations ranged in value from 26 to 46 mN/m. At high shear rates, DPPC, 
DMPC, and lecithin formulations of CoQ10 presented increased shear-thickening 
behavior. In addition, the formulations showed a decrease in mass and drug output over 
time within a 15-minute nebulization event, along with decreased aerodynamic and 
geometric sizes. The lecithin dispersion had the worst performance in terms of Fine 
Particle Dose (FPD), whilst the DPPC and DSPC dispersions showed similarly high 
FPDs. The results suggest that the rheological properties may be the determining factor in 
identifying potential formulations with a satisfactory aerosolization profile for the 
nebulization of dispersions. 
 
5.1. INTRODUCTION 
Aerosolization of dispersed formulations is expected to generate droplets 
containing variable drug concentration due to the heterogeneous nature of the dosage 
form. Therefore, it is crucial to characterize the formulations for in vitro drug deposition, 
which can be performed with cascade impactors.[1] Laser diffractometry (LD) can 
alternatively be used for this purpose when considering solution dosage forms. The non-
homogeneous characteristic of dispersion systems may possibly give rise to droplets with 
heterogeneous concentrations of drug particles, deeming LD an unsuitable technique.[2-
4] The United States Pharmacopoeia (USP) recommends the Next Generation Impactor 
(NGI) be used for this testing.[5] In addition, USP recommends an evaluation be 
performed of the delivered drug from the aerosol output. 
The alveolar surfactant in humans is comprised 90% of phospholipids and 10% of 
neutral lipids.[6] Among the various types of phospholipids, phosphatidylcholine (PC) is 
predominant (76%). Among the different PC saturated and unsaturated fatty acid chains, 
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DPPC is the main component (81% of PC) with dimyristoyl phosphatidylcholine 
(DMPC) and distearoyl phosphatidylcholine (DSPC) each comprising 3% of PCs.[6] 
DPPC and DSPC are also present in the mixture of phospholipids that comprise the 
excipient soybean lecithin in widely varying concentrations depending on the source and 
extraction method.[7, 8]  
In the previous chapter, we have defined high pressure homogenization 
(microfluidization) as a suitable manufacturing process to obtain a phospholipid-
stabilized dispersion of Coenzyme Q10 (CoQ10) with small drug particle size. The type of 
phospholipid used influenced drug particle size in dispersion. Processing formulations for 
more than 50 passes in the microfluidizer did not further decrease particle size (Chapter 
4, Section 4.4). Lecithin was used as model excipient and dispersions of CoQ10 were also 
characterized for surface tension, zeta potential and rheology. Evaluation of nebulization 
performance (steady aerosolization over time) from an Aeroneb Pro® nebulizer using LD 
and gravimetrical analysis showed continuous aerosolization of CoQ10 dispersions for 15 
minutes. The investigation suggests that the rheological behavior of the dispersions 
appears to play a role in the nebulization performance.  
The aim of this study was to use synthetic phospholipids to prepare formulations 
of CoQ10 that can potentially provide improved nebulization performance, which would 
have the potential to deliver an improved Fine Particle Dose (FPD) of CoQ10 when 
compared to lecithin dispersions. We have chosen three synthetic phospholipids to 
stabilize these dispersions given their physiological occurrence in the lungs: DMPC, 
DPPC, and DSPC. They present 14, 16 and 18 carbons in their saturated fatty acid chains 
and molecular weights of 678, 734, and 790 g/mol, respectively. Besides the 
characterization tests performed in our previous study, the formulations were further 
characterized for in vitro drug deposition using NGI and Total Emitted Dose (TED) using 
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both NGI and a Dose Uniformity Sampling Apparatus (DUSA) for Dry Powder Inhalers 
(DPIs) adapted for nebulizers. The results were thoroughly analyzed in conjunction with 
the nebulization performance tests for continuous aerosolization and for identifying the 
physicochemical properties governing the mechanism of aerosol generation of dispersed 
systems of CoQ10 from the micropump nebulizer. We confirmed our previous results by 
demonstrating that rheology of dispersions plays a significant role in the hydrodynamics 
of aerosol production using active vibrating-mesh nebulizer. 
 
5.2. MATERIALS AND METHODS 
5.2.1. Materials 
Coenzyme Q10 was supplied by Asahi Kasei Corp. (Tokyo, Japan). Lecithin 
(granular, NF) was purchased from Spectrum Chemical Mfg. Corp. (Gardena, CA, USA). 
Genzyme Pharmaceuticals (Liestal, Switzerland) provided 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). DMPC was also purchased from 
Lipoid GmbH (Ludswighafen, Germany). Sodium chloride (crystalline, certified ACS) 
was acquired from Fisher Chemical (Fisher Scientific, Fair lawn, NJ, USA) and the 
deionized water was obtained from a central reverse osmosis/demineralizer system 
commonly found in research laboratories. Hexane and ethanol 200 proof were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and methanol from Fisher Chemical (Fisher 
Scientific, Fair lawn, NJ, USA), all of which were from HPLC grade. The external filter 
for NGI testing (glass fiber, GC50, 75 mm) and the filter for DUSA (glass fiber, AP40, 
47 mm) testing were purchased from Advantec MFS Inc. (Dublin, CA, USA) and from 
Millipore (Billerica, MA, USA), respectively. Syringes (1 mL) and syringe filters 
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(hyperclean, 17 mm, 0.45 µm, PTFE) were obtained from Becton Dickinson (Franklin 
Lakes, NJ, USA) and Thermo Scientific (Bellefonte, PA, USA), respectively. 
 
5.2.2. Formulation 
Formulations (100 mL) were prepared using hot high pressure homogenization to 
determine the effect of the type of phospholipid on the aerosolization profile – 
nebulization performance and in vitro drug deposition of particles for pulmonary 
delivery. We have chosen 2.5% w/w to be the maximum phospholipid concentration in 
our formulations, the same concentration as is in the approved drug product Survanta® 
(Abbott Laboratories, Abbott Park, IL, USA). During preliminary studies (see Appendix 
B), it was found that the maximum nominal drug loading that could be achieved with 
formulations not presenting intermittent mist within a 15-minute nebulization event using 
the Aeroneb Pro® nebulizer was 4% w/w. Therefore, formulations with synthetic 
phospholipids were prepared at a drug-to-lipid ratio of 4:2.5.  
Following overnight hydration while stirring, a phospholipid dispersion 
containing 2.5% w/w of phospholipid (DMPC, DPPC, or DSPC) in water was added to 
the molten CoQ10 (4% w/w) at 55 °C. The formulation was then predispersed using high 
shear mixing with an Ultra-Turrax® TP 18/10 Homogenizer with 8 mm rotor blade (IKA-
Werke GmbH, Staufen, Germany) for 5 minutes at 20,000 rpm. Subsequently, each 
formulation was passed 50 times through an M-110P Bench-top Microfluidizer® 
(Microfluidics, Newton, MA, USA) at approximately 30,000 psi while maintaining a 
temperature between 55 and 65 °C. Following microfluidization, 0.9% w/v of sodium 
chloride was added to the final formulation for reasons outlined in the previous chapter 
(Section 4.4). 
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The particle size distributions of the formulations were then analyzed using Laser 
Diffraction (LD) and/or Dynamic Light Scattering (DLS). The surface tension, zeta 
potential and rheology were also evaluated. For nebulization performance, aerosol output 
generated from an Aeroneb Pro® nebulizer (Aerogen, Galway, Ireland) was analyzed 
using LD and gravimetrical analysis. In vitro drug deposition was evaluated using a NGI 
while the TED was analyzed from both the NGI results and from measurement using a 
Dose Uniformity Sampling Apparatus (DUSA). Besides the characterization and 
nebulization performance presented in the previous chapter, the in vitro drug deposition 
of lecithin dispersion of CoQ10 (drug-to-lipid ratio: 1:1) passed 50 times through the 
Microfluidizer® was prepared and analyzed. This was evaluated against the synthetic 
phospholipid formulations (DMPC, DPPC, or DSPC dispersions of CoQ10). Details of the 
preparation, characterization and evaluation of nebulization performance of the lecithin 
dispersion are presented in the previous chapter. Testing was performed immediately 
following preparation, except for stability of drug particle size in the dispersions in which 
the samples were tested 7 days after preparation.  
 
5.2.3. Characterization 
5.2.3.1. Particle Size Distribution 
Particle size distribution testing of the dispersed formulations was performed with 
LD using a wet sample dispersion unit stirring at 1,000 rpm coupled to a Malvern 
Spraytec® (Malvern Instruments, Worcestershire, UK) equipped with a 300 mm lens. The 
dispersed formulations were added to distilled water (dispersant) until approximately 5% 
obscuration was attained. The internal phase and dispersant refractive indexes were 1.45 
and 1.33, respectively, based on reports related to lecithin in the literature[9]. A timed 
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measurement was performed for 45 seconds with 1 second sampling periods (a total of 45 
data acquisition periods). Results are presented as Dv(X) and span, where X is the 
cumulative percentile of particles under the referred size (e.g. Dv(50) corresponds to the 
median volume of the particles). Span is the measurement of particle size distribution 
calculated as [Dv(90) – Dv(10)]/Dv(50)]. Therefore the higher the span, the more 
polydisperse the particle size distribution was. 
In addition, the nanoparticle hydrodynamic diameter of the dispersed formulations 
was characterized with DLS using a Malvern Zetasizer Nano ZS® (Malvern Instruments, 
Worcestershire, UK) at 25°C and pre-equilibrated for 2 minutes. The intercept of the 
correlation function was between 0.5 and 1.0. Distilled water was used for dilution of the 
dispersions whenever needed.  
 
5.2.3.2. Surface Tension 
Surface tension testing was performed using a TA.XT.plus Texture Analyzer 
(Texture Technologies, Scarsdale, NY, USA) from the maximum pull on a disk as 
described in Chapter 3. Briefly, the container and glass disk probe were thoroughly 
degreased, cleaned with ethanol and allowed to dry. The probe was attached to the texture 
analyzer arm, and lowered until the bottom surface of the probe contacted the surface of 
the liquid formulation contained in the reservoir. The temperature of the liquid was 
measured and recorded. At the start of testing, the probe was raised from the surface of 
the liquid at a constant speed (0.05 mm/s) for 10 mm, while the texture analyzer 
registered at 5 points per second the force exerted as a function of either time or distance. 
Using the maximum (detachment) force the surface tension was calculated using the 
equation below: 
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  (Equation 5.1) 
 
Where X is probe radius, V is volume and k is the meniscus coefficient. For more 
details, see Chapter 3. The density values used to calculate surface tension were assumed 
to be the same as the density of water at the measurement temperature. 
 
5.2.3.3. Zeta Potential 
Electrophoretic light scattering was used to perform zeta potential testing with a 
Malvern Zetasizer Nano ZS® (Malvern Instruments, Worcestershire, UK). The samples 
were analyzed at a constant temperature of 25°C and constant (neutral) pH. Samples were 
diluted with distilled water, obtaining conductivity values ranging from 400 to 1400 
µS/cm. Each sample was analyzed in triplicate and subjected to 10 to 100 runs each 
measurement, with automatic optimization of attenuation and voltage selection.  
 
5.2.3.4. Rheology 
Rheological behavior of the dispersed formulations were tested using a AR-G2 
rheometer (TA Instruments, New Castle, DE, USA) equipped with a cone-and-plate 
geometry (cone diameter: 40 mm; truncation: 54 µm). Zero-gap and rotational mapping 
were performed prior to testing. All measurements were executed with fresh sample 
dispersion at a constant temperature of 25°C with no pre-shear. Excess sample around the 
edge of the probe was trimmed and water was added to the solvent trap compartment. 
The samples were measured at the steady state flow step over a range of shear rates (from 
1000 to as low as 0.01 s-1) decreasing logarithmically (5 points per decade). The lower 
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and upper limits of shear rate were determined, respectively, by the instrument sensitivity 
and hydrodynamic limitations (high probe speed will cause the liquid sample to spill 
away from the measurement zone) for each formulation. The sample period was 20 
seconds and considered in equilibrium after 2 consecutive analyses within 5% tolerance, 
not exceeding a maximum measurement time of 2 minutes. The results were evaluated 
using Rheology Advantage Data Analysis software (TA Instruments, New Castle, DE, 
USA). 
  
5.2.3.5. Nebulization Performance 
Based on previous experience, the performance of vibrating-mesh nebulizers can 
be affected by mesh clogging, resulting in variable aerosol emission (i.e. intermittent 
mist), since this formulation is a dispersed system.[10] To analyze the nebulization 
performance of these formulations, the changes in transmission over time were evaluated 
from LD technique measurements. The nebulization performance of the dispersions was 
evaluated using the “open bench” method with a Malvern Spraytec® instrument (Malvern 
Instruments, Worcestershire, UK) equipped with 300 mm lens.[11] The nebulizer 
reservoir was positioned with the vibrating mesh located 25 mm above the upper edge of 
the laser beam at a distance of 25 mm between the lens and the center of the aerosol 
cloud. Air suction was positioned 10 cm beneath the laser beam. The device and air 
suction apparatus positions were not disturbed throughout the entire measurement period. 
The internal phase and dispersant refractive indexes were 1.33 (water) and 1.00 (air), 
respectively. Formulation (10 mL) was added to the nebulizer reservoir. At the start of 
nebulization, aerosol characteristics were continuously measured every second for 15 
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minutes. The slope of the transmission-time curves (transmittograms) were considered 
when comparing the different phospholipid formulations. 
In addition, the Total Aerosol Output (TAO) was gravimetrically measured for 
each of the formulations studied. Before aerosolization, the nebulizer was weighed after 
each formulation was dispensed into the reservoir. The remaining formulation in the 
nebulizer reservoir was re-weighed after undergoing 15 minutes of nebulization. The 
difference in weight before and after nebulization results in the calculated TAO. The 
weight of the nebulizer mouthpiece was not considered during the measurements. 
Importantly, neither transmittogram nor TAO provide information regarding drug 
output from the nebulizer. Information is limited solely to total mass output (droplets 
emitted over time). In the aerosolization of these dispersions, droplets not containing drug 
particles (empty droplets) are potentially generated. However, our purpose with this test 
is to investigate the capability of the Aeroneb Pro® nebulizer to continuously and steadily 
aerosolize the aqueous dispersions of CoQ10 over time. Intermittent mist can be identified 
in the transmittograms while TAO elucidates the magnitude of total mass being 
aerosolized. Saline solution (12 mL of 0.9% w/v NaCl in water) was used as the control. 
 
5.2.3.6. In vitro Aerodynamic Deposition 
To evaluate in vitro aerosol deposition, we have designed the study as follows. 
Within a 15-minute nebulization event, the first and last 15 seconds (herein called initial 
and final sections or phases) of aerosol generation were collected using NGI or DUSA for 
DPI (both from Copley Scientific, Nottingham, UK). This design helps in determining 
whether the slope in transmission, previously observed for lecithin formulations and 
related to TAO (Chapter 4, Section 4.3), translates into similar drug mass output.  
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To measure the aerodynamic properties of the formulations, the NGI was set up 
with airflow of 15 L/min and the drug collected from the induction port, the seven stages 
of the cascade impactor, the micro-orifice collector (MOC) and the external filter was 
analyzed using High Performance Liquid Chromatography (HPLC). The sum of the 
masses in each of the mentioned compartments of the NGI hardware setup provides the 
TED measured from the NGI. The mass deposited in each stage is also used to determine 
the deposition pattern and to calculate the Mass Median Aerodynamic Diameter 
(MMAD) as described in the General Chapter <601> of the USP.[12] This parameter is 
the equivalent droplet size in which half (50%) of the droplets are smaller and the other 
half are larger than the specified cutoff diameter, based on the drug amount deposited in 
different stages of the NGI. Commonly, the Geometric Standard Deviation (GSD) is 
reported to indicate the dispersity droplet size distribution around the MMAD. The FPD 
was calculated from the sum of drug mass deposited on impaction Stages 3 through 7, 
MOC and external filter (aerodynamic cutoff diameter below 5.39 µm). Finally, the Fine 
Particle Fraction (FPF) was calculated by dividing FPD by TED from NGI, as described 
above. Since our objective herein was to perform a comparative analysis of the different 
dispersions of CoQ10, it was decided not to refrigerate the NGI equipment prior to 
analysis, as was recently recommended.[5, 13] Therefore, an underestimation of MMAD 
values may have occurred due to droplet evaporation. 
During the NGI analysis, losses may occur during drug collection due to 
deposition in inner compartments between stages of the cascade impactor or in the 
nebulizer mouthpiece. Therefore, mass balance is recommended to be performed. During 
preliminary studies, it was observed that a 15-minute aerosol generation from dispersions 
prepared with synthetic phospholipids caused high amounts of formulation to accumulate 
in the nebulizer mouthpiece. For this reason, mass balance from NGI analysis was 
 232
deemed inappropriate at the final phase of each nebulization period due to the 
accumulated drug in the nebulizer mouthpiece. To certify that an acceptable mass 
recovery during the analysis of TED from NGI was being achieved, we evaluated the 
TED from an adapted DUSA (Figure 5.1). In the DUSA testing, the aerosol was 
deposited directly onto a glass fiber filter, positioned on one end of the DUSA, which 
was connected to a vacuum pump. The nebulizer mouthpiece was positioned onto the 
opposite end, and directly connected to the DUSA using a silicone adapter. TED was 
determined from the drug amount collected in the glass fiber filter and from the internal 
walls of the DUSA, which was analyzed using HPLC generated data following a timed 
nebulization. TED values from NGI and DUSA methods should not have varied 
significantly, thus ensuring a satisfactory mass balance. 
To further analyze the dose that may potentially be delivered to the lungs, the 
FPD results were extrapolated from 15-second measurements to calculate an estimated 
total delivered drug (estimated total FPD or FPDet) within a 15-minute period as follows: 
 
ܨܲܦ௘௧ ൌ ∑ ܨܲܦ௜ିଵ ൅ ቀி௉஽೙ିி௉஽೔షೕ௡ିଵ ቁ௡௜ୀଶ   (Equation 5.2) 
 
Where i is an integer number representing 15-second intervals, referring to the 
time duration of NGI and TED analyses. The j value is the subsequent integer number 
smaller than i and n is the number of 15-second fractions within a 15-minute nebulization 
period (n = 60).Based on FPDet, the rate of delivery of the Fine Particle Dose (FPDr) was 
also calculated. 
 
 233
5.2.3.7. HPLC Analysis of CoQ10 
This method was adapted from the previously developed method presented in the 
Appendix A. The Waters HPLC and column system (Waters Co., Milford, MA, USA) 
connected with UV detection consisted of a 1525 binary pump, a 717 autosampler, a 
2487 dual λ absorbance detector, set at 275 nm, and a Symmetry® RP-C8 column (3.9 x 
150 mm, 5 µm) connected to Symmetry® C8 guard column (3.9 x 20 mm, 5 µm). The 
mobile phase consisted of methanol:hexane at 97:3 (v/v) and was eluted at a flow rate of 
1.0 mL/min. Stock solution of CoQ10 was initially dissolved in hexane:ethanol at a ratio 
of 2:1 (v/v) and subsequently diluted with the mobile phase to obtain the desired 
concentrations. The linearity range was determined by injecting 50 µL of samples at a 
controlled temperature of 40 ºC. Chromatogram peaks were acquired within run time of 9 
minutes and the peak areas were used to determine curve linearity. 
All samples were collected from NGI and DUSA testing with ethanol, with the 
exception of drug collection from the NGI plates (Stages 1 through 7 and MOC) for 
analysis of lecithin dispersions. Due to the low solubility of the formulation in ethanol, a 
mixture of hexane:ethanol 2:1 v/v was used instead. The samples collected in glass fiber 
filters (external filter in NGI and filter from DUSA) were vortexed for 30 seconds prior 
to filtering with 0.45 µm syringe filters. The mobile phase was used for sample dilution. 
 
5.2.4. Statistical Analysis 
The data is expressed as mean ± standard deviation with the exception of surface 
tension, which was expressed as mean ± standard error. For rheology studies, standard 
errors were provided by the software used to analyze the best fit of the results to the 
rheological models. Samples were analyzed at least in triplicate and evaluated for 
statistical differences with One-Way ANOVA for significance when p < 0.05 using 
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NCSS/PASS software Dawson edition.[14] Post hoc comparisons were performed to 
identify statistically significant differences among groups using Tukey-Kramer method. 
A paired t-test was performed to analyze statistical differences (p < 0.05) within the same 
nebulization event for different formulations and to compare TED methods: specific 
phases for each formulation for NGI versus DUSA methods. 
 
5.3. RESULTS AND DISCUSSION 
In this study, we used synthetic phospholipids (DMPC, DPPC, and DSPC) to 
prepare formulations of CoQ10 and compared the results with the previously investigated 
lecithin formulation (Chapter 4). Soybean lecithin is a mixture of different types of 
phospholipids, with concentrations varying widely depending on the source and 
extraction method.[7, 8] We also extended the investigation to further than the capability 
of the device to generate aerosol uninterruptedly. Since it is a dispersed system, the 
aerosolization of this dosage form may generate droplets from the device that may 
contain different drug amounts. Therefore, we evaluated the aerodynamic properties of 
the formulation using a cascade impactor based on the drug amount deposited in each 
stage of the NGI apparatus. Furthermore, we investigated the TED based on drug 
collected in a filter delivered directly from the nebulizer mouthpiece. The nebulization 
performance in conjunction with the aerodynamic properties can provide a basis for the 
comparison of the inhalable potential of the formulations. It also allows us to identify 
which physicochemical properties favor an effective drug emission of the CoQ10 
dispersions from the Aeroneb Pro® nebulizer. 
The HPLC method has shown linearity in the concentration range of CoQ10 from 
100 ng/mL to 10 µg/mL, with a correlation coefficient (r2) of 0.9997. Extraction of filters 
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spiked with CoQ10 and the phospholipids did not appear to interfere with the CoQ10 peak, 
which was eluted at approximately 6.6 minutes.  
Upon observation of the hydrodynamic size in the dispersions (Figure 5.2 and 
Table 5.1), it was observed from the LD results that the drug particle size of the lecithin 
formulation was mostly in the submicron range. Synthetic phospholipid formulations 
presented some larger particles, although analysis of Dv(X) and span does not present 
statistical differences among formulations (except for Dv(10) of DMPC and DSPC 
dispersions). Further analysis of drug particle size distribution using DLS shows that 
lecithin dispersions presented larger nanoparticles with a higher polydispersity than any 
other formulation (Figure 5.3). Among synthetic phospholipids, the DSPC dispersion 
presented the largest drug nanoparticles while the DMPC formulation presented the most 
monodisperse profile. Following processing, the synthetic phospholipids presented some 
microparticles, although the population of particles in the nanometric scale was primarily 
smaller than drug particles that were produced from lecithin dispersions of CoQ10. 
The module of zeta potential of lecithin dispersion of CoQ10 was significantly 
higher than that which was found for the formulations prepared with synthetic 
phospholipids (Figure 5.4). The mixture of different types of phospholipids at various 
concentrations depending on the source and extraction method[7, 8] that comprises 
soybean lecithin is known to provide widely variable zeta potential values for 
dispersions.[15] Nonetheless, the zeta potential values of synthetic phospholipids that 
were close to zero may be attributed to the presence of sodium chloride in the 
formulations. Increase in ionic strength at neutral pH greatly increases the zeta potential 
of negatively charged phospholipids like DMPC, DPPC, and DSPC.[16]  
We have previously found that an increased number of passes in the 
microfluidizer causes a decrease in surface tension, possibly due to a more efficient 
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encapsulation. In this study, all dispersions were processed 50 times in the high pressure 
homogenizer. Hence, less surfactant is available in “solution” than is needed to cause a 
decrease in surface tension. Among synthetic phospholipids, a significant increase in 
surface tension was observed in this study which followed an increase in the number of 
carbons in the acyl chains of the phospholipids used to prepare the formulations. As was 
previously discussed, the formulations were designed to have the same amount of DMPC, 
DPPC, and DSPC at 2.5% w/w. With a different number of carbons in each respective 
acyl chain, the molecular weights vary slightly. Consequently, the molar concentrations 
of the phospholipids in the dispersions were 36.9, 34.1 and 31.6 mM, respectively. The 
structure of phospholipids in water dispersions depended directly on the number of 
phospholipid molecules.[17] Therefore, the differences in surface tension can be 
explained by the number of phospholipid molecules available in “solution” to cause a 
decrease in surface tension at a constant temperature.[18] Interestingly, the surface 
tension of the CoQ10 dispersion prepared with lecithin, comprised of a mixture of 
phospholipids, falls between the DMPC and DSPC values (Figure 5.5). 
It is well known that particle characteristics like size, size distribution, shape, 
charge, deformability, and the interactions between particles and the surrounding fluid 
play significant roles in the rheological behavior of dispersed systems.[19] To evaluate 
the rheology of the dispersions, we plotted shear stress as a function of shear rate and fit 
the results to the best rheological model. It was determined that the Herschel-Bulkley was 
the model that best represented most of the formulations: 
 
ߪ ൌ  ߪ௬ ൅  ߢ · ߛሶ ௡  (Equation 5.3) 
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Where σ is shear stress, σy is yield stress, κ is consistency coefficient (or Non-
Newtonian viscosity), ߛሶ  is shear rate and n is flow index (n = 1: Newtonian fluid; n < 1: 
shear-thinning; n > 1: shear-thickening). The Power Law model is similar to Herschel-
Bulkley, except that it does not present yield stress value. Standard errors are 35.92 ± 
3.57, 9.83 ± 0.17, 10.27 ± 0.35, 21.15 ± 8.17 for lecithin, DMPC, DPPC and DSPC 
dispersions, respectively. The three elements of the Herschel-Bulkley model are 
presented in Figure 5.6. DSPC dispersion of CoQ10 was governed by Power Law and 
therefore did not present yield stress. Despite that, the yield stresses of the formulations 
are shown to be statistically different but no trend can be found. DSPC formulation had a 
significantly higher Non-Newtonian viscosity than the other analyzed samples, possibly 
due to its evident shear-thinning behavior (n < 1). Most interestingly, the flow index 
results indicated that DPPC, DMPC, and lecithin dispersions respectively presented 
increasing shear-thickening behavior (n > 1).  
We further analyzed the rheology by holding shear rate and viscosity as the 
independent and dependent variables, respectively, in order to fit the results to the general 
flow curve of aqueous dispersions (Figure 5.7Figure 5.). Graphical representations are 
presented in Figure 5.8, which clearly shows the accentuated shear-thinning event 
previously mentioned for DSPC formulation. Relevant equations related to these models 
are shown in Table 5.2. By fitting these curves to the rheological models, we found that 
the formulations presented rather different behavior (Table 5.3). Standard errors are 93.49 
± 8.60, 43.27 ± 10.55, 41.34 ± 8.57, 16.00 ± 4.74 for lecithin, DMPC, DPPC and DSPC 
dispersions, respectively.  
The lecithin formulation of CoQ10 fits to the Sisko model, indicating that the 
investigated shear rate range falls within the mid-to-high shear-rate range related to the 
general flow curve of dispersions. This is confirmed by the extremely small characteristic 
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time seen in Table 5.3 and the curve shape at higher shear rates shown in Figure 5.8. 
Moreover, this result confirms the shear-thickening behavior presented from the 
evaluation of the Herschel-Bulkley model (Figure 5.6). From all formulations studied 
only the lecithin dispersion presented thixotropic behavior. This indicates a time-
dependent change following interruption of shear stress (in this case, shear-thinning 
event) during structure recovery from the shear-thickening behavior presented by this 
dispersion in the shear rate range studied. Therefore, all other formulations analyzed 
promptly recover to their initial state at cessation of shear stress.  
The DMPC and DPPC dispersions fit to the Cross model, thus both zero-rate and 
infinite-rate viscosities are presented. Characteristic times however differ greatly, with 
the lowest value shown for the DMPC formulation. This indicates that, similarly to 
lecithin dispersion, the DMPC formulation falls towards the upper range of shear rate 
related to the general flow curve of dispersions (Table 5.3), explaining the second 
Newtonian plateau (3.66 cP) being greater than the first Newtonian zone (1.13 cP). 
Therefore, the rheological behavior of the DMPC dispersion is closer to the Sisko than 
the Cross model. For this reason, both lecithin and DMPC dispersions present rate index 
(or Cross rate constant) values above unity, reflecting the absence of the power law 
region in the shear rate range investigated. When the viscosity within this specific range 
is appropriately extending from the first to the second Newtonian zone, 1 – m is close to 
the rate index n.[20-22] Inarguably, the shear-thickening behavior is evident from the 
curve shape at higher shear rates (Figure 5.8). The larger characteristic time of the DPPC 
formulation indicates that the curve falls more towards the lower range of shear rates and 
therefore supports the infinite-rate viscosity being smaller than the zero-rate viscosity. 
The Cross rate constant is close to unity, which indicates a degree of shear-thinning 
behavior in the power law region. Observation of the curve shape of DPPC dispersion in 
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Figure 5.8 supports these findings and the relatively low degree of shear-thickening 
behavior presented in the Herschel-Bulkley model (Figure 5.6). This relatively low 
degree of shear-thickening behavior, when compared to lecithin and DMPC formulations, 
can be attributed to differences in rheology at higher shear rates. 
The rheological behavior of the DSPC dispersion fits to the Williamson model. 
The statistically significant higher characteristic time in conjunction with the flow curve 
shape of this dispersion indicate that the shear rate range investigated falls within the 
low-mid shear rate range of the general flow curve of dispersions (Figure 5.8). The rate 
index value reflects the shear-thinning behavior at the power law region (Table 5.3). 
As mentioned in the previous chapter, it is important to investigate the capability 
of vibrating-mesh nebulizers to continuously and steadily aerosolize dispersions, with 
concomitant analysis of fluid rheology as opposed to simpler kinematic viscosity 
measurements. Previous works have focused on the viscosity of the dispersion media per 
se, regardless of the interactions between the dispersed particles within the surrounding 
fluid.[23, 24] As described in Chapter 1, the nebulizer used in this study (Aeroneb Pro®) 
functions by imparting a high vibration frequency (128 KHz) on a perforated plate to 
generate the aerosol droplets. This high frequency mechanical stress is directly 
transferred to the liquid formulation. Therefore, analysis of rheology parameters at higher 
shear rates may better translate to what is actually occurring in the vicinity of the 
vibrating membrane. 
The Aeroneb Pro® nebulizer has previously demonstrated its ineffectiveness to 
produce aerosols from solutions that have viscosities higher than approximately 2-3 cP, 
depending on other physicochemical properties of the liquid (i.e. surface tension).[25] 
Notably, the viscosities of lecithin, DMPC, and DPPC formulations investigated in this 
study at high shear rates may be considered sufficiently low to provide continuous 
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nebulization. The infinity-rate viscosity of DSPC dispersion was not identified within the 
shear rate range studied. Since the hydrodynamic characteristics of this specific 
formulation allowed for further analysis expanding the upper range of shear rate to 3000 
s-1, an infinite-rate viscosity of approximately 1 cP was observed following the Cross 
model. Therefore, all formulations were expected to be nebulized using this active 
vibrating-mesh nebulizer. 
We acknowledge that some standard error values obtained from fitting the results 
to rheological models are rather high. These high values may be attributed to a limited 
shear rate range studied using this experimental design. Further evaluation of rheological 
behavior at lower shear rates using creep tests could be accomplished, and by 
superimposing the results to this data could help to provide lower standard errors.[21] 
However, our interest in this study lies in the formulation behavior at higher shear rates. 
It is also recognized that a direct correlation between the rotational shear rate that was 
applied during rheology tests and the vertical membrane oscillation during nebulization is 
improbable. Nonetheless, an understanding of the formulation reaction to the stress 
applied should give valuable information as to what can be expected from the active 
membrane nebulization of such dispersions. 
To compare the nebulization performance of the formulations, we set up the 
Malvern Spraytec® with the “open bench” method as described in the previous chapter. 
The transmittograms presented in Figure 5.9 show a nebulization event of 15 minutes. At 
the end of this duration the transmission values go back up to 100% for all formulations. 
This result indicates that the measurement was properly performed with no fogging of the 
detector lens. To evaluate the nebulization performance of these formulations, the 
generated transmittograms were fitted to a linear regression in order to analyze the slopes 
of the curves. By comparing their slopes, it can be inferred how steady a given 
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nebulization event was. The slopes of the transmittograms and the TAO results are 
presented in Figure 5.10. Aerosolization of saline (control) has shown to be steady over 
time, which is indicated by a slope close to zero and the highest TAO. This confirms the 
feasibility of delivering solutions with this type of nebulizer. The lecithin formulation 
presented a steady nebulization for the initial 5 minutes (300 seconds), followed by an 
increase in transmission after this time point. Interestingly, the DMPC dispersion 
presented a transmission profile with a pattern opposite to the one displayed with the 
lecithin formulation of CoQ10. At the start of nebulization, a slight slope can be observed 
for up to about 8 minutes (480 seconds) followed by steady nebulization to the end of the 
testing period. DPPC and DSPC dispersions presented a very shallow slope throughout 
the whole nebulization event.  
The lecithin dispersion of CoQ10 presented a low TAO that was not statistically 
different from DMPC formulation, and the highest slope. On the other hand, although 
DPPC and DSPC formulations presented similar slopes (not statistically different), the 
TAO from DSPC showed a higher mass output than that which was shown for the DPPC, 
despite both being steadily nebulized. These findings indicate the importance of 
analyzing the slope of the transmittograms in conjunction with the mass output (or TAO). 
The DSPC formulation presented the best results among the aqueous dispersions of 
CoQ10, exhibiting a low slope value and the highest TAO among the phospholipid 
dispersions. In summary, the respective order of increasing nebulization performance of 
CoQ10 was: 
 
Lecithin < DMPC < DPPC < DSPC  
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These findings can be evaluated concomitantly with the respective rheological 
behavior of the formulations at higher shear rates. It is apparent when looking at the 
curve shapes (Figure 5.8) that, at high shear rates, lecithin and DMPC dispersions present 
the characteristic shear-thickening behavior following the second Newtonian plateau of 
the general flow curve of dispersions. This is confirmed by their low respective 
characteristic times. The occurrence of shear-thickening following the shear-thinning 
event happens due to an arrangement instability following the two-dimensional layering 
of the fluid. Being above a critical shear stress causes the random arrangement of 
particles, resulting therefore in an increase in viscosity.[19] This consequent random 
arrangement of the dispersed particles may be the cause of limitation to a steady 
nebulization performance presented by these two formulations. On the other hand, the 
high characteristic times and shear-thinning behavior at the power law region presented 
mainly by DSPC and to a lesser extent DPPC dispersions at high shear rates may explain 
an improved nebulization performance of these formulations. These results suggest that a 
high characteristic time corresponding to a shear-thinning behavior at high shear rates 
may favor the nebulization performance, while shear-thickening (low characteristic time) 
has the counter effect. Therefore, these results suggest that the rheological behavior at 
high shear rates may be directly related to the nebulization performance of the 
dispersions. 
However, the mass output may not be correlated to drug emission in the case of 
nebulization of dispersions, as was previously discussed. To verify drug aerosolization 
and to gain understanding of the aerodynamic properties, the in vitro deposition of the 
phospholipid formulations of CoQ10 was analyzed using NGI and adapted DUSA. 
Analysis of drug deposition at initial and final time fractions of the 15-minute 
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nebulization period allowed for an evaluation of this data in conjunction with the 
nebulization performance previously discussed. 
The TED of lecithin, DMPC, DPPC and DSPC formulations are presented in 
Figure 5.11. The lecithin dispersion of CoQ10 presented a statistically significant decrease 
in drug aerosolization comparing initial and final phases of nebulization period, following 
both NGI and DUSA analysis. This difference in drug amount emitted at the beginning 
and at the end of the nebulization confirms that the slope (25.99 x 10-3 ± 2.80 x 10-3 %/s) 
observed in the results from nebulization performance using LD is not only related to 
decreased mass output, but also to the amount of drug being aerosolized. Overall, the 
lecithin dispersion also presented a significantly smaller TED both at the initial and final 
phases when compared to the synthetic phospholipid formulations.  
Following NGI analysis, no statistical difference was found within the same 
nebulization event for the dispersions prepared with synthetic phospholipids. However, 
the DMPC dispersion presented a significantly smaller TED within the same nebulization 
event following the DUSA method. It is more appropriate in this case to consider the 
TED results related to DUSA since the droplets containing the drug are directly deposited 
in a filter, while the TED from the NGI analysis may have losses associated with the NGI 
apparatus. Nevertheless, a satisfactory mass balance was reached, since no statistical 
difference was found when comparing each phase from each formulation for the two 
methods to determine TED. Again, the slope result (16.06 x 10-3 ± 2.88 x 10-3 %/s) from 
nebulization performance testing of DMPC dispersion is in agreement with the difference 
in drug amount being aerosolized within the same 15-minute nebulization period. DPPC 
and DSPC dispersions of CoQ10 aerosolized approximately equal amounts in both phases 
of nebulization. These results demonstrate the steadiness of nebulizing these formulations 
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as seen during nebulization performance testing which presented small linear regression 
slope values. 
In addition to testing the capacity of vibrating-mesh nebulizers to continuously 
aerosolize these dispersions, it should also be observed that the droplets containing drug 
particles present aerodynamic properties that allow CoQ10 delivery to the lungs. These 
aerodynamic properties can be seen in Figures 5.12 and 5.13, where the deposition 
patterns of the studied formulations are presented. Interestingly, the lecithin formulation 
presented a higher droplet size related to drug mass fraction deposited at the initial phase 
of nebulization than at the final section (Figure 5.12). The DMPC formulation presented 
a similar pattern to the lecithin formulation, but to a much smaller degree. Formulations 
of DPPC and DSPC had a more balanced droplet size throughout the 15-minute 
nebulization event. As for drug amount deposited (as opposed to drug fraction), it is clear 
from Figure 5.13 that the overall deposition of lecithin formulation was low both at the 
initial and final phases when compared to the other formulations, as previously seen with 
the TED results. Among the three synthetic phospholipids studied, the DMPC 
formulation presented the lowest deposition, with agreement of the TAO and TED 
results. Formulations of DPPC and DSPC had high drug amounts deposited while 
maintaining the aerodynamic properties throughout the 15-minute nebulization event. 
To further compare the aerodynamic properties of the aerosolized dispersions, the 
MMADs and GSDs are presented in Figure 5.14. The MMAD and GSD values at the 
initial phase are similar when comparing all of the formulations. At the end of 
nebulization, these values were quite variable at different degrees, indicating that the 
aerosolization process had a different impact on the size of the emitted droplet containing 
drug nanoparticles depending on the type of phospholipid used to disperse CoQ10. 
Remarkably, it appears that the changes seen within the same nebulization event for 
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lecithin and DMPC dispersions through the slope from the transmittogram results (Figure 
5.10) are reflected not only in the amount of drug being aerosolized, as observed in the 
TED results (Figure 5.11), but also on the aerodynamic properties shown in their in vitro 
NGI deposition profiles (Figures 5.12 and 5.13). As the nebulization progresses, the 
droplets aerosolized become smaller and decrease in quantity. 
By analyzing the fine particles (with aerodynamic sizes below 5.39 µm), we can 
acquire a better understanding of the drug output that may potentially be deposited into 
the lungs. Figure 5.15 shows the FPDet and FPF values for the formulations of CoQ10 
studied. The FPF appears to increase over time for all of the dispersions aerosolized with 
the Aeroneb Pro® nebulizer, confirming that the droplet sizes are decreasing as a result of 
the nebulization process. As seen with the MMAD differences obtained at initial and final 
phases of aerosolization of lecithin dispersions of CoQ10, the FPD of this formulation 
drastically changes over time within the same nebulization event. Moreover, the MMAD 
values of aerosolized DMPC dispersions are significantly shown to decrease, while the 
FPD is not statistically different. The DPPC formulation presents a steady nebulization 
performance and, consequently, similar TED values within the nebulization event, as 
previously shown. Although the MMAD values are not statistically different, it can be 
observed from the FPD results that the DPPC formulation presents a significantly higher 
amount of drug particles that are aerosolized by the end of the nebulization period. A 
similar behavior was observed for the DSPC dispersion of CoQ10, but this fell short from 
the value of statistical significance (P = 0.08). In general, these findings confirm that the 
aerodynamic size of the aerosolized dispersions decreased over time within the same 
nebulization event. 
Figure 5.16 shows that the geometric sizes of the droplets containing CoQ10 
particles also decrease over time, more so for lecithin and DMPC dispersions. Aerosols 
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of DPPC and DSPC formulations presented a steadier droplet size within the 15-minute 
nebulization period, which were more similar to the saline (control). The discrepancy in 
aerodynamic and geometric sizes may be attributed to the different testing setups as 
discussed in a previous study.[26] The “open bench” method using LD technique 
evaluates the volume-based geometric sizes as soon as the droplets are generated from 
the vibrating-mesh. On the other hand, larger particles are excluded from MMAD 
calculation due to inertial impaction of droplets onto the nebulizer mouthpiece adapted to 
the aerosol generating vibrating-mesh and onto the induction port attached to the NGI 
setup. 
We have observed unprecedentedly high doses with the potential to reach the 
lungs based on FPD, results presented in Table 5.4, with DPPC and DSPC formulations 
presenting the highest values. These doses are approximately 10 to 40 times greater than 
itraconazole nanodispersions previously aerosolized using the same type of nebulizer 
(vibrating-mesh device) and as much as 280 times greater than previous aerosolization of 
budesonide suspension (Pulmicort Respule®, AstraZeneca, UK) using a Sidestream® 
PortaNeb® jet nebulizer (Medic-Aid Ltd., UK).[27-29] Most importantly, the 
experimental design in the present study allows for verifying further whether there was a 
burst or a steady aerosol generation throughout the desired 15-minute nebulization event. 
Further studies are warranted to verify the effective drug loading, which we 
anticipate to be somewhat different from the nominal drug concentration. During hot high 
pressure homogenization, water evaporation may occur. In addition, the small volume of 
formulation prepared (100 mL) may allow for drug loss deposited in the internal walls of 
the container of the manufacturing equipment. Moreover, stability studies of the 
formulations should be performed. 
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The changes identified in nebulization performance of CoQ10 within a 
nebulization event using LD technique have been confirmed by the changes in 
aerodynamic properties of these formulations. Most importantly, the rheological behavior 
of these dispersions was in agreement with the capacity of the active vibrating-mesh 
nebulizer used in this study to steadily nebulize phospholipid-stabilized formulations of 
CoQ10. It is well known that the concentration of dispersions has a significant role in 
determining the critical shear rate at which the shear thickening event post-second 
Newtonian plateau starts to happen.[19] Thus, the knowledge of rheology of dispersions 
may be used in future studies to identify the maximum drug loading based on this critical 
shear rate while still maintaining satisfactory nebulization performance. The aerosol 
generation from nebulizers occurs through an applied stress (i.e. air jet stream, ultrasonic 
force, vibrating-mesh, etc.) into or onto the bulk liquid formulation. Therefore, 
rheological studies of dispersions together with the analysis of nebulization performance 
using LD technique may greatly favor the formulation development of poorly-water 
soluble drugs for inhalation therapy using nebulizers. Nonetheless, special attention 
should be given to the functioning mechanism of the different types of nebulizers as 
described in Chapter 1 and how it may be related to the shear stress applied in the 
rheological studies. 
 
5.4. CONCLUSIONS 
Despite the similarities between the chemical structures of the excipients, the 
formulations of CoQ10 prepared with different phospholipids presented very different 
physicochemical properties which were holistically analyzed using the rheology of the 
dispersions. Evaluation of the non-Newtonian behavior at higher shear rates may indicate 
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the aerosolization profile (nebulization performance and in vitro drug deposition) of these 
formulations. Formulations of CoQ10 presenting low characteristic time (lecithin and 
DMPC) and therefore shear-thickening behavior at high shear rates presented a 
continuous, but not steady, nebulization performance. Decreased mass and drug output as 
well as decreased aerodynamic and geometric droplet sizes were also significant for these 
dispersions within the same 15-minute nebulization event. On the other hand, 
formulations presenting high characteristic time (DPPC and DSPC) and therefore a slight 
shear-thickening behavior or shear-thinning characteristic of power law region at high 
shear rates presented a steady nebulization performance. This was followed by a steady 
mass and drug output while maintaining the aerodynamic and geometric droplet sizes 
within the same nebulization event. The experimental design presented in this study may 
be a useful predictive tool to identify formulations with potential to deliver poorly-water 
soluble drugs as colloidal systems when aerosolized using vibrating-mesh nebulizers. 
Nonetheless, these findings warrant in vivo studies to determine the amount of CoQ10 that 
can be successfully aerosolized and deposited into animal lungs. 
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5.5. TABLES 
 
Formulation Dv(10) (µm) Dv(50) (µm) Dv(90) (µm)
Lecithin 0.24 ± 0.00 0.45 ± 0.00 0.81 ± 0.00 
DMPC 0.21 ± 0.01* 0.81 ± 0.14 37.84 ± 27.25 
DPPC 0.22 ± 0.01 0.85 ± 0.10 36.30 ± 34.26 
DSPC 0.25 ± 0.02* 2.41 ± 1.93 97.24 ± 103.06 
Results are expressed as means ± standard deviations (n = 3). * P < 0.05 following Tukey-Kramer test. 
Table 5.1 – CoQ10 particle sizes in aqueous dispersions of phospholipid formulations 
represented as Dv(10), Dv(50), and Dv(90) values. 
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Model Equation 
Cross 
ߟ െ ߟஶ
ߟ଴ െ ߟஶ ൌ
1
ሺ1 ൅ ሺܭ · ߛሶ ሻ௠ሻ 
Sisko ߟ ൌ ߟஶ ൅ ܭ · ߛሶ ௡ିଵ
Williamson ߟ ൌ
ߟ଴
ሺ1 ൅ ሺܭ · ߛሶ ሻ௡ሻ 
η0 and η∞ are the asymptotic values of viscosity at very low (zero-rate viscosity) and very high (infinite-rate 
viscosity) shear rates; K is the characteristic time (the lower the value, the further to the right the curve 
lies); m is a dimensionless constant indicating rheological behavior (viscosity as a function of shear rate) in 
the shear thinning region where m = 0 refers to Newtonian behavior and increasing values tending to unity 
corresponds to increasing shear thinning behavior; n is the power-law index and values below and above 
unity represent shear-thinning and shear thickening events, respectively; and ߛሶ  is shear rate. 
Table 5.2 - Rheological models and their respective equations applied in this study. 
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Formulation Model Zero-rate 
viscosity 
(mPa.s)§ 
Infinite-rate 
viscosity 
(mPa.s) 
Characteristic 
time (s) 
Rate index (n) 
or Cross rate 
constant (m) 
Thixotropy 
(Pa/s) 
Normalized 
Thixotropy (s-1) 
Lecithin Sisko N/A 0.95 ± 0.01 8.60x10-4± 
14.9x10-4 
23.35 ± 1.90* 85.48 ± 0.79 16.92x10-4± 
0.31x10-4 
DMPC Cross 1.13 ± 0.01 3.66 ± 3.11 9.06x10-4 ± 
5.38x10-4 
2.59 ± 0.52 Zero Zero 
DPPC Cross 5.31 ± 0.96 1.61 ± 0.01 0.51 ± 0.03 0.70 ± 0.05 Zero Zero 
DSPC Williamson 621.17 ± 446.30 N/A 15.19 ± 11.12* 0.54 ± 0.10 Zero Zero 
Results are expressed as means ± standard deviations (n = 3). N/A: not applicable when referred to this rheological model (compare to equations in table 
2). § Groups are statistically different but post hoc test was unable to distinguish differences among groups. * P < 0.05 when compared to other 
formulations.  
Table 5.3 – General flow curve data of CoQ10 dispersions.  
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Formulation FPDet (mg) FPDr (µg/min) 
Lecithin 24.84 1656 
DMPC 126.30 8420 
DPPC 168.36 11224 
DSPC 173.79 11586 
Table 5.4 – Estimated total (FPDet) and rate of delivery (FPDr) of fine particle doses from 
aqueous dispersions of CoQ10 containing different phospholipids. 
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5.6. FIGURES 
 
 
 
Figure 5.1 – Schematic diagram of Dose Uniformity Sampling Apparatus (DUSA) for Dry Powder Inhalers (DPIs) adapted for 
nebulizers. 
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Figure 5.2 – Particle size distributions from laser diffraction technique of aqueous 
dispersions of CoQ10 following 50 passes in the Microfluidizer®. Results are 
expressed as means ± standard deviations (n = 3). Some standard deviations are 
too small to be visible. 
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Figure 5.3 – Z-average and PdI values of aqueous dispersions of CoQ10 following 50 
passes in the microfluidizer. Results are expressed as means ± standard 
deviations (n = 3). Some standard deviations are too small to be visible (n = 
3). § Not statistically different. 
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Figure 5.4 – Zeta potential of CoQ10 dispersions. Results are expressed as means ± 
standard deviation (n = 3).* P < 0.05 when compared to synthetic 
phospholipids. 
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Figure 5.5 – Surface tension of CoQ10 dispersions. Results are expressed as means ± 
standard error (n ≥ 5). The temperature values during measurement were 
25ºC, 25ºC, 19ºC and 17ºC, respectively. § Not statistically different. 
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Figure 5.6 – Elements of Herschel-Bulkley model for aqueous dispersions of CoQ10, 
expressed as means ± standard deviations (n = 3). Yield stress of DSPC 
formulation is not presented because it follows Power Law model. Some 
standard deviations are too small to be visible. * P < 0.05. § Not statistically 
different.
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Figure 5.7 – General flow curve of aqueous dispersions. Adapted from ref. [19]. 
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Figure 5.8 – Rheological behavior of CoQ10 dispersions. Graphs presented in different 
scales are expressed as means ± standard deviations (n = 3). 
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Figure 5.9 – Transmittograms of saline (control) and lecithin, DMPC, DPPC and DSPC dispersions of CoQ10. Results are 
expressed as means (n = 3) of percentage transmission relative to nebulization of CoQ10 dispersions for15 minutes. 
The slope values from the linear regression analysis of the curves are evaluated as measurement of steadines in 
aerosol production. 
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Figure 5.10 – Slope of transmittograms (top) and Total Aerosol Output, TAO (bottom), 
expressed as means ± standard deviations (n = 3) relative to nebulization of 
CoQ10 dispersions for15 minutes. § Not statistically different.
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Figure 5.11 – TED from NGI (top) and from DUSA for DPI adapted for nebulizers 
(bottom) of dispersions of CoQ10. Results are expressed as means ± standard 
deviations (n = 3) of total drug deposited within a 15 second period at initial 
and final phases of a 15-minute nebulization event. TED: Total Emitted 
Dose; DUSA: Dose Uniformity Sampling Unit; DPI: Dry Powder Inhaler. * 
P < 0.05 when compared to synthetic phospholipids. † P < 0.05 within 
nebulization event. § Not statistically different compared to each other. ‡ Not 
statistically different compared to other synthetic phospholipids. 
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Figure 5.12 – In vitro deposition profiles of lecithin, DMPC, DPPC and DSPC dispersions of CoQ10 at a flow rate of 15 L/min 
using an Aeroneb Pro® nebulizer. Results are expressed as means ± standard deviations (n = 3) of the percentage of 
total drug deposited within a 15-second period at initial and final phases of a 15-minute nebulization event.
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Figure 5.13 – In vitro deposition profiles of lecithin, DMPC, DPPC and DSPC dispersions of CoQ10 at a flow rate of 15 L/min 
using an Aeroneb Pro® nebulizer. Results are expressed as means ± standard deviations (n = 3) of the drug amount 
deposited within a 15-second period at initial and final phases of a 15-minute nebulization event. 
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Figure 5.14 – Aerodynamic properties of lecithin, DMPC, DPPC and DSPC dispersions 
of CoQ10 at a flow rate of 15 L/min using an Aeroneb Pro® nebulizer. 
Results are expressed as means ± standard deviations (n = 3) of MMAD or 
GSD within a 15-second period at initial and final phases of a 15-minute 
nebulization event. * P < 0.05 within nebulization event. § P < 0.05 when 
compared to each other. 
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Figure 5.15 – Estimated total dose (FPDet) and fraction (FPF) of aerosolized fine particles 
from lecithin, DMPC, DPPC and DSPC dispersions of CoQ10 at a flow rate 
of 15 L/min using an Aeroneb Pro® nebulizer. Results are expressed as 
means ± standard deviations (n = 3) related to a 15-second period at initial 
and final phases of a 15-minute nebulization event. * P < 0.05 when 
compared to synthetic phospholipids. † P < 0.05 within nebulization event. § 
Not statistically different compared to each other. ‡ P < 0.05 when compared 
to each other.
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Figure 5.16 – Average Dv(50) of CoQ10 dispersions aerosolized using Aeroneb Pro® nebulizer for 15 minutes (n = 3).
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Chapter 6: Pulmonary Deposition and Systemic Distribution in Mice of 
Inhalable Formulations of Coenzyme Q10 
Abstract 
Coenzyme Q10 (CoQ10) is a poorly-water soluble compound that is being 
investigated for the treatment of carcinomas. In vitro deposition studies of the 
aerodynamic properties of dispersions prepared with synthetic phospholipids have shown 
that high doses of this anticancer agent may potentially be delivered to the lungs. The aim 
of the research presented in this chapter was to investigate systemic distribution along 
with lung and nasal depositions in mice following single-dose pulmonary delivery of 
CoQ10 formulations prepared with synthetic phospholipids. An Aeroneb Pro® vibrating-
mesh nebulizer was used to generate aerosols into a nose-only inhalation chamber. 
Following calculation of the estimated dose delivered, the drug concentration in the blood 
plasma, lung tissue, and nasal cavity was analyzed. The estimated doses delivered were 
166.2, 229.1 and 226.9 mg/kg of mouse body weight for DMPC, DPPC, and DSPC 
dispersions of CoQ10, respectively. For up to 48 hours, high drug concentrations were 
found in the lungs while no quantifiable levels of CoQ10 were observed in the blood 
plasma. The drug deposition in the nasal cavity up to one hour post dosing was lower 
than that which was measured in the lungs. These findings suggest that exogenous CoQ10 
clears slowly from mouse lungs when high amounts are delivered. 
 
6.1. INTRODUCTION 
In the work described in earlier chapters, the feasibility of preparing 
phospholipid-stabilized dispersions for potential pulmonary delivery has been explored. 
By direct administration to the lung, it was anticipated that high doses of this anticancer 
agent could be deposited using an Aeroneb Pro® vibrating-mesh nebulizer. We had also 
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discussed the influence of the physicochemical properties of the dispersions of CoQ10 on 
the aerosolization profile. As described in the previous chapter, the rheology of 
dispersions at high shear rates may be indicative of the aerosolization profile 
(nebulization performance and in vitro drug deposition). Dipalmitoyl phosphatidylcholine 
(DPPC) and distearoyl phosphatidylcholine (DSPC) dispersions were shown to 
demonstrate continuous and steady aerosolization over time. Each dispersion displayed 
comparably high amounts of respirable doses of CoQ10, exhibiting potential to be 
delivered effectively to the deep lungs. The dimyristoyl phosphatidylcholine (DMPC) 
dispersion showed a lower Fine Particle Dose (FPD) comparatively to the other synthetic 
phospholipids, but a significantly higher FPD compared with the lecithin formulation.  
The aim of the study presented in this chapter was to evaluate the in vivo systemic 
distribution, lung, and nasal depositions in mice following pulmonary delivery of CoQ10 
formulations prepared with synthetic phospholipids. Three synthetic phospholipids were 
selected to stabilize these dispersions because of their physiological occurrence in the 
lungs, these were: DMPC, DPPC and DSPC. Due to the low in vitro deposition profile of 
the model excipient lecithin, compared with those displayed with the synthetic 
phospholipids, the lecithin formulation was not selected for use in the animal study. The 
animal dosing apparatus consisted of a nose-only inhalation chamber with aerosol 
generated from an Aeroneb Pro® vibrating-mesh nebulizer.[1-3] A high and sustained 
dose of CoQ10 into the mice’s lungs was achieved, which varied from 1.8 to 3.0% of the 
theoretical exposure. 
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6.2. MATERIALS AND METHODS 
6.2.1. Materials 
CoQ10 was supplied by Asahi Kasei Corp. (Tokyo, Japan). Genzyme 
Pharmaceuticals (Liestal, Switzerland) provided 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). DMPC was also obtained from 
Lipoid GmbH (Ludswighafen, Germany). Sodium chloride (crystalline, certified ACS) 
was acquired from Fisher Chemical (Fisher Scientific, Fair lawn, NJ, USA) and the 
deionized water was obtained from a central reverse osmosis/demineralizer system 
commonly found in research laboratories. Mouse restraint tubes (item E2QY-PC), 
anterior nose inserts (item E2TE-N) and posterior holders (item E2TA-N) were 
purchased from Battelle Toxicology Northwest (Richland, WA, USA). A fan (12V, 
0.10A, model OD4020-12HB) was purchased from Knight Electronics (Dallas, TX, 
USA). HPLC grade hexane and ethanol 200 proof were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Syringes (1 mL) and needles (gauges 21G1 and 23G1) were 
obtained from Becton Dickinson (Franklin Lakes, NJ, USA). Heparinized tubes (1.3 mL 
microtubes Lithium Heparin (LH) with screw cap closure, product no. 41.1393.105) were 
purchased from Sarstedt AG & Co. (Numbrecht, Germany). Microcentrifuge tubes (1.5 
mL, clear, RNase/DNase free, BL3152) were obtained from Bio-Link Scientific, LLC 
(Wimberley, TX, USA). 
 
6.2.2. Formulation 
Formulations were prepared using high pressure homogenization as described in 
the previous chapter. In brief, following overnight hydration while stirring, a 
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phospholipid dispersion containing 2.5% w/w of phospholipids (DMPC, DPPC, or 
DSPC) in water was added to the molten CoQ10 (4% w/w) at 55 °C. The formulation was 
then predispersed, using an Ultra-Turrax® TP 18/10 Homogenizer with 8 mm rotor blade, 
by high shear mixing (IKA-Werke, Staufen, Germany) for 5 minutes at 20,000 rpm. 
Subsequently, the formulation was passed 50 times through a M-110P “Plug-and-Play” 
Bench-top Microfluidizer® (Microfluidics, Newton, MA USA) at approximately 30,000 
psi while maintaining the temperature between 55 and 65 °C. Following 
microfluidization, 0.9% w/v of sodium chloride was added to the final formulation. A 
formulation for the control group was similarly prepared using DPPC in absence of drug 
(CoQ10 was not added). 
 
6.2.3. Pulmonary Delivery to Mice 
The protocol for this animal study was approved by the Institutional Animal Care 
and Use Committee (IACUC) at the University of Texas at Austin, Austin, TX. Animals 
were caged in groups of 4, and maintained on a normal rodent chow diet with free access 
to water. A nose-only chamber apparatus capable of dosing six mice at a time was 
assembled according to Figure 6.1.[1-3] Prior to dosing, CD-1® IGS ICR mice (Charles 
River Laboratories International, Inc., Wilmington, MA, USA) were individually 
acclimatized for approximately 10 minutes per day for 3 days into restraint tubes, 
restricted by an anterior nose insert and a posterior holder. The dosing apparatus was 
placed inside a fume hood to collect escaping aerosol containing drug. To avoid influence 
from the airflow provided by the fume hood, an erlenmeyer container was placed at the 
end of the tubing system (as an air buffer). The airflow rate was set to 1 L/min to ensure 
proper drug aerosolization into the nose-only chamber (internal volume: 230 mL; 
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diameter: 3.8 cm; length: 20.3 cm) using an Aeroneb Pro® vibrating-mesh nebulizer 
(Aerogen, Galway, Ireland). Following preparation, all formulations (saline control, 
DMPC, DPPC, or DSPC) were dosed for 15 minutes to mice weighing from 23 to 33g 
each, at time of dosing. Each single-dose studied group consisted of thirty-six male 
animals. At each time point (0.5, 1, 3, 8, 24, and 48 hours after the end of the 
aerosolization event) six animals randomly selected from different dosing events of the 
same formulation were sacrificed by narcosis with carbon dioxide. As part of the 
collection process, blood was withdrawn by cardiac puncture, lungs were harvested, and 
a nasal wash was performed. The samples were extracted for analysis with liquid 
chromatography coupled with tandem mass spectrometry (LC/MS/MS). 
 
6.2.3.1. Estimated Dose 
To estimate the dose to which mice were exposed during this study, it was 
assumed that the nose-only chamber gradually fills with the aerosol containing CoQ10. 
Therefore, the drug concentration steadily increases until it reaches a plateau. At steady-
state, it is also assumed that the rate of drug entering the chamber is equal to the rate of 
drug leaving the chamber (dC/dt=0). Therefore, the following equation can be used to 
measure the drug concentration inside the chamber at any given time: 
 
ܥ ൌ ி௉஽ೝி · ൫1 െ ݁ିఒ·௧൯  (Equation 6.1) 
 
Where C is the drug concentration, FPDr is the rate of delivery of the Fine 
Particle Dose (the amount of particles with aerodynamic cutoff diameter below 5.39 µm 
per minute) as determined in the previous chapter, F is the airflow rate, λ is the chamber 
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air-change rate and t is any given time within the nebulization period. The chamber air-
change rate, λ, can be determined based on the airflow rate and on the chamber internal 
volume, V, as follows: 
 
ߣ ൌ ி௏  (Equation 6.2) 
 
Based on these assumptions, the following equation describes the estimated dose 
delivered to mice: 
 
ܧݏݐ݅݉ܽݐ݁݀ ܦ݋ݏ݁ ൌ ܴܯܸ · ி௉஽ೝி · ቄݐԢ ൅
௏
ி · ൣ൫݁ିఒ·௧ᇱ൯ െ 1൧ቅ  (Equation 6.3) 
 
Where RMV is the species-specific Rate Minute Volume and t’ is the duration of 
the nebulization event. The estimated dose as calculated above can then be normalized by 
the animal body weight, W (g). RMV is calculated as previously reported:[4] 
 
ܴܯܸ ൌ 4.19 · ܹ଴.଺଺  (Equation 6.4) 
 
6.2.4. Analysis of CoQ10 Levels in Lung Tissue, Blood Plasma, and Nasal Cavity 
The analyses were performed according to an internal protocol from Berg 
Diagnostics (Natick, MA, USA). Briefly, the method was validated in the drug 
concentration range of 0.1 to 600 µg/mL. Following liquid extraction, CoQ10 levels were 
determined using liquid chromatography coupled with tandem mass spectrometry (LC-
MS/MS). 
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Following harvesting of the mice’s lungs, the tissue was weighed (wet weight) 
and subsequently frozen in dry ice, where it was kept until transference to a -80ºC 
refrigerator for storage prior to analysis. Following sample thawing at time of analysis, 
lung tissue (50 ± 1.5 mg) was weighed and subsequently homogenized with Dulbecco’s 
Phosphate Buffer Saline (dPBS). Homogenate (100 µL) and internal standard were added 
to isopropanol (IPA) and the sample vortexed. Following centrifugation, the supernatant 
(100 µL) was added to another tube containing IPA. The sample was vortexed again and 
transferred to LC-MS/MS vial for analysis. 
Following cardiac puncture, approximately 1 mL of mice blood was collected in 
heparinized tubes and kept in ice bath until centrifugation for 10 minutes at 7000g. The 
supernatant was then transferred to 1.5 mL microcentrifuge tubes and kept refrigerated at 
-80ºC until analysis, which was similar to the described procedure for lung tissue. 
To evaluate the amount of drug deposited into the nasal cavity, a solvent wash 
was performed. The mice nasal cavity was directly accessed from the posterior portion of 
the hard palate by inserting a needle into the mice nasopharynx and flushing the nasal 
fossa with hexane:ethanol 2:1 (v/v). The solvent was collected into a scintillation vial 
from the anterior (frontal) portion of the nose and subsequently allowed to dry at room 
temperature. The sample was then re-suspended and injected into LC-MS/MS. 
 
6.2.5. Statistical Analysis 
Samples were tested for normality using the Shapiro Wilk test (p < 0.05) and 
outliers were excluded from the data analysis. The data is expressed as mean ± standard 
deviation. Pharmacokinetic parameters were determined using Microsoft Office Excel 
2007 software (Redmond, WA) with the add-in program PKSolver.[5] Statistical analysis 
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was performed using NCSS/PASS software Dawson edition.[6] At each time point, lung 
tissue samples were analyzed for statistical differences among different groups with One-
Way ANOVA for significance (p < 0.05). The same analysis was performed for nasal 
wash samples, with additional post hoc multiple comparison tests performed to identify 
statistically significant differences between treated and control groups using Dunnett’s 
method (p < 0.05). A paired t-test was performed to analyze statistical differences (p < 
0.05) within the same treatment group for changes in drug deposition in the nasal cavity 
over time. 
 
6.3. RESULTS AND DISCUSSION 
The drug concentration in the blood plasma and lung deposition profile of the 
CoQ10 dispersions that were previously developed have been determined over time in this 
study. The investigation has also been extended to determine the drug deposition in the 
nasal cavity following inhalation. Using an Aeroneb Pro® nebulizer to generate aerosol 
into a nose-only inhalation chamber, mice were dosed for 15 minutes with control, 
DMPC, DPPC, and DSPC formulations. The dose delivered to the mice’s lungs was 
estimated based on the FPDr values as was determined during the in vitro 
characterization of drug deposition using the Next Generation Impactor (NGI), described 
in the previous chapter. 
Figure 6.2 shows the calculated drug concentration-time profile within the nose-
only chamber. The plateau is reached at 3.0 minutes and the concentration at steady-state, 
CSS, is equal to FPDr since the airflow rate during this experiment was 1 L/min (Table 
6.1). The chamber air-change rate was 4.35 min-1. The estimated doses delivered to mice 
of aerosolized DMPC, DPPC, and DSPC dispersions of CoQ10 for 15 minutes increases 
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in this respective order (Figure 6.3). When normalized to the body weight of animals, 
similar estimated doses were delivered to mice receiving either DPPC or DSPC 
formulations. These doses of CoQ10 were found to be greater than when the mice were 
dosed with the DMPC dispersion. 
The drug concentration in plasma was below the quantitative level (0.1 µg/mL) 
for all studied groups at every time point. The baseline concentration of CoQ10 in mice 
blood plasma is approximately 0.1 µmol/L (86 ng/mL).[7-9] In the lungs, the drug 
concentration was also below the quantitative level for the control group at every time 
point investigated. It is evident from Figure 6.4 that CoQ10 stays in the lungs at relatively 
high concentrations for up to 48 hours. The mechanism by which CoQ10 could be 
absorbed through the lung epithelium is unknown, but it is known that CoQ10 is 
dependent on multiple carrier-mediated transport mechanisms for absorption through the 
gastrointestinal tract.[10] In the GI tract, chylomicrons sequester exogenous CoQ10 and 
transfer it to the liver prior to systemic distribution mediated by very low density 
lipoproteins (VLDL). Despite the lipophilicity of CoQ10, it is believed that passive 
diffusion is only part of a more complex absorption process involving an additional 
active and facilitated transport phenomena.[10] The small amount of translocation of the 
drug from the lungs to the systemic circulation may be in part due to this low 
permeability. In addition, the dispersions are formulated in the nano-size range. The 
stealthiness of particles below 0.2-0.5 µm to alveolar macrophages has been extensively 
reviewed.[11-13] In addition to size, other physicochemical properties of the drug may 
influence the translocation of nanoparticles across the air-blood barrier; such as particle 
material, in vivo solubility, and binding affinity to cell membranes (e.g. through surface 
charge and structure).[14, 15] The solubility of CoQ10 in water at 20ºC is less than 5 
µg/mL.[16] It has been previously shown that phospholipids induce migration of 
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insoluble particles to the lung periphery of rodents.[17] Therefore, the presence of 
phospholipids in these formulations may have also caused a greater lung peripheral 
distribution of the drug nanoparticles. The translocation of insoluble nanoparticles across 
the air-blood barrier is known to be minimal compared to the long term clearance from 
the alveoli up to the mucociliary escalator and into the GI tract, which may take 
weeks.[11, 14] A significant spreading of drug towards the lung periphery due to the 
presence of phospholipids in the formulations investigated in this study may help in 
explaining why the clearance of CoQ10 from the lungs was not detected after 48 hours 
and similarly why the drug levels in the plasma were below the quantitative limit. 
Additionally, since the drug clearance from the lungs was not significant in the 
time period studied, the elimination constants and half-lives could not be determined for 
the nebulized formulations of CoQ10 in this study. Other pharmacokinetic parameters are 
presented in Table 6.2. The lung deposition profiles of aqueous dispersions of CoQ10 
using different phospholipids presented relatively similar results. The Cmax ranged from 
604.0 to 791.3 µg/g of wet lung tissue, and was observed 1 hour (tmax) post dosing for all 
treated groups. These values translate to approximately 4.0 to 5.0 mg/kg of mouse body 
weight and correspond to 1.8 to 3.0% of the theoretical exposure dose (Figure 6.5). The 
AUC0-48 results were surprisingly different; with the DMPC formulation of CoQ10 
presenting the highest value regardless of whether the smallest estimated dose that the 
mice were exposed to was presented. Although DPPC and DSPC dispersions of CoQ10 
presented high estimated dose, their Cmax and AUC0-48 values varied widely. No statistical 
differences were found in drug concentration at the same time point among the treated 
groups (Figures 6.4 and 6.5). 
The drug deposition in the nasal cavity was lower than that which was measured 
in the lungs (Figure 6.6), not exceeding an average of 1.7 mg/kg of mouse body weight 
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among the treated groups. Only the DPPC group demonstrated a statistically significant 
decreasing trend for the first two time points investigated. A small amount of CoQ10 was 
observed in the control group, possibly from an endogenous source. Finally, all mice 
were alive and presenting healthy signs 48 hours after the end the nebulization event. 
This demonstrates the safety of delivering high amounts of exogenous CoQ10 to the 
lungs. 
In the previous chapter, unprecedentedly high doses with potential to reach the 
lungs based on FPDet results was predicted, with DPPC and DSPC formulations 
presenting the highest values. These doses are approximately 10 to 40 times greater than 
itraconazole nanodispersions previously aerosolized using the same type of nebulizer 
(vibrating-mesh device) and as much as 280 times greater than previous aerosolization of 
a budesonide suspension (Pulmicort Respule®, AstraZeneca, UK) using a Sidestream® 
PortaNeb® jet nebulizer (Medic-Aid Ltd., UK).[1, 18, 19] In this study, it was verified 
that the high doses that mice were exposed to translate into an improved drug deposition 
into the mice’s lungs. Cmax values of CoQ10 were as much as 75-fold and 165-fold higher 
than previous studies using the same nebulizer to deliver dispersions of cyclosporine A 
and itraconazole, respectively.[1, 18, 20] This is a significant improvement in deliverance 
of high amounts of drug to the lungs, considering that the estimated doses in this present 
study were not proportionally higher to the same extent when comparing to previous 
reports. We believe that the in vitro methods utilized in the experimental design to screen 
appropriate formulations with optimized potential to deliver high drug amounts to the 
lungs were essential in achieving these results.  
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6.4. CONCLUSIONS 
Following a single-dose pulmonary delivery, the drug concentration in the blood 
plasma was below the quantitative level of the validated method and high drug 
concentrations remained in the lungs for up to 48 hours. The deposition in the nasal 
cavity was lower than that which was measured in the mice’s lungs. The Cmax and AUC0-
48 values were not directly related to the estimated doses at which mice were exposed to 
during nebulization of CoQ10 formulations. The findings in this in vivo study indicate that 
high amounts of exogenous CoQ10 can be successfully aerosolized and deposited into the 
lungs of rodents in a nose-only inhalation chamber. Further studies comprising analysis at 
longer time points are warranted to determine the elimination rate from lung tissue. 
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6.5. TABLES 
 
Formulation FPDr (mg/min) 
Mouse 
weight (g)
RMV 
(mL/min) 
Estimated Dose 
After 15 minutes of 
nebulization (mg) 
Normalized to body 
weight (mg/kg) 
DMPC 8.420 28.8 ± 1.4 38.50 4.787 166.2 
DPPC 11.224 26.1 ± 1.5 36.07 5.980 229.1 
DSPC 11.586 29.5 ± 2.0 39.11 6.693 226.9 
Results of mouse weight are expressed as mean ± standard deviations (n = 36 per group). FPDr is the rate of delivery of the Fine Particle Dose (the 
amount of particles with aerodynamic cutoff diameter below 5.39 µm per minute) and RMV is the Rate Minute Volume calculated based on 10 mL/kg at 
120 breaths per minute.[21] 
Table 6.1 – Estimated doses delivered to mice during nebulization of CoQ10 dispersions. 
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Pharmacokinetic Parameter DMPC DPPC DSPC 
Cmax (µg/g wet tissue) 777.7 604.0 791.3 
tmax (h) 1 1 1 
AUC0-48 (mg·h/g) 28.228 21.144 26.830 
Table 6.2 – Pharmacokinetic parameters for lung deposition of a single-dose of CoQ10 
following 15 minutes of nebulization of phospholipid-stabilized dispersions 
to mice based on non-compartmental analysis of tissue concentration versus 
time. 
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6.6. FIGURES 
 
 
Figure 6.1 – Nose-only dosing apparatus used to aerosolize CoQ10 to mice. Six mice are 
individually restrained in a tube, exposing their noses to the chamber. The 
nebulizer is positioned between the chamber and the fan that will provide 
sufficient airflow to fill the chamber with the drug aerosol. The tubing 
system is open to avoid drug recirculation. 
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Figure 6.2 – Estimated drug concentration-time profiles of CoQ10 inside the nose-only 
inhalation chamber. 
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Figure 6.3 – Cumulative estimated doses of CoQ10 from synthetic phospholipid 
formulations aerosolized to mice into a nose-only inhalation chamber during 
15 minutes.
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Figure 6.4 – Mean lung concentrations normalized to wet lung tissue of CoQ10 from 
synthetic phospholipid dispersions following aerosolization to mice into a 
nose-only inhalation chamber during 15 minutes. Error bars indicate 
standard deviation (n = 6). 
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Figure 6.5 – Mean lung concentrations normalized to animal body weight of CoQ10 from 
synthetic phospholipid dispersions following aerosolization to mice into a 
nose-only inhalation chamber during 15 minutes. Error bars indicate 
standard deviation (n = 6). 
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Figure 6.6 – Deposition of CoQ10 in the nasal cavity of mice 0.5 and 1 hour post 15-
minute nebulizer dosing. Results are expressed as means ± standard 
deviations (n = 6). * P < 0.05 when compared to control group. † P < 0.05 
when compared within the same group.
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Chapter 7: Summary, Conclusions and Recommendations 
 
In the research work presented in this dissertation, a suitable formulation for 
pulmonary delivery of Coenzyme Q10 (CoQ10) for the purpose of treating lung 
malignancies was successfully developed and tested in vitro and in vivo. In this chapter, a 
summary of each research project is presented, along with the conclusions obtained from 
them and recommendations deemed appropriate for future studies based on these 
conclusions. 
Initially, an analytical method to accurately, precisely and reproducibly measure 
the surface tension of liquids was developed. As earlier indicated, this interfacial 
phenomenon had previously been demonstrated to have an influence on the 
aerosolization profile of liquids from nebulizer devices. As described in Chapter 3, a 
glass disk probe was manufactured and connected to the arm of a texture analyzer 
instrument. From the measurement of the detachment force of the probe from the surface 
of a bulk liquid, the calculation of surface tension was extrapolated using the theory of 
the maximum pull on a rod. The maximum pull on rod a theory was applied in a novel 
way to describe the mechanism presented in this work, for the maximum pull on a disk. 
Results within 5% of the literature values were obtained, for standard solutions, and it 
was also found that the accuracy of this method may be related to the probe diameter 
used to measure the detachment force from the bulk liquid surface. For this reason, 
further studies are warranted to test glass disk probes with different dimensions in order 
to achieve even more accurate results when compared to literature values for standard 
solutions. Also, it is suggested that a method optimization may be done by reducing the 
sample volume to a minimum while maintaining the infinite interface conditions, which 
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is related to the probe diameter and the liquid surface free from wall interference. 
Regardless of this being a non-destructive test, a small volume of samples may be 
required in cases where liquids containing expensive ingredients (i.e. active 
pharmaceutical ingredients, excipients, etc.) may be need to be evaluated in order to 
lower costs. Nevertheless, the present method has shown satisfactory results, and was 
used to analyze the surface tension of formulations of CoQ10 presented in this work. 
In Chapter 4, soybean lecithin, a mixture of phospholipids, was initially used as a 
model excipient to allow for the determination of a suitable manufacturing process in 
order to acquire an aqueous submicron dispersion of CoQ10. High shear mixing and 
ultrasonication were also evaluated in the manufacturing process, but high pressure 
homogenization was ultimately selected given the satisfactory results obtained. This high 
pressure homogenization was also deemed appropriate with a potential for scale up 
capabilities. To achieve an optimized number of passes in the microfluidization system, 
formulations of CoQ10 stabilized with lecithin (1:1 w/w) were analyzed for particle size 
distribution using laser diffraction (LD) and dynamic light scattering (DLS), surface 
tension according to the method previously described, zeta potential, and rheological 
behavior. Formulations prepared with dipalmitoylphosphatidylcholine (DPPC) were also 
analyzed at the same (1:1) drug-to-lipid ratio. These physicochemical properties were 
then considered in terms of nebulization performance of the CoQ10 dispersions as 
aerosolized by an Aeroneb Pro® vibrating-mesh nebulizer. Previous studies had shown 
that this type of nebulizer can have the pores of the mesh clogged and consequently 
present variable aerosol output results. To ensure continuous and steady aerosol 
generation from the dispersed phospholipid containing formulations, the nebulization 
performance was investigated using LD to analyze the percentage transmission over time 
(transmittogram) related to aerosol output. It was found that the physicochemical 
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properties and the nebulization performance of the formulations varied according to the 
different phospholipids used to stabilize the dispersions. It was also found that 50 passes 
would be a satisfactory processing protocol to attain aqueous submicron dispersions of 
CoQ10 with continuous nebulization capabilities for 15 minutes at this drug-to-lipid ratio, 
regardless of the type of phospholipids utilized in the formula preparation. The results 
suggested that the rheological behavior of the CoQ10 formulations could be used to help 
explain the aerosolization profiles. 
Considering these findings, the synthetic phospholipids dimyristoyl-, dipalmitoyl- 
and distearoyl- phosphatidylcholines (DMPC, DPPC, and DSPC, respectively) were used 
for stabilizing the dispersions of CoQ10 described in Chapter 5. Their physicochemical 
properties and nebulization performances were compared to the lecithin formulation 
previously investigated in Chapter 4. Since the LD technique employed to analyze 
nebulization performance was able to analyze the aerosol in terms of mass output and not 
drug output, the formulations of CoQ10 were investigated for their aerodynamic 
deposition profiles and emitted doses. The slope of the transmittogram was compared to 
drug output at initial and final 15-second periods in a 15-minute nebulization event in the 
cascade impactor tests. It was found that higher slopes corresponded to decreased mass 
and drug output as well as reduced droplet sizes over time. Formulations of CoQ10 
stabilized with DPPC and DSPC presented a similar aerosol profile, emitting high 
amounts of drug with potential to reach the lungs following nebulization. The DMPC 
dispersion presented an intermediate result compared to that of the other synthetic 
phospholipids and lecithin formulations. From the physicochemical properties 
investigated, the rheology of the formulations was indicative of aerosolization profile 
since DMPC and lecithin formulations both presented shear-thickening behavior at high 
shear rates. The applied stress in this experimental design may parallel the high frequency 
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of vibrating-mesh from the nebulizer used. Formulations of CoQ10 prepared with DPPC 
and DSPC presented a steady profile within the 15-minute nebulization period. 
Nevertheless, additional studies are necessary to determine the state matter of the drug 
particles in these dispersions, for instance, through differential scanning calorimetry. 
Further elucidation of drug encapsulation may be obtained through cryo-electron 
microscopy. In addition, the drug concentrations presented in this research project are 
nominal values. Therefore, evaluations of drug loading and manufacturing robustness are 
worthy of further investigation, including an analysis of particle size distribution and 
drug concentration prior to the microfluidization process. Stability of formed dispersions 
of CoQ10 to the nebulization process is suggested to be considered as well as evaluation 
of performance of different types of nebulizers to aerosolize these formulations. 
Finally in Chapter 6, the drug deposition in the pulmonary airways was evaluated 
in mice that were exposed for 15 minutes by restraining them in a nose-only inhalation 
chamber and subjecting them to aerosols of CoQ10 prepared with DMPC, DPPC, and 
DSPC. While CoQ10 levels were below the quantitative limit in the blood plasma and in a 
DPPC-containing saline control group for up to 48 hours, the drug deposition in the lungs 
achieved high doses within this time interval for all treated groups. Cmax and AUC0-48 
values reached 791 µg/g and 26.8 mg·h/g of lung tissue, respectively, at 1 hour after the 
end of pulmonary administration using an Aeroneb Pro® vibrating-mesh nebulizer. 
Proportionally to animal body weight, the concentration of drug found in the nasal cavity 
was lower than in the lungs. In conclusion, high levels of CoQ10 were determined in the 
lungs after 48 hours. The determination of the time to completely clear the drug from the 
lungs is an investigation warranted for future studies, which could be designed for a 
larger animal (e.g. rats) in order to compare differences in lung deposition of these 
dispersions of CoQ10. The formulations presented in this dissertation were manufactured 
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for immediate use following preparation. Therefore, further studies to identify 
formulation stability at different temperatures are necessary to move forward into further 
preclinical and clinical studies.  
The work presented in this dissertation shows that evaluation of aerosol output 
using a LD technique may favor rapid screening of formulations that have potential for 
pulmonary delivery. Following the selection of suitable candidates, analysis of 
aerodynamic deposition profiles must be performed to determine the drug output from the 
aerosol generated from these formulations. By evaluating continuous aerosol output from 
a nebulizer it was demonstrated that investigation of the rheology of dispersions may be 
useful in predicting the overall nebulization performance of formulations for use with 
vibrating-mesh nebulizers. This may be especially important in the formulation 
development process for the inhalation therapy of poorly-water soluble compounds, 
where colloidal systems may be involved. 
In a broader sense, this work presents a novel method used in order to measure the 
surface tension of liquids. This new method of surface tension evaluation could be 
applied in a variety of settings, including the paint and cosmetic industries, in addition to 
the food and pharmaceutical industries. 
Lastly, this body of work is an important proof-of-concept to demonstrate the 
delivery of high amounts of exogenous CoQ10 to the lungs via inhalation. It is hoped that 
further studies can build on the understanding of nebulization performance as well as the 
mouse deposition studies to the future development of therapies to treat lung carcinomas, 
either as primary or supportive care. 
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Appendices 
 
APPENDIX A: LOW CONCENTRATION RANGE DETERMINATION OF COENZYME Q10 
USING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
 
A.1. Introduction 
Coenzyme Q10 (CoQ10) is a lipophilic drug that is being evaluated for the 
treatment of certain diseases related to the mitochondrial function. Preclinical and clinical 
studies require the determination of small amounts of this compound in different 
biological fluids and tissues. Currently, there are many analytical methods of HPLC with 
ultraviolet (UV) detectors available to determine CoQ10. However, for high sensitivity 
analysis, more sophisticated and complex methods are required, such as: HPLC followed 
by chemical reactions, HPLC with electrochemical detectors (ECD) and liquid 
chromatography-triple quadrupole (tandem) mass spectrometry (LC – MS/MS). Among 
the parameters for validation of HPLC methods are accuracy, precision, range, linearity 
and limits of detection (LOD) and quantification (LOQ). Signal-to-noise (S/N) ratio is a 
quick and simple method to determine LOD and LOQ, which are essential when 
analyzing low concentration of drugs.  
 
A.2. Purpose 
The aim of this study was to develop an analytical method with improved 
sensitivity to determine CoQ10 using reverse-phase high performance liquid 
chromatography. 
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A.3. Methods 
The Waters HPLC and column system consisted of a 1525 binary pump, a 717 
autosampler, a 2487 dual λ absorbance detector, set at 275 nm, and a Symmetry RP-C8 
column 5 µm (3.9 x 150 mm) connected to Symmetry C8 guard column 5 µm (3.9 x 20 
mm). The mobile phase (MP) consisted of Methanol:Hexane at 97:3 (v/v). Stock solution 
of pure CoQ10 was initially dissolved in Hexane:Ethanol (diluent) at a ratio of 2:1 (v/v) 
and subsequently diluted with the mobile phase to obtain the desired concentration. Limit 
of Detection (LOD), Limit of Quantification (LOQ) and linearity (3-interday curves) 
were determined by injecting 50 µL samples at a controlled temperature of 30ºC. 
Chromatogram peaks were acquired within run time of 11 minutes at a flow rate of 1.0 
mL/min. Area and height of peaks were used to determine curve linearity. LOD and LOQ 
were defined by signal-to-noise (S/N) ratio calculations according to method from the 
European Pharmacopoeia, with minimum acceptable values of 3 and 10, respectively. 
Concentration points were 10, 25, 37.5 and 50 ng/mL (n = 6). 
For mobile phase preparation, solvents were filtered prior to use through 0.45 µm 
nylon membrane filters and sparged for 10 minutes with helium gas. For preparation of 
stock and working standard solutions (500 µg/mL), 12.5 mg of CoQ10 was accurately 
weighed in a 25 mL amber volumetric flask and dissolved in hexane-ethanol (2:1 v/v). 
Subsequently, this stock standard solution was diluted with MP to 10 µg/mL. To avoid 
light degradation of the API, standard solutions were kept in amber containers during 
drug manipulation. Working standard solutions were prepared by transferring suitable 
aliquots of stock solution to transparent tubes and diluted to final concentration with MP. 
Finally, the working standard solutions were transferred to polypropylene conical 
containers and placed them in amber HPLC vials for analyses.  
 
 301 
A.4. Results 
The retention time (RT) of CoQ10 was determined as approximately 8 minutes and 
injection of blank sample (diluent) shown not to interfere in peak determination at 275 
nm. Temperature control was observed to be essential to obtain symmetric peaks at lower 
concentrations. LOD and LOQ were defined as 10 ng/mL (n = 6; S/N ratio = 6.0; SD = 
0.6; RSD = 10.5%) and 25 ng/mL (n = 6; S/N ratio = 12.6; SD = 1.3; RSD = 10.1%); 
respectively. The curve linearities were obtained using height or area of the 
chromatogram peaks in the range of 25 to 2500 ng/mL with r2 ≥ 0.9999 (n=3 for each 
concentration). 
 
A.5. Conclusion 
The method can be used as an alternative to more complex and expensive 
methods for analysis of CoQ10 in small concentrations. The ease of sample preparation 
and small retention time allows for a quick analysis. The possibility of using either the 
area or the height of chromatogram peaks gives more flexibility to adapt this method to 
different applications. Further studies on extraction of CoQ10 from biological materials, 
stability, and internal standard selection are needed to define the role of this method. This 
study provides an alternative and suitably stable method to determine CoQ10 at very low 
concentrations using an economically viable RP-HPLC system. 
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APPENDIX B: DETERMINATION OF APPROPRIATE COENZYME Q10 CONCENTRATION IN 
PHOSPHOLIPID-STABILIZED DISPERSIONS FOR CONTINUOUS VIBRATING-MESH 
NEBULIZATION. 
 
B.1. Introduction 
Coenzyme Q10 (CoQ10) is a poorly-water soluble compound that is being studied 
for the treatment of lung malignancies. The phospholipid concentration in the drug 
product Survanta® is 2.5% w/w, which is the same concentration that we have chosen to 
use when stabilizing phospholipid dispersions of CoQ10 prepared using microfluidization. 
Aeroneb Pro® micropump device is a vibrating-mesh nebulizer that is capable of 
aerosolizing dispersed system but that has been reported to present variable 
aerosolization due to clogging of mesh pores. 
 
B.2. Purpose 
The purpose of the preliminary study presented in this appendix is to establish a 
maximum nominal drug loading to phospholipid-stabilized dispersions of CoQ10 while 
maintaining continuous vibrating-mesh nebulization. 
 
B.3. Methods 
The preparation of the formulations is described in detail as in Formulation C of 
Chapter 4, Section 4.3.4, Table 4.1. In particular, the formulations investigated in this 
study were prepared with 50 microfluidization discrete passes using 2.5% w/w of 
dimyristoyl phosphatidylcholine (DMPC) and 7.5%, 7.0%, 6.0%, 5.0%, or 4.0% w/w of 
CoQ10. The dispersions were then aerosolized no later than one day after preparation 
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using an Aeroneb Pro® nebulizer for 15 minutes. The aerosolization profile was 
monitored via analysis of Total Aerosol Output (TAO) and using laser diffraction with a 
Malvern Spraytec® coupled with an inhalation cell as described in Chapter 4, Section 4.4.  
 
B.4. Results and Discussion 
The nebulization performances of the DMPC-stabilized formulations of CoQ10 are 
presented in Figure B.1. It can be observed that as the drug concentration decreases, the 
aerosolization becomes more continuous. The TAO values for decreasing drug 
concentrations are, respectively, 1.25g (12.4%), 1.62g (16.1%) and 2.15g (21.4%). The 
TAO results are in agreement with the analysis of nebulization performance from laser 
diffraction, with increasing values as the drug concentrations decrease. The transmission 
values do not return to 100% at the end of nebulization, due to the reasons described in 
Section 4.4 of Chapter 4. Although a formulation containing 5% w/w of CoQ10 was 
prepared, the analysis using laser diffraction could not be performed appropriately due to 
this technique artifact. Based on visual observation, it was determined that this drug 
concentration was not suitable for continuous aerosolization of the CoQ10 dispersion 
because of generation of intermittent mist during nebulization. For the 4.0% w/w CoQ10 
formulation, this intermittence was only observed at the end phase of nebulization, 
therefore being chosen as the appropriate nominal drug concentration. 
 
B.5. Conclusion 
The nominal concentration of 4% w/w of CoQ10 was determined to be the 
appropriate drug loading for continuous aerosolization with the Aeroneb Pro® nebulizer 
as established using DMPC at 2.5% w/w to stabilize the dispersions. 
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B.6. Figures 
 
Figure B.1 – Transmittograms of aerosolization of DMPC-stabilized dispersions with different concentrations of CoQ10. 
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